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ABSTRACT 
 
 Brain and central nervous system (CNS) cancers are the leading cause of cancer-related 
death in children (Ostrom QT et al., 2015).  Low-grade brain and CNS tumors that require 
minimal surgical resection due to their location in critical regions are associated with long-term 
morbidity throughout the life of the child (Armstrong GT et al., 2011).  Children diagnosed with 
high-grade, aggressive brain and CNS tumors generally have a poor outcome and suffer 
significant deficits in neurological and neuroendocrine function as a result of intensive therapy 
(Fangusaro J et al., 2012).  Effective, targeted therapeutics for the treatment of pediatric brain 
and CNS cancer are needed.  Gaining a better understanding of the molecular mechanisms 
underlying pediatric brain and CNS cancer initiation and progression will benefit the 
development of therapeutics.  Animal models are an important component for the improvement 
of our understanding of the biology of these cancers (Huszthy PC et al., 2012).   The zebrafish 
has recently emerged as a system for modeling human diseases including brain and CNS cancers.  
We have characterized two distinct zebrafish brain and CNS tumor models, a low-grade, glial-
like tumor model and a high-grade CNS primitive neuroectodermal-like tumor model.  The 
transgenic Tg(flk1:RFP)is18 zebrafish line develops low-grade glial-like tumors in the optic 
pathway including the retina, optic nerve and optic tract. These tumors exhibited histological 
features similar to those observed in human pediatric pilocytic astrocytoma.  Differential gene 
expression analysis revealed a neuroglial progenitor signature in the tumors of the retina.  The 
second brain tumor model helped establish the use of nuclease-mediated somatic mutagenesis in 
zebrafish for the study of tumor suppressor function in cancer.  In this model we generated 
genetic mosaic adults using TALENs targeting the rb1 (retinoblastoma1) tumor suppressor.  
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These mosaic adults developed predominantly undifferentiated, primitive neuroectodermal 
tumors (67% of tumors) as well as differentiated, glial-like tumors (33% of tumors). This was the 
first demonstration that somatic inactivation of a tumor suppressor causes cancer in zebrafish and 
highlighted the utility of site-specific nucleases as a rapid, simple, and cost efficient method to 
screen potentially hundreds of candidate tumor suppressor genes that impact tumorigenesis.  
These models will be useful for the study of pediatric brain and CNS tumorigenesis. 
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CHAPTER 1: INTRODUCTION 
 
General Introduction 
 Brain and central nervous system (CNS) tumors are the most common solid tumor 
amongst infants and children age 0-14 and are the leading cause of cancer-related death amongst 
children (Louis DN et al., 2015). The World Health Organization grades brain and CNS tumors 
I-IV based on histopathological features and malignant potential.  Grade I tumors are the least 
malignant and are associated with a better overall outcome while grade IV tumors are the most 
malignant and have a significantly poorer long-term prognosis (Louis DN et al., 2007).  Children 
diagnosed with low-grade brain and CNS tumors have an overall survival rate of 80-90% 
(Bandopadhayay P et al., 2014).  However, patients with low-grade brain and CNS tumors that 
are not amenable to surgical resection often experience long-term morbidities from the disease 
(Armstrong GT et al., 2011).  High-grade brain and CNS tumors (WHO grades III and IV) are 
generally associated with a much poorer prognosis that varies with the type of tumor diagnosed.  
5-year survival rates range from 15% for high-grade gliomas and atypical teratoid/ rhaboid brain 
tumors to 70% for grade IV medulloblastoma (Ostrom QT et al., 2015).  Current therapeutic 
strategies for high-grade tumors are associated with significant neurological and neuroendocrine 
deficits in surviving children (Fangusaro J et al., 2012, Reddy AT et al., 2000).  The long-term 
morbidities of surgically intractable low-grade brain and CNS cancers and poor survival rates 
and treatment-associated effects in high-grade tumors highlight a need for more effective, 
targeted therapies for pediatric brain cancer treatment. Gaining a better understanding of the 
molecular biology underlying pediatric brain cancer initiation and progression will benefit the 
development of therapeutics.  Animal models are an important component of improving of our 
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understanding of the biology of brain and CNS cancers (Huszthy PC et al., 2012).  The 
development of animal models of the two most frequently diagnosed pediatric brain and CNS 
tumor types, astrocytoma and embryonal tumors, has been a research focus (Ostrom QT et al., 
2015).    
 
Overview of astrocytoma  
 Astrocytoma is classified under a broad category of tumors referred to as gliomas, which 
are the most common type of brain and CNS cancer in children ages 0-14 (Ostrom QT et al., 
2015).  Gliomas arise from glial cells, which include astrocytes, oligodendrocytes, and 
ependymal cells, or from precursors of these cells.  Astrocytoma is the most common type of 
pediatric glioma accounting for ~30% of all diagnosed gliomas (Ostrom QT et al., 2015). Low-
grade astrocytoma usually grows slowly and includes benign, pilocytic astrocytoma (Grade I) 
and infiltrative, diffuse astrocytoma (Grade II).  Higher-grade astrocytoma is malignant and 
characterized by aggressive growth and infiltration of surrounding tissues. These include 
anaplastic astrocytoma (Grade III) and glioblastoma (Grade IV).  The prognosis for Grade III 
and IV is significantly poorer compared to lower-grade astrocytoma (Louis DN et al., 2007).  In 
the pediatric population (ages 0-14) pilocytic astrocytoma is the most commonly diagnosed brain 
and CNS tumor and accounts for the majority of all diagnosed astrocytoma.  Pilocytic 
astrocytoma is rare in adults (Ostrom QT et al., 2015).  These tumors arise most frequently in the 
cerebellum, optic pathway, and brainstem and show limited potential for progression to higher-
grade disease (Ostrom QT et al., 2013).  For patients with tumors amenable to surgical resection, 
the overall prognosis is good. Significant morbidity and reduced long term survival is observed 
in patients with tumors located in areas of the brain and CNS that make them intractable to 
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resection such as the hypothalamus (Zhang J et al., 2013).  Tumor recurrence occurs in 20% of 
cases that undergo surgical resection.  Prediction of low-grade astrocytoma growth rates and 
progression to higher-grade disease is difficult, highlighting the need for a better understanding 
of the molecular mechanisms underlying low-grade astrocytoma progression (Rodriguez EF et 
al., 2011).    
 Pediatric high-grade astrocytoma accounts for 6-12% of all diagnosed astrocytoma in 
children and is typically located in the cerebrum and brainstem (Tomaselli S et al., 2013).  The 
majority of diagnosed glioblastoma is primary or de novo glioblastoma while secondary 
glioblastoma is observed rarely.  Primary glioblastoma arises rapidly as a grade IV lesion 
without any clinical or histological evidence of a lower-grade, precursor lesion.  Secondary 
glioblastoma manifests more slowly from the progression of a low-grade diffuse astrocytoma 
(Grade II) or anaplastic astrocytoma (Grade III) lesion.  Progression to glioblastoma occurs in 
most patients with grade III anaplastic astrocytoma (Goodenberger ML et al., 2012). Despite the 
intensive research on glioblastoma, our understanding of the molecular pathogenesis of this brain 
and CNS tumor and the ability to successfully treat it remain limited.  Although children 
diagnosed with high-grade astrocytoma tend to have a better prognosis than adults, overall 
survival is dismal, with a 5-year survival of ~15 to 35% (Ostrom QT et al., 2015, Fangusaro J et 
al., 2012).  Despite advancements, current glioblastoma treatments have been shown to have no 
effect on overall survival, highlighting a critical need for improved therapies (Okada H et al., 
2009). Central to the development of therapies is the identification and investigation of the 
functional significance of the genetic alterations that underlie the molecular pathogenesis of low-
grade and high-grade astrocytoma. 
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Genetics of low and high-grade astrocytoma 
 Key genetic alterations resulting in the activation of the MEK/MAPK and 
PI3K/AKT/mTOR signaling pathways have recently been implicated in low-grade astrocytoma 
(Chen YH et al., 2013).  Individuals with inherited mutations in the neurofibromatosis 1 (NF1) 
gene show a predisposition for the development of pilocytic astrocytoma in the optic pathway.   
Sporadic forms of pilocytic astrocytoma are associated with activation of the BRAF oncogene 
through a BRAF fusion event or activating mutation.  These NF1 and BRAF genetic alterations 
result in activation of the RAF/MEK/ERK and PI3K/AKT/mTOR pathways (Chen YH et al., 
2013).  Alterations of the PI3K/AKT/mTOR pathway have recently been associated with 
anaplastic cases of pilocytic astrocytoma (Rodriguez EF et al., 2011).  
 Sequencing and copy number alteration studies have shown that distinct genetic and 
chromosomal alterations are associated with pediatric and adult high-grade astrocytoma (Sturm 
D et al., 2014, Fangusaro J et al., 2012).  Deregulation of the RTK/RAS/PI3K is frequently 
observed in pediatric and adult high-grade astrocytoma.  In pediatric high-grade astrocytoma this 
deregulation primarily occurs through amplification of platelet-derived growth factor receptor 
alpha (PDGFRA) while occurring through amplification or mutation of endothelial growth factor 
receptor (EGFR) in adult high-grade astrocytoma (Sturm D et al., 2014, Gerges N et al., 2013).  
Mutations in NF1, TP53, RB1 and ATRX tumor suppressors are more frequently observed in 
pediatric high-grade astrocytoma than the adult form (Sturm D et al., 2014, Gerges N et al., 
2013).  Deregulation of these tumor suppressor pathways is observed in many types of cancers 
and results in cell death evasion and unregulated cell proliferation, two hallmark functions of 
cancer cells (Okada H et al., 2009).  Gain of function histone mutations that affect the epigenetic 
landscape of high-grade astrocytoma are the most distinctive genetic alterations between 
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pediatric and adult high-grade astrocytoma (Sturm D et al., 2014).  A higher degree of 
chromosomal stability is associated with pediatric high-grade astrocytoma.  Pediatric high-grade 
astrocytoma frequently shows single copy gains of 1q and chromosome 7 and singly copy loss of 
13q and 14q and chromosome 10 (Sturm D et al., 2014).  The development of genetically 
engineered mouse models (GEMMs) of astrocytoma has been guided by insights gained from 
comprehensive molecular characterization of pediatric and adult astrocytoma (Kegelman TP et 
al., 2014).   
 
Mouse models of low- and high-grade astrocytoma  
 GEMMs of low-grade astrocytoma that are generated using the pediatric-specific genetic 
lesions such as Nf1 inactivation or BRAF activation are generally considered models of pediatric 
astrocytoma. Although distinct genetic alterations are associated with pediatric and adult high-
grade astrocytoma, the same three signaling pathways, the RTK/RAS/PI3K pathway and the 
TP53 and RB1 tumor suppressor pathways, are deregulated in both (Stylli SS et al., 2015, Chen J 
et al., 2012).  The majority of GEMMs of high-grade astrocytoma have been generated by 
disruption of components of these pathways that are frequently disrupted in both pediatric and 
adult high-grade astrocytoma.  Because of this, there are few distinct GEMMs of pediatric high-
grade astrocytoma.  Many GEMMs have been generated using Nestin or GFAP promoters to 
create overexpression, gain-of-function and/or loss-of-function alleles of components of the three 
main deregulated pathways in neural progenitors or astrocytes and subventricular zone glial 
progenitors, respectively (Kegelman TP et al., 2014, Chen J et al., 2012).  NF1, TP53, PTEN, 
and RB tumor suppressors are frequently targeted for the generation of GEMMs of astrocytoma 
(Janbazian L et al., 2014, Chow LM et al., 2011, Jacques TS et al., 2010).  
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 Reilly and colleagues inactivated Nf1 and p53 to create the first mouse model of 
astrocytoma to be generated by loss of tumor suppressors.  Mice carrying heterozygous germline 
mutations in Nf1 and p53 develop variable grades of astrocytoma with 90% presenting with 
tumors by 6 months of age. Interestingly, these mice failed to develop benign, pilocytic 
astrocytoma as is seen in NF1 patients (Reilly KM et al., 2000).  A pediatric optic pathway 
astrocytoma model was generated by astrocyte specific (GFAP) inactivation of Nf1 in an Nf1 
heterozygous background.  100% of the mice developed optic nerve and chiasm tumors with 
features of low-grade astrocytoma beginning around 8 months of age.  The brains of the mice 
were normal, showing no evidence of tumor formation (Banjenaru ML et al., 2003).  In another 
study, astrocyte/ SVZ glial progenitor specific loss of floxed Nf1 using GFAP-Cre in a p53 
homozygous background resulted in a high-grade astrocytoma incidence of 100% but with an 
onset of 5-10 months (Zhu Y et al., 2005).   They also showed that loss of p53 before or 
coinciding with Nf1 loss is required for tumor initiation in their model (Zhu Y et al., 2005).  
Further studies demonstrated that inactivation of Pten cooperates with this tissue-specific p53/ 
Nf1 model to decrease latency and increase tumor grade (Kwon CH et al., 2008). Similar 
cooperating effects of Pten loss were observed in a low-grade astrocytoma GEMM generated by 
inactivation of pRb and its other family members p107 and p130 in astrocytes/ SVZ glial 
progenitors.  Loss of Pten reduced latency by almost 50% and increased tumor grade to high-
grade (Xiao A et al., 2002).  In addition to tumor suppressor inactivation, pediatric and adult 
astrocytoma frequently exhibits oncogene amplification and mutation that leads to aberrant 
activation of the RTK/RAS/PI3K pathway (Stylli SS et al., 2015). 
 Although direct mutation or amplification of Ras is relatively rare in high grade-
astrocytoma, researchers have successfully used oncogenic forms of Ras to promote 
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gliomagenesis in mice.  Ding and colleagues showed that GFAP-driven expression of activated 
Ras, V12Ha-Ras, resulted in highly penetrant, variable-grade astrocytoma by 6 months (Ding H et 
al., 2001).  Similar tumor penetrance and grade with reduced latency was observed with GFAP-
driven oncogenic K-Ras(G12D) (Abel TW et al., 2009).  Forty-five percent of adult glioblastoma 
exhibits amplification and/or mutation of the receptor tyrosine kinase (RTK) epidermal growth 
factor receptor (EGFR) while 13% show amplification of the RTK ligand platelet-derived growth 
factor alpha (PDGFA) (Cancer Genome Atlas Research Network, 2008).  The role of these 
alterations in gliomagenesis has been investigated using somatic cell gene transfer systems 
(Holland EC et al., 1998, Dia C et al., 2005).  Using the RCAS/ tv-a viral system for delivery of 
oncogenes to specific cell types Holland and colleagues investigated the role of EGF signaling in 
gliomagenesis (Holland EC et al., 1998).  They showed that delivery of an RCAS vector carrying 
a constitutively active EGFR to the subventricular zone of transgenic mice expressing GFAP or 
Nestin driven tv-a was insufficient to induce astrocytoma formation. The same experiments in 
mice homozygous for loss of the INK4a-ARF tumor suppressor locus, yielded variable grade 
glioma in 40% of the mice by 2.5 months of age with Nestin-tv-a (Holland EC et al., 1998).  
Similarly, overexpression of PDGFB delivered using an RCAS vector and GFAP or Nestin-
driven tv-a failed to induce glioma unless in the INK4a-ARF sensitized background (Dai C et al., 
2001).  The tumors arising were histologically similar to oligodendroglioma, a type of glioma 
that is distinct from astrocytoma.  Variable-grade tumors with a distinct astrocytic lineage arose 
when these PDGFB experiments were performed in combination constitutively active Akt (Dai C 
et al., 2005). 
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Overview of central nervous system (CNS) primitive neuroectodermal tumors 
 CNS primitive neuroectodermal tumor (CNS-PNET) refers to a World Health 
Organization (WHO) class of heterogeneous, embryonal tumors that account for 3% of pediatric 
brain and CNS tumors (Louis DN et al., 2007, Reddy AT et. al, 2000).  These aggressive, grade 
IV tumors occur predominantly in children and adolescents and are rare in adults.  CNS-PNET 
histological features include small, round undifferentiated or poorly differentiated neuroepithelial 
cells, dense cellularity, and the capacity for divergent differentiation along neuronal, astrocytic 
and ependymal lineages (Louis DN et al., 2007).  These tumors are primarily located in the 
cerebrum but can also occur in the brain stem and spinal cord (Pfister SM et al., 2010).  Children 
diagnosed with CNS-PNETs receive clinical treatment similar to that established for patients 
with high-risk medulloblastoma (MB), a histologically similar PNET arising specifically in the 
cerebellum.  The 5-year survival rate with this treatment is 50% compared to approximately 80% 
for patients with MB (Inda MM et al., 2006).  These outcomes suggest that although similar 
histologically, CNS-PNETs and MBs are distinct tumor entities with differing molecular 
signatures and cellular origins.  This also highlights a critical need for improved, targeted 
therapeutics for the treatment of CNS-PNETs. 
 
Genetics of CNS primitive neuroectodermal tumors 
 The rarity of CNS-PNETs has impeded characterization of the genomic and mutational 
landscape of these tumors (Picard D et al., 2012). Furthermore, recent changes in WHO 
classification of embryonal tumors have made appropriate classification of these tumors a 
challenge (Louis DN et al., 2007).  Although the tumors that fall under the umbrella category of 
primitive neuroectodermal tumors appear similar histologically, the limited available data 
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suggests that distinct copy number alterations, mutations and expression profiles are associated 
with each (Picard D et al., 2012).    
 In contrast to medulloblastoma, analysis of CNS-PNET somatic copy number alterations 
revealed few recurring copy number alterations (CNAs).  A recurrent CNA identified in CNS-
PNETs is the focal amplification of a region of chromosome 19q13 that contains the C19MC 
miRNA cluster (Picard D et al, 2012).  This amplification is most frequently found in embryonal 
tumors with abundant neuropil and true rosettes (ETANTRs), a subgroup of CNS-PNETs with a 
dismal outcome, and ependymoblastoma (Li M et al., 2009).  CNS-PNETs characterized by an 
embryonic/ neural stem cell expression profile (discussed below) also recurrently carried the 
19q13 amplification.  Another frequently occurring CNA is the deletion of chromosome 9p that 
includes the cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B).  The CKDN2A/B tumor 
suppressor locus codes for multiple protein products that function in the cell-cycle regulating RB 
pathway (Picard D et al., 2012).  In a small study (20 cases) performed by Li and colleagues 20% 
of analyzed CNS-PNETs showed focal amplification of CDK/CYCLIND genes, which also 
function in the RB pathway (Li M et al., 2012).  These findings highlight the potential role of the 
RB pathway in CNS-PNET tumorigenesis. Less frequently occurring copy number alterations 
include gain of 19p, 2p, and 1q and loss of 14q (Chan TSY et al., 2015, Jones DTW et al., 2014).  
Investigation of the mutational landscape of CNS-PNETs yielded few recurrently mutated genes.   
 Sequencing of 33 CNS-PNETs identified an H3.3 GA point mutation in 4 of the 
tumors (11%) that resulted in a glycine  arginine at amino acid 34.  This mutation is observed 
in 25% of glioblastoma suggesting similarity in the molecular features of glioblastoma and some 
tumors diagnosed as CNS-PNETs (Gessi M et al., 2013). Inherited germline mutations that are 
associated with an increased risk of developing CNS-PNETs have been identified.  Turcot 
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syndrome Type I is associated with mutations in DNA mismatch repair genes hMLH1, hMSH2, 
hPMS1 and hPMS2 (De Vos M et al., 2004).  In addition to CNS-PNETs these patients have an 
increased risk of developing colorectal tumors and glioma.  Individuals carrying heterozygous 
germline mutations in the tumor suppressor TP53 suffer from Li-Fraumeni syndrome and present 
with a wide range of cancers including breast cancer, osteosarcoma, sarcoma and leukemia.   
Nearly half of those diagnosed with Li-Fraumeni syndrome are diagnosed with cancer by the age 
of thirty (Mai PL et al., 2012).  Li-Fraumeni syndrome is also associated with development of 
CNS-PNETs (Weber RG et al., 1998). 
 Picard and colleagues performed molecular characterization that included gene 
expression, genomic alteration, and immunohistochemical analysis of 123 primary CNS-PNETs 
(Picard D et al., 2012).  Gene expression analysis revealed three distinct molecular subgroups in 
hemispheric CNS-PNETs.  Expression of neural lineage and differentiation genes was 
significantly different between the 3 subgroups.  Group 1 tumors demonstrated an embryonic, 
neural stem cell expression signature and were referred to as primitive neural.  Genes associated 
with stem cell pluripotency including LIN28 and CRABP1 showed strong upregulation.  Tumors 
with significant upregulation of genes associated with oligo-neural differentiation including 
OLIG1/2 and SOX10 were classified as Group 2, oligoneural.  Group 3, mesenchymal, tumors 
were more similar to group 2 tumors than group 1 and demonstrated an epithelial and 
mesenchymal differentiation expression signature.  These expression profiles correlated with 
clinical behavior and outcome.  Children with Group 1 tumors were significantly younger and 
had poorer overall prognosis even when correcting for age and treatment biases.  An increased 
incidence of metastasis was observed in Group 3 tumors (Picard D et al., 2012).  These recent 
findings provide some of the first insights into the molecular mechanisms underlying CNS-
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PNET formation and progression.  These findings will be useful for the development of models 
of CNS-PNETs.  Currently, few GEMMs of CNS-PNETs have been established, due in part to 
the relatively limited molecular characterization of CNS-PNETs. 
 
Mouse models of CNS primitive neuroectodermal tumors 
 Conditional inactivation of Rb1 (Retinoblastoma1) and p53 tumor suppressors in the 
subventricular stem cells of adult mice resulted in CNS-PNETs in 20% of mice with a latency of 
9 months. The additional inactivation of PTEN in this model reduced latency to 100 days and 
increased penetrance to 51% suggesting cooperativity between these three pathways.   
Interestingly, loss of p53 and Pten in the subventricular stem cells altered the phenotype to 
glioma (Jacques TS et al., 2010).  This study highlighted the potential of subventricular zone 
stem cells as a CNS-PNET cell or origin.  A GEMM of CNS-PNET was generated using the 
RCAS/ tv-a viral system to drive overexpression of c-Myc in astrocytes and subventricular zone 
glial progenitors (GFAP) in a p53-deficient background.  34% of mice developed CNS-PNETs 
with a latency of 14 weeks (Momota et al., 2008).  The reported characterization of only a 
limited number of GEMMs demonstrates a need for animal models of CNS-PNETs.  The 
zebrafish offers a unique opportunity for the modeling of CNS-PNETs and other brain and CNS 
cancers. 
 
Zebrafish as models of cancer 
 Although well established as a system for the study of developmental processes, the 
zebrafish has recently emerged as a system for modeling human diseases including cancer.  This 
is due in part to the unique research advantages that the zebrafish offers over other vertebrate 
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systems, including high fecundity, rapid generation time, relatively inexpensive maintenance 
costs, and amenability to genome editing techniques and high throughput screens (Shive HR et 
al., 2010). At the genome level, an orthologue for approximately 70% of human genes can be 
found in the zebrafish genome (Howe K et al., 2013). As vertebrates, the molecular mechanisms 
and signaling pathways regulating embryonic development and anatomy are highly conserved 
between zebrafish and humans (Santoriello C et al., 2012).  This combination of technical 
advantages and level of vertebrate conservation has led to use of the zebrafish model for 
comparative cancer research.    
 Zebrafish cancer models of T-cell leukemia and melanoma were amongst the first models 
established (Langeneau DM et al., 2003, Patton EE et al., 2005). Thorough histological and 
molecular characterization of these tumors showed that they resembled human tumors, affirming 
the zebrafish as a tool for studying cancer and encouraging the development of other cancer 
models.  Since then, cancer models of liver, malignant peripheral nerve sheath, 
rhabdomyosarcoma, and testicular cancers have been developed in the zebrafish (Lam SH et al., 
2006, Berghmans S et al., 2005, Langeneau DM et al., 2007, Shive HR et al., 2010) .   With the 
development and characterization of zebrafish models of many diverse types of cancers, the 
zebrafish has been established as a valuable system for studying human cancer.  Zebrafish 
models of brain and CNS cancer have emerged only within the last 3 years.   
 
Zebrafish models of Brain and CNS Cancer 
 The first zebrafish brain cancer model was developed through the cooperative disruption 
of the nf1 and p53 tumor suppressors. Shin and colleagues showed that heterozygous inactivation 
of nf1a and homozygous inactivation of nf1b in a p53-deficient background resulted in formation 
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of high-grade glioma and malignant peripheral nerve sheath tumors in 8% and 92% of adult 
zebrafish, respectively. Interestingly, glioma did not develop within the optic pathway as is 
commonly observed in (15%) children carrying heterozygous germline mutations in NF1 (Shin J 
et al., 2012).  
 The most recent brain and CNS tumor models utilize expression of oncogenes to disrupt 
the PI3K/AKT/mTOR, RAF/MEK/ERK or sonic hedgehog pathways, which leads to the 
development of glioma (Jung IH et al., 2013, Ju B et al., 2015, Ju B et al., 2014).  In one study, 
transgenic zebrafish overexpressing a dominant-active form of Akt (DAAkt1) in the hindbrain 
developed glioma of varying histological grades within the cerebellum at a high frequency (Jung 
IH et al., 2013).  Co-expression of the dominant-active form of Akt DAAkt1 with a dominant 
active form of Rac resulted in a significant increase in tumor incidence as well as histological 
grade and invasiveness. The first optic pathway glioma model was established by expression of a 
constitutively activate form of smoothened (smoa1) in neural progenitors.  These fish also 
developed retinal medulloepithelioma, melanoma, and primitive neuroectodermal tumors. Array-
based differential gene expression analyses of retinal tumors and wild type eyes demonstrated a 
radial glia and progenitor cell expression signature within the tumors (Ju B et al., 2014).  Most 
recently, transient transgenic expression of oncogenic KRAS(G12V) in neural progenitors using 
the keratin5 (krt5) promoter induced brain and CNS tumors at a low frequency.  By 1 year of 
age, approximately 50% of injected zebrafish developed tumors within the head region.  
Histological analyses of 15 tumors revealed that only 3 (20%) of the tumors were within the 
brain while the remaining were malignant peripheral nerve sheath tumors in the cranial cavity.  
The three brain tumors displayed histopathological features consistent with glioma. The 
researchers used the gfap promoter to transiently express oncogenic KRAS(G12V) in radial glia.  
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These zebrafish developed tumors in the head region at a frequency similar to the krt5 driven 
KRAS(G12V). Of the 10 gfap driven KRAS(G12V) induced tumors further analyzed, 6 were 
within the brain and were histologically consistent with high-grade gliomas.  Interestingly, none 
of the gliomas expressed the glial markers gfap and s100B, which are frequently used to 
diagnose human glioma (Ju B et al., 2015).  Currently, few models of zebrafish brain and CNS 
cancer have been developed and characterized.  This is partially due to the limited reverse 
genetic techniques available for use in zebrafish until recently. Highly efficient, targeted 
nuclease techniques including transcription activator-like effector nucleases (TALENs) and the 
clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system have recently 
been established in zebrafish (Christian M et al., 2010, Jinek M et al., 2013, Dahlem TJ et al., 
2012, Hwang WY et al., 2013).  These techniques will be useful for the generation and study of 
zebrafish cancer models.  
 
Nuclease-mediated mutagenesis for the investigation of tumor suppressor function in 
zebrafish 
 The development of reverse genetic (targeted nuclease) techniques including TALENs 
and CRISPR/Cas9 system have allowed for the investigation of the functional role of essentially 
any gene of interest in model systems (Christian M et al., 2010, Jinek M et al., 2013).  TALENs 
are customizable DNA binding proteins fused to a FokI endonuclease domain.  Modular 
assembly of the DNA binding domain allows for the targeting of the FokI endonuclease to 
specific sites within a genome.  Dimerization of the FokI domains of a pair of TALENs creates 
double strand DNA breaks that are repaired by homologous recombination and the error-prone, 
Non-Homologous End Joining (NHEJ) pathway, creating insertion-deletion (indels) mutations 
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(Christian M et al., 2010).  When targeted to a 5’ exonic sequence, these indels frequently result 
in frame-shift or non-sense mutations that disrupt gene function. The more recent CRISPR/Cas9 
system is an RNA-guided nuclease system.  Within the cell, a sequence-specific single strand 
(chimeric) guide RNA (sgRNA) is loaded into the Cas9 endonuclease protein targeting it to a 
specific site in a genome.  Like the FokI endonuclease, the Cas9 endonuclease creates double 
strand DNA breaks that are repaired through homologous recombination and the NHEJ pathway 
(Jinek M et al., 2013). Both of these techniques have been used to create germline mutants in 
zebrafish and mice for the study of gene function (Bedell VM et al., 2012, Sung YH et al., 2014). 
Recently these techniques have emerged as an efficient strategy for the analysis of gene function 
in somatic tissues (Zhang S et al., 2014, Sanchez-Rivera FJ et al., 2014, Varshney GK et al., 
2015). 
 Bedell and colleagues demonstrated that TALEN-mediated somatic inactivation of genes 
involved in vascular development in zebrafish resulted in embryonic phenotypes that mimicked 
those previously observed from morpholino-based gene knockdown (Bedell VM et al., 2012).  
The CRISPR/Cas9 system has been used to create germline mutants in zebrafish and mice for the 
study of adult phenotypes.  The CRISPR/Cas9 system has been adapted for tissue-specific gene 
disruption in zebrafish allowing for the somatic investigation of adult phenotypes (Ablain J et al., 
2015). Nuclease-mediated somatic mutagenesis has emerged as a powerful tool for the study of 
tumor suppressor function (Zuckermann M et al., 2015, Sanchez-Rivera FJ et al., 2014, Zhang S 
et al., 2014). Most recently, malignant brain tumor models were developed using 
CRISPR/Cas9 somatic inactivation of multiple tumors suppressors in embryonic and neonatal 
mouse brain (Zuckermann M et al., 2015). The in vivo study of tumor suppressor function is 
frequently hindered by their essential requirement during embryonic development.  Furthermore, 
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mouse and zebrafish models of human cancer frequently require several genetic crosses into 
conditional and/or sensitizing genetic backgrounds.  Nuclease-mediated somatic mutagenesis 
circumvents these impediments while allowing for the investigation of the functional role of 
multiple genes in tumorigenesis at one time.  Nuclease-mediated techniques have emerged as 
valuable tools for the investigation of gene function through germline and somatic mutagenesis.  
They provide an opportunity to investigate tumor suppressor function in zebrafish cancer 
models. 
 
RB tumor suppressor pathway 
The RB pathway is disrupted in nearly every type of sporadic human cancer including 
pediatric astrocytoma and CNS-PNETs, suggesting that this pathway is important for brain and 
CNS tumorigenesis (Indovina P et al., 2013, Sturm D et al., 2014, Gerges N et al., 2013, Picard 
D et al., 2012, Li M et al.).  The protein at the center of this pathway is pRb (Retinoblastoma1).  
pRb (Retinoblastoma1) has been well studied with much of the research focusing on its 
canonical function as a negative regulator of the G1-S phase transition of the cell cycle. 
However, within the past decade, emerging evidence has demonstrated a role for pRb in the 
regulation of many other cancer relevant processes, including genome stability and cellular 
differentiation (Viatour P et al., 2011).  
 
Regulator of cell cycle transition 
 Inhibition of the G1-S phase transition occurs through the direct interaction of active, 
hypophosphorylated pRb with members of the E2F transcription factor family at the promoters 
of E2F target genes.  This interaction prevents E2F recruitment of transcriptional coactivators 
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such as histone acetylases and promotes the recruitment of corepressors including histone 
deacetylases and DNA methyltransferase. Transcription of E2F target genes that promotes 
continuation of cell cycle entry is repressed. Mitogenic signaling stimulates cyclin-dependent 
kinases (CDKs) that phosphorylate pRb resulting in the disruption of pRb-protein interactions 
and activation of E2F target cell cycle genes.  CDKs are themselves targets of E2F leading to a 
positive feedback loop and amplification of mitogenic signals.  Cyclin dependent kinase 
inhibitors 2A/B are negative regulators of CDKs.  pRb is dephosphorylated as a cell moves 
through mitosis, resetting the system (Henley SA et al., 2012). 
 
Role of pRb in genome or chromosome stability 
 In vivo and in vitro studies implicate inactivation of pRB in chromosome instability 
(CIN), a hallmark of cancer. CIN, which is a high frequency of whole or partial chromosome 
gain or loss, is associated with a poor cancer prognosis and drug resistance to therapeutics.   
Research has shown that disruption of pRb function leads to chromosome instability through 
multiple E2F-dependent and independent mechanisms.  These E2F-dependent mechanisms 
involve the deregulation of E2F target genes including those involved in spindle assembly 
checkpoint control such as MAD2 and maintenance of centrosome stability (Indovina P et al., 
2013).  Misexpression of these genes as a consequence of pRb inactivation leads to chromosome 
instability, mitotic defects, and aneuploidy.  E2F-independent mechanisms involve the disruption 
of interactions between pRb and protein complexes that function in chromosome segregation. 
For example, loss of pRb results in improper recruitment of cohesion and condensin II 
complexes to chromatin.  During mitosis this leads to merotelic kinetochore attachments and 
missegregation of chromosomes (Chinnam M et al., 2011, Manning AL et al., 2011). 
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Role of pRb in Differentiation  
 An initial role for pRb in differentiation was demonstrated with the development of an 
Rb1 knockout mouse (Indovina P et al., 2013).  In embryonic lethal Rb1 homozygotes lens cell 
differentiation was abnormal with cells showing reduced expression of differentiation markers.  
Subsequent in vivo and in vitro studies have shown that pRb is critical for proper differentiation 
of myocytes, adipocytes, osteoblasts, and other cell types (Indovina P et al., 2013).  A role for 
pRb in differentiation has been demonstrated in the zebrafish.  Zebrafish homozygous for a 
nonfunctional, protein-truncating allele have a reduced number of differentiated retinal ganglion 
cells (Gyda M et al., 2012).  pRb regulates differentiation through functional and/or direct 
interaction with chromatin-modifying enzymes, lineage-specific transcription factors and 
negative regulators of differentiation (Burkhardt DL et al., 2008).  pRb has been shown to be 
critical for the maintenance of cellular differentiation in some mature cell types such as 
hepatocytes.  Loss of Rb1 in mature hepatocytes but not neurons is sufficient for re-entry into the 
cell cycle (Burkhardt DL et al., 2008).   The RB tumor suppressor pathway is deregulated in 
most sporadic human cancers including astrocytoma and and functions in many biological 
processes including proliferation, genome stability and differentiation (Indovina P et al., 2013).  
These findings  
 
Objective 
 The objective of this thesis is to develop and characterize models of pediatric brain and 
CNS cancers in zebrafish for the investigation of the molecular and cellular mechanisms 
19 
 
underlying brain and CNS tumorigenesis.  Molecular and cellular characterization of a transgenic 
zebrafish line Tg(flk1:RFP)is18 that develops low-grade glioma of the retina, optic nerve and 
optic tract was performed.  TALEN-mediated somatic mutagenesis of rb1 tumor suppressor in 
zebrafish resulted in CNS- PNET formation and demonstrated that F0 founder zebrafish could be 
used for the modeling and studying of brain and CNS cancer.  Similar to the Tg(flk1:RFP)is18 
line, initial characterization of the molecular and cellular nature of rb1 somatic inactivation-
induced brain tumors was performed.  Characterization of these zebrafish cancer models 
involved various molecular and bioinformatics techniques including immunohistochemistry, in 
situ hybridization and transcriptional profiling.   
 
Thesis Organization 
 This thesis is a composition of shared projects including the Tg(flk1:RFP)is18 project 
(Chapter 2) and rb1 somatic inactivation-induced brain tumor RNA sequencing project (Chapter 
4). Chapter 3 is composed of the results of experiments that were formulated and completed by 
me. The Tg(flk1:RFP)is18 project was collaborative and resulted in a first author publication 
(Chapter 2) with experiments performed by me and those listed in the publication. I performed 
experiments involving the molecular characterization of the retinal tumors and lincRNAis18 
expression (part of Figure 4, Figures S5, S6, and S9) and assisted in the generation of a 
lincRNAis18 deletion allele (Figure 2 and S7).  I contributed to the manuscript writing and 
editing.  The research in chapter 3 resulted in a first author publication in which I wrote and 
edited the manuscript with Maura McGrail.  The shared rb1 somatic inactivation-induced brain 
tumor RNA sequencing project that is currently ongoing and unpublished is described in chapter 
4.  Chapter 5 provides a summary of this thesis.
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CHAPTER 2: MOLECULAR AND CELLULAR CHARACTERIZATION OF A 
ZEBRAFISH OPTIC PATHWAY TUMOR LINE IMPLICATES GLIA-DERIVED 
PROGENITORS IN TUMORIGENESIS 
 
Adapted from: Molecular and cellular characterization of a zebrafish optic pathway tumor line 
implicates glia-derived progenitors in tumorigenesis. (2014) PLoS One 9(12):e114888 
 
Staci L. Solin, Ying Wang, Joshua Mauldin, Laura E. Schultz, Deborah E. Lincow, Pavel A. 
Brodskiy, Crystal A. Jones, Judith Syrkin-Nikolau, Jasmine M. Linn, Jeffrey J. Essner, Jesse M. 
Hostetter, Elizabeth M. Whitley, J. Douglas Cameron, Hui-Hsien Chou, Andrew J. 
Severin, Donald S. Sakaguchi, and Maura McGrail 
 
 
Abstract 
 In this study we describe the molecular and cellular characterization of a zebrafish mutant 
that develops tumors in the optic pathway. Heterozygous Tg(flk1:RFP)is18 transgenic adults 
develop tumors of the retina, optic nerve and optic tract. Molecular and genetic mapping 
demonstrate the tumor phenotype is linked to a high copy number transgene array integrated in 
the lincRNA gene lincRNAis18/Zv9_00007276 on chromosome 3. TALENs were used to isolate 
a 147kb deletion allele that removes exons 2–5 of the lincRNAis18 gene. Deletion allele 
homozygotes are viable and do not develop tumors, indicating loss of function of the 
lincRNAis18 locus is not the trigger for tumor onset. Optic pathway tumors in the 
Tg(flk1:RFP)is18 mutant occur with a penetrance of 80–100% by 1 year of age. The retinal 
tumors are highly vascularized and composed of rosettes of various sizes embedded in a fibrous 
matrix. Immunohistochemical analysis showed increased expression of the glial markers GFAP 
and BLBP throughout retinal tumors and in dysplastic optic nerve. We performed transcriptome 
analysis of pre-tumorous retina and retinal tumor tissue and found changes in gene expression 
signatures of radial glia and astrocytes (slc1a3), activated glia (atf3, blbp, apoeb), proliferating 
neural progenitors (foxd3, nestin, cdh2, her9/hes1), and glioma markers (S100β, vim). The 
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transcriptome also revealed activation of cAMP, Stat3 and Wnt signal transduction pathways. 
qRT-PCR confirmed >10-fold overexpression of the Wnt pathway components hbegfa, ascl1a, 
and insm1a. Together the data indicate Müller glia and/or astrocyte-derived progenitors could 
contribute to the zebrafish Tg(flk1:RFP)is18 optic pathway tumors. 
 
Introduction 
Glia play critical roles in the function and maintenance of the nervous system. They are 
involved in neuronal homeostasis and repair, but can also undergo reprogramming in response to 
injury to generate progenitors that repopulate missing neurons and glia (Gallo V et al., 2014) In 
the retinas of mice, frog and fish one population of cells that can be reprogrammed in response to 
injury is Müller glia (Gallina D et al., 2014). In normal retina Müller glia have stem-like 
behaviors, dividing asymmetrically to produce progenitors of the rod photoreceptor lineage 
(Stenkamp DL, 2011). After photoreceptor or retinal neuron damage, Müller glia can 
dedifferentiate and produce progenitors that give rise to the major neural retinal cell types. The 
zebrafish retina has been used extensively as a model system to investigate the molecular 
mechanisms required for this process (Lenkowski JR et al., 2014, Goldman D, 2014, Gorsuch 
RA et al., 2014). Major signal transduction pathways activated in reprogrammed Müller glia in 
zebrafish include EGF (Wan J et al., 2012), Stat3 (Sun L et al., 2014, Nelson CM et al., 2012, 
Kassen SC et al., 2009) and Wnt (Ramachandran R et al., 2011, Ramachandran R et al., 2012). 
Understanding how these signaling pathways promote glia reprogramming and neural 
regeneration is important for advancing treatments of central nervous system injury and disease. 
In this study we present the characterization and molecular cloning of a zebrafish 
transgenic line Tg(flk1:RFP)is18 that develops highly penetrant tumors in the retina and optic 
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tract with features of retinoblastoma and fibrous glioma. The tumor phenotype is linked to a high 
copy number array of an RFP expressing reporter transgene in line Tg(flk1:RFP)is18. The 
transgene integrated in a long intergenic noncoding RNA gene lincRNAis18, which was 
previously identified in the zebrafish embryonic transcriptome as Zv9_00007276 and 
Zv9_00007274 (Pauli A et al., 2012). Isolation of a second targeted deletion allele of the 
lincRNAis18 gene did not result in tumor formation, suggesting loss of function of the locus is 
not the initiating event that triggers tumor onset. Histological, cytological, and transcriptome 
analyses in pre-tumorous retina and tumor tissue reveal gene signatures of radial glia, neural 
progenitors, and injury induced activation of glia and astrocytes. The Tg(flk1:RFP)is18 tumors 
are similar to the zebrafish model of optic pathway glioma driven by activated Sonic hedgehog 
signaling in neural progenitors (Ju B et al., 2014). Our analyses indicate the Tg(flk1:RFP)is18 
tumors originate from neural progenitors derived in part from an activated glial cell population 
that includes reprogrammed Müller glia. 
 
Results 
Isolation and molecular mapping of the optic pathway tumor line Tg(flk1:RFP)is18 
We isolated a transgenic zebrafish line in which heterozygous adults develop neoplasia of 
the retina, optic nerve and optic tract. Transgenic line Tg(Tol2<flk1:RFP-CAAX>)is18 
(abbreviated as Tg(flk1:RFP)is18) was generated using a Tol2 transposon reporter construct that 
expresses membrane-targeted RFP-CAAX throughout vascular endothelial cells (Fig. 1A, B). 
Heterozygous Tg(flk1:RFP)is18 adults developed large ocular tumors that first became evident at 
approximately 5 months of age (Fig. 1C) with a penetrance of >80%. Multigenerational genetic 
analysis demonstrated that the tumor phenotype was linked to inheritance of the 
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Tg(flk1:RFP)is18 transgene, as determined by RFP expression (Fig. 1D). In each generation non-
transgenic siblings were healthy and showed no evidence of tumor formation. These results 
indicated that the tumor phenotype was due either to the location of the Tg(flk1:RFP)is18 
transgene in the genome or the presence of the transgene itself. Attempts to map the 
Tg(flk1:RFP)is18 transgene integration site by standard ligation mediated PCR and inverse PCR 
methods suggested that during isolation of the line, multiple copies of the entire 
pTol2<flk1:RFP> construct, including the vector backbone, had integrated as a concatemer 
array. We confirmed by genomic Southern blot that the Tg(flk1:RFP)is18 line contains an array 
with ∼100 copies of the Tol2<flk1:RFP> construct (Fig. 1E). Genomic DNA from 
Tg(flk1:RFP)is18 individuals from 3 consecutive generations hybridized with an RFP-specific 
probe revealed multiple bands, including the expected 1.3 kb EcoRI-ScaI fragment from the 
Tol2<flk1:RFP> construct. In each generation non-transgenic siblings that lacked RFP 
expression in vascular tissue did not inherit the concatemer (Fig. 1E). Together these results 
provided strong evidence that the transgene in line Tg(flk1:RFP)is18 is a stable, high-copy 
number concatemer that displays Mendelian transmission from one generation to the next.   
To clone the genomic DNA flanking the Tg(flk1:RFP)is18 concatemer integration site 
and map its location in the zebrafish genome, we designed a custom SureSelect Target 
Enrichment kit (Agilent Technologies) with single stranded biotinylated RNA probes that tile 
across the entire pTol2<flk1:RFP> vector (S1 A Figure; Table 1).  Random sheared 
Tg(flk1:RFP)is18 genomic DNA was hybridized to the biotinylated bait library in order to 
capture all of the concatemer transgene sequences.  Since the genomic DNA was randomly 
sheared, we predicted a percentage of the captured sequences would span the junction of the ends 
of the concatemer and the genomic DNA. Five independent genomic DNA samples isolated from 
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muscle or tumor tissue, representing 3 Tg(flk1:RFP)is18 individuals from 3 different 
generations, were captured and used to produce barcoded Illumina libraries for multiplex paired 
end sequencing (S2 Table). Sequences from the captured libraries were filtered to remove reads 
in which both ends mapped to the zebrafish genome or the pTol2<flk1:RFP> construct. The 
remaining paired end reads contained Tol2<flk1:RFP> transgene sequences at one end and 
zebrafish genomic sequences at the other. Four candidate integration sites that contained 9 or 
more reads from multiple samples (S3 Table) were chosen for further analysis. Three of the four 
sites mapped to regions with highly repetitive DNA, indicating non-specific capture of during 
hybridization. The fourth site had 80 reads that aligned to either side of position 24.212 Mb on 
chromosome 3 of the v9 zebrafish genome (S1 B Figure). This location maps in between the 
HoxBa cluster and the Hp1 heterochromatin binding protein family member cbx1a (Fig. 2A). 
The integration site was confirmed by sequencing of PCR amplification products that span the 
Tg(flk1:RFP)is18 transgene-genomic DNA junction (S1 C, D Figure). An 8 bp duplication was 
present at the integration site, which indicated a simple Tol2 transposon integration (S1 C 
Figure). However, additional molecular analyses confirmed that the high copy array detected by 
genomic southern (Fig. 1E) is also tightly linked to the integration site on chromosome 3. 
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Figure 1. Genetic linkage of zebrafish ocular tumor model in transgenic line 
Tg(flk1:RFP)is18  
(A) Endothelial-specific membrane targeted RFP expression in live 3 dpf zebrafish larva from 
transgenic line Tg(flk1:RFP)is18. (B) Endothelial-specific membrane targeted RFP expression 
and nuclear eGFP expression in live 3 dpf Tg(flk1:RFP)is18; Tg(fli1:eGFP)y1 zebrafish larva. 
(C) Gross morphology of ocular tumors in heterozygous is18/+ adults at 5 months and 1 year of 
age. (D) Pedigree of one family showing trans-generational linkage analysis of ocular tumor 
phenotype with inheritance of the Tol2<flk1:RFP> transgene in heterozygous is18/+ 
individuals. Two families, A and B, were established from the F4 generation. Marked individuals 
were used in subsequent STR/STS linkage (L/S) and Southern blot analyses (#). (E) Diagram of 
endothelial-specific RFP reporter construct pTol2<flk1:RFP-CAAX> with positions of EcoRI 
and SacI sites. Genomic Southern blot hybridized with RFP probe detects 1.3 kb EcoRI -SacI 
fragment (arrows) of the Tol2<flk1:RFP-CAAX> transgene. The high copy-number 
Tol2<flk1:RFP> transgene array is transmitted specifically to RFP expressing, tumor positive 
Tg(flk1:RFP)is18 progeny through the F6 generation. 
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 Genomic Southern blot analysis of restriction fragment length polymorphism caused by 
the transgene integration confirmed the location of the Tg(flk1:RFP)is18 concatemer on 
chromosome 3 (S2 and S3 Figures). Further confirmation of the location of the transgene 
concatemer was obtained by PCR linkage analysis with chromosome 3 sequence tagged site 
(STS) and short tandem repeat (STR) markers (S4 Figure). We identified a haplotype segregating 
on the transgene-containing chromosome 3 for 4 STS markers: Z7419, G39247, Z5197, and an 
STR in exon 5 of cbx1a (Table 1). PCR linkage analysis demonstrated that the Tg(flk1:RFP)is18 
chromosome 3 haplotype at marker Z5197 located ∼105 Kb from the integration site segregated 
with the transgene and tumor phenotype in 100 RFP expressing progeny from a tumor-bearing 
F5 adult Tg(flk1:RFP)is18 female outcrossed to a WIK wild type male (Table 1). As expected, 
one recombinant was recovered between the transgene and marker Z7419 located ∼1.05 Mb 5′ to 
the integration site (Table 1). Together with the genomic Southern blot analyses, the linkage data 
provided strong evidence that the optic pathway tumor phenotype in line Tg(flk1:RFP)is18 was 
due to the presence of a high copy number concatemer that had integrated at position 24.212 MB 
on chromosome 3. 
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Table 1. Linkage of Tg(flk1:RFP)is18 transgene integration site to position 24.219 Mb Chromosome 3. 
   Genotype Haplotype Analysis# Linkage Analysis$ 
Primer 
pair 
Marker* 
 
Chr3 
Position 
is18/+ 
F5#3 
female 
WIK 
male 
 
10 is18/+ 
siblings 
 
10 +/+ 
siblings 
 
100 is18/+ 
offspring 
100 +/+ 
siblings 
1                Z7419                  23158018           L/M              M/S             6/10 L/M          6/10 M/M         57/100  L/M        NA 
                               4/10 L/S           4/10 M/S          42/100  L/S         NA 
                                                                                                                                                                          1/100  M/M        NA  
2                G39247              24163628           L/S              L/L            10/10  L/S           10/10  L/L         NA                     NA 
3                transgene -         24219944           +                    -                10/10                  0/10                   100/100             0/100 
     genomic  DNA 
4                      transgene           -                            +                    -               10/10                   0/10                   100/100              0/100 
5                Z5197                            24324461            L/S               S/S            10/10  L/S           10/10  S/S         100/100  L/S      NA 
6                     cb1xa  STS          24360325            L/M              M/S          6/10 L/M            6/10 M/M          NA                     NA 
                              4/10 L/S              4/10 M/S           NA                     NA 
7                      Z7486                          59983229            L/S               L/S            3/10 L/L              4/10 L/L            NA                      NA 
          59983229               L/S               L/S            4/10 L/S              2/10 L/S             NA                     NA 
          59983229            L/S               L/S            3/10 S/S              4/10 S/S             NA                      NA 
 
*Microsatellite STS markers Z7419, G39247, Z5197, Z7486.  cbx1a STS is a Short Simple Repeat located in the 5th intron of 
the cbx1a gene. Genotype determined by size of PCR amplification products after gel electrophoresis. L, long; M, middle; S, 
short allele PCR products. is18 transgenic genotype (+ or -) confirmed by PCR with primers that amplify across the genomic  
DNA-transgene junction (3) or amplify an internal fragment of the transgene concatemer (4).  
#Genotype of is18/+ female and WIK male was determined. Segregation of STS markers in 10 is18/+ and 10 +/+ siblings was 
used to determine the haplotype of the chromosome containing the is18 transgene integration.  The Tg(RFP)is18 
chromosome haplotype in the region surrounding the integration site is Z7419-L, G39247-S, Z5197-L, cbx1a  STS-L.  
$100 is18/+ and 100+/+ siblings from a cross between a Tg(flk1:RFP)is18/+  female and WIK wild type male  were  genotyped 
by PCR.  1/100 Tg(flk1:RFP)is18/+ progeny was homozygous Z7419  M/M and  heterozygous G39247  L/S. This indicates a 
single recombination event between markers Z7419 and G39247 and genetic map distance of 1 centimorgan. 
 
2
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Zebrafish Tg(flk1:RFP)is18 transgene integration in the lincRNAis18 gene 
 
We searched NCBI, Ensembl, and the recent zebrafish embryonic transcriptome study 
(Pauli A et al., 2012) for long intergenic noncoding RNAs (lincRNAs) that map to the region 
between the HoxBa cluster and cbx1a on chromosome 3 and identified two. One of the genes, 
si:ch211-84g22.1 ENSDARG00000097724, was located ∼14 kb 3′ to the integration site (Fig. 
2A). The second lincRNA was identified by a ∼930 bp transcript FDR202-P00026-DEPE-
F_N10 FDR202 EH545544/Zv9_00007276 containing 8 exons that map to a genomic region 
spanning ∼350 kb (Fig. 2A). The 5′ region and first exon overlaps the cbx1a gene, and 
downstream exons 6, 7, and 8 map in the intergenic regions between genes in the HoxBa cluster 
(Fig. 2A). A shorter transcript of ∼480 bp (si:ch211-246i5.4 ENSDARG00000097621/FDR202-
P00032-DEPE-R EH568666.1/Zv9_00007274) terminates in an alternative third exon. Neither 
transcript is predicted to encode a polypeptide longer than 73 amino acids (reading frame 3). We 
named the locus encoding these transcripts lincRNAis18. The shorter transcript is designated 
lincRNAis18.v1, the longer transcript is designated lincRNAis18.v2 (Fig. 2A). The 
Tg(flk1:RFP)is18 concatemer integration site is in the second intron of lincRNAis18.v2 (Fig. 
2A). Since the concatemer contains many copies of the SV40 bidirectional polyadenylation 
sequence, the transgene is predicted to cause premature transcriptional termination of 
lincRNAis18.v2. Together, the data showed that the optic pathway tumor phenotype was linked 
to the integration of the Tg(flk1:RFP)is18 concatemer in the second intron of lincRNAis18.v2. 
 We performed a number of experiments to determine whether lincRNAis18 is involved in 
formation of ocular tumors in Tg(flk1:RFP)is18 heterozygotes. We examined the expression 
pattern of lincRNAis18 by in situ hybridization and RT-PCR to determine whether it is expressed 
in the zebrafish retina. in situ hybridization on adult retina detected a low level of lincRNAis18 
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expression in the inner nuclear layer and the ganglion cell layer (S5 A Figure), indicating it is not 
highly expressed in the retina. RT-PCR on an adult tissue panel revealed high levels of 
lincRNAis18.v2 transcripts in the male and female germline and lower levels in muscle and retina 
(S5 B Figure). High levels of maternally supplied lincRNAis18.v2 were observed in the 
developing embryo before the onset of zygotic transcription (S5 C Figure) then rapidly declined 
later stages. Multiple alternatively spliced forms of lincRNAis18 were cloned from wild type 
adult retina, ovary and embryonic and larval stages (S5 Figure). Exons 1, 2 and 8 were 
consistently present in all isoforms, indicating a possible functional role of these exons. 
Although a low level of lincRNAis18.v2 expression was detected in the retina, the specificity of 
expression in this tissue, and its absence from other adult tissues except muscle, suggested it may 
have a role in retina function. 
 To further examine the coding potential of lincRNAis18, we searched the recently 
published ribosome profiling datasets of expressed transcripts from 8 early developmental stages 
of zebrafish (Chew GL et al., 2013). The datasets included 2–4 cell, 256 cell and 1000 cell 
embryos in which a high level of maternally supplied lincRNAis18 is present. None of the ∼900 
million 35 bp sequence reads fully aligned with the lincRNAis18 sequence, providing further 
evidence that lincRNAis18 represents a novel lincRNA that most likely is not translated into a 
functional protein. Database searches showed lincRNAis18 has no significant homology with 
lincRNAs from other species. Despite the lack of homologous sequences in other vertebrate 
species, the high levels of lincRNAis18 expression in the embryo suggests it could play an 
important role in early zebrafish development. 
 To determine whether homozygosity results in additional phenotypes, all surviving 
progeny from the is18/+ heterozygous intercross were raised and sacrificed at 4 weeks of age for 
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PCR genotyping of genomic DNA. Some larvae began to develop edema by 7 dpf and as the 
larvae were aged many developed edema and did not survive. At 4 weeks of age, each of the 96 
surviving RFP-expressing juveniles was sacrificed and genotyped. All were heterozygous for a 
wild type and a Tg(flk1:RFP)is18 chromosome (data not shown), indicating that homozygous 
Tg(flk1:RFP)is18/Tg(flk1:RFP)is18 individuals die from edema between 7 dpf and 4 weeks of 
age. These data indicate that homozygous Tg(flk1:RFP)is18 larvae lack expression of 
lincRNAis18.v2 (Fig. 2B), due to premature transcription in the transgene, as predicted by the 
location of the transgene integration in intron 2. However, this does not rule out the possibility 
that the onset of edema and homozygous lethal phenotype might be caused by the presence of the 
Tg(flk1:RFP)is18 transgene concatemer or its effect on nearby genes. 
 To test the hypothesis that disruption of expression of lincRNAis18.v2 is homozygous 
lethal and involved in tumor formation, we isolated a second allele using TALEN genome 
editing to create a deletion in the lincRNAis18 gene (Fig. 2C). TALENs targeting exons two and 
five (S7 Figure) were co-injected to create a deletion that removes 147 kb of genomic DNA and 
fuses exon two to exon five. Exons further upstream or downstream were not targeted in order to 
avoid affecting the genomic region surrounding the cbx1a and HoxBa cluster genes. We 
recovered 1 founder out of 27 that transmitted the deletion allele to F1 progeny. Sequencing of 
the exon 2 - exon 5 junction fragment and genotyping with STR markers confirmed the identity 
of F1 individuals carrying the deletion allele lincRNAis18e2e5del (Fig. 2D). To test whether the 
deletion allele was homozygous lethal, heterozygous lincRNAis18e2e5del F1 adults were 
intercrossed and the progeny were raised to adulthood. Genotyping identified homozygous F2 
adults (S8 Figure), demonstrating that deletion of the genomic sequences between exons two and 
five of lincRNAis18 did not result in lethality. By 8 months neither heterozygous nor 
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homozygous lincRNAis18e2e5del adults developed ocular tumors. Together, these data suggest that 
tumor onset in Tg(flk1:RFP)is18 individuals is most likely not due to a loss of function of the 
lincRNAis18 gene, or disruption of expression of lincRNAis18.v2. However, since the deletion 
allele that was generated is predicted to produce a transcript containing exons 1, 2/5, 6, 7 and 8, 
it does not represent a null allele, and may retain some function that prevents homozygous 
lethality and tumor onset. Alternatively, because the Tg(flk1:RFP)is18 transgene mutation 
segregates as a dominant allele, it might create a dominant effect on the expression of other 
lincRNAis18 transcript isoforms. It is also possible that the presence of the high copy number 
transgene in Tg(flk1:RFP)is18 adults induces ocular tumor formation through an oncogenic 
mechanism that induces overexpression of nearby genes. Transcriptome analyses presented 
below do not support the latter mechanism. 
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Figure 2. The Tg(flk1:RFP)is18 transgene integration site on chromosome 3 disrupts 
expression of lincRNAis18.v2. 
 
 (A) Integration site of the transgene array at 24.2 Mb on chromosome 3. The integration sits 
downstream of the HoxBa cluster and upstream relative to the heterochromatin binding family 
member cbx1a. lincRNAis18 exon I overlaps with a 5’ regulatory region of the cbx1a gene. 
Positions of upstream and downstream microsatellite markers, G39247 and Z5197, and an 
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STS/STR in cbx1a, are shown. (B) RT-PCR analyses with primers in exon 1 and exon 8 of 
lincRNAis18.v2 showing expression of lincRNAis1.v2 is disrupted in 6 dpf homozygous 
Tg(flk1:RFP)is18 larvae. 5 individual larvae of each genotype are shown. The genotype of each 
larva was confirmed (Figure S6). Control, expression of ribosomal protein S6 kinase b, 
polypeptide 1, rps6kb1. (C) TALENs targeting exons 2 and 5 of lincRNAis18. (D) Predicted 
structure of the lincRNAis18e2e5del deletion allele. Sequence of amplicon spanning exon 2 – exon 
5 junction from F1 lincRNAis18e2e5del/+ adult genomic DNA. 
 
Histopathology of the zebrafish Tg(flk1:RFP)is18 optic pathway tumors reveals features of 
retinoblastoma and fibrous glioma 
 Histopathology of the tumor positive fish revealed large intraocular masses that filled the 
vitreal space and displaced the lens (Fig. 3B–D). By one year of age affected individuals 
frequently developed tumors in both eyes (Fig. 3D). Advanced retinal tumors were not 
characterized by necrosis or high mitotic activity. The tumors were composed of neuroepithelial-
like cells with areas of dysplastic tissue forming rosettes of various sizes (Fig. 3J, M 
arrowheads). Blood vessels were present throughout the tumors, indicating neovascularization in 
the advanced tumors. There were extensive glial fibrillar structures within the tumors (Fig. 3J, M 
arrow) and the optic nerve and tract (Fig. 3K, L). In advanced tumors the optic nerves and tract 
were completely replaced by neoplastic tissue, and the architecture of the brain lobes was highly 
disrupted (Fig. 3C, D, K, L). Cells having a “salt and pepper” chromatin dispersion pattern were 
present, again consistent with neuro-ectodermal tumor cell cytomorphology (Fig. 3N, 
arrowheads). Areas of necrosis were present throughout the optic lobe (Fig. 3P arrows). 
Examination of tumors in younger adults revealed relatively normal organization of the retina at 
the ciliary marginal zone. In a 5-month old adult with a large ocular mass (Fig. 3B), the neural 
retinal layers were observed to be intact at the ciliary marginal zone (Fig. 3I). These initial 
examinations indicated the ocular masses likely originated from cells located in the differentiated 
tissue of the neural retina, not from the retinal stem cell population that resides at the ciliary 
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marginal zone. Overall, the retinal tumors appeared similar to fibrous glioma with features 
present in human retinoblastoma. 
 
 
Figure 3. Histological analysis of Tg(flk1:RFP)is18 tumors reveals similarities with 
retinoblastoma and glioma. 
 
Coronal sections through heads of wild type (A, E–H) and Tg(flk1:RFP)is18/+ adults (B–D, I–
L). (B) 5-month-old Tg(flk1:RFP)is18/+ adult with retinal tumor filling the vitreous. 1-year-old 
Tg(flk1:RFP)is18/+ adults with unilateral (C) or bilateral tumors (D). Tumor cells extend 
through the optic pathway to the tectum. (E,F) Ciliary marginal zone and mature retina in wild 
type. (G) Fibrillar ribbon-like structure of a wild type optic nerve exiting the eye. (H) Section 
through forebrain shows the sacus dorsalis and left and right lobes of the anterior region of the 
optic tectum. (I) Intact ciliary marginal zone in the tumorous retina from Tg(flk1:RFP)is18/+ 
adult shown in B. Degeneration of the retinal pigment epithelium and photoreceptor outer 
segments is evident. Disorganization of the retinal layers adjacent to the ciliary marginal zone is 
present. Streaking across the inner plexiform layer appears similar to reactive Müller glia. (J) 
Advanced tumors contain rosettes and blood vessels extending throughout the tumor tissue. (K) 
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Disorganization and dysplasia in the optic nerve of the Tg(flk1:RFP)is18/+ adult in C. (L) Brain 
from the adult in panel D showing dysplasia of the optic tract with infiltration and disruption of 
normal brain structures. (M) Dysplastic areas of advanced tumor with rosettes of various sizes 
(arrowheads) and extensive glial fibrillar proliferation (arrow). (N) “Salt and pepper” chromatin 
dispersion pattern (arrowheads) consistent with a neuroectodermal tumor cell. (O) 
Disorganization of the optic nerve with absence of organized fibrils. (P) Expansion of the optic 
lobe with possible areas of necrosis (arrowheads). CMZ, ciliary marginal zone; GCL, ganglion 
cell layer; INL, inner nuclear layer; OL, optic lobe; ON, optic nerve; ONL, outer nuclear layer; 
OT, optic tract. Scale bars A, B, C, D 500 µm; E, F, G, I, J, N 20 µm; H, K, L 100 µm; M, O, P 
50 µm. 
 
 
Evidence for involvement of glia in Tg(flk1:RFP)is18 tumor proliferation 
 
 To gain further insight into the identity of the Tg(flk1:RFP)is18 retinal tumors we 
examined the expression of retinal neural markers in cryosections of tumor tissue. The calcium 
binding protein Recoverin is normally expressed in all photoreceptors in the retina (Fig. 4A), 
while the antibody RT97, which broadly recognizes neuronal intermediate filament proteins, also 
labels photoreceptor outer segments (Fig. 4A). In tumors Recoverin was detected in the cell 
bodies and RT97 labeled structures projecting into the center of the rosettes (Fig. 4E–H). RT97 
also strongly labeled the fibrous stroma of the tumor (Fig. 4E–F), indicating the presence of 
neuronal processes in this matrix. The synaptic vesicle marker SV2 was also detected throughout 
the fibrous stroma (G). These analyses were consistent with the histopathology suggesting the 
tumors likely originate from the neural retina. 
 To examine the proliferative cell populations in the Tg(flk1:RFP)is18 retinal tumors, we 
labeled adult fish with BrdU for 2 hours, followed by a 4 hour recovery period. In wild type 
retina BrdU incorporation was detected at the ciliary marginal zone where progenitor cells reside 
(Fig. 4D, arrow). Very rarely BrdU was detected in single cells in more central retina, consistent 
with the slow cycling of the Müller glia-rod photoreceptor lineage. We examined BrdU 
incorporation in advanced tumors and found robust labeling throughout the tumor mass with 
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some overlap with rosettes (Fig. 4H). BrdU did not consistently co-label cells expressing a 
specific retinal neural cell type marker, making it difficult to conclusively determine the identity 
of proliferating cells in very advanced tumors. Moreover, histopathology did not indicate high 
mitotic activity in the advanced tumors (Fig. 3). This suggests the possibility that the large 
number of cells that incorporated BrdU was not due to DNA synthesis during S phase but was 
the result of the activity of global DNA repair processes. 
 Numerous studies have demonstrated that the Müller glia can be activated in response to 
retinal injury and reprogrammed to produce progenitors that repopulate all retinal neural cell 
types (Gorsuch RA et al., 2013). To determine if the Tg(flk1:RFP)is18 tumors showed evidence 
of reprogrammed Müller glia-derived progenitors, we examined the expression of Müller glia 
and activated Müller glia markers by immunolocalization. The glial specific marker GFAP was 
detected in the Müller glia end feet located in the ganglion cell layer in wild type retina (Fig. 4I–
L). Very little GFAP expression was detected in the glia of the wild type optic nerve (Fig. 4K, 
arrow). In the Tg(flk1:RFP)is18 retinal tumors intense labeling of GFAP was detected extending 
throughout the tumor mass (Fig. 4M, N), indicating a glial cell type. Increased expression was 
also evident in the dysplastic optic nerve at the lamina cribrosa of an eye with an advanced tumor 
(Fig. 4O), indicating expansion of the astroglia of the optic nerve. To visualize activated Müller 
glia, we examined immunolocalization of Brain Lipid Binding Protein/fatty acid binding protein 
(BLBP/fabp). In wild type retinas BLBP is expressed in progenitor cells at the ciliary marginal 
zone (Fig. 4L) but is absent from Müller glia. In the Tg(flk1:RFP)is18 retinal tumors an increase 
in BLBP was detected throughout the tumor and did not appear to co-localize with GFAP 
positive Müller glia cells (Fig. 4L, P). This suggested BLPB was labeling a population of cells 
distinct from mature Müller glia. Together these results indicate Tg(flk1:RFP)is18 tumors might 
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be the result of abnormal levels of glial proliferation, with features similar to activated Müller 
glia and the neural progenitors derived from them. 
 
 
Figure 4. Characterization of lincRNAis18 tumors indicates a glial cell origin. 
 
Immunolabeling and in situ hybridization of cryosections from wild type retina (A–D, I, J, M–P) 
and advanced lincRNAis18 tumors (E–H, K, L, Q–T). Cells in rosettes in the tumors label with 
neurofilament marker RT-97 (red) and photoreceptor marker recoverin (green) (E, F). The 
synaptic vesicle marker SV2 (green), which is enriched in the retinal plexiform layers (C), was 
distributed throughout the fibrous tumor mass (G). (D) BrdU (green) incorporated into 
proliferating progenitor cells at the ciliary marginal zone of the wild type retina (arrow). (H) 
Intense labeling of BrdU incorporation was detected in cells forming rosettes and throughout the 
tumor mass. In wild type the glial marker GFAP is most evident in the Müller glia end feet that 
sit in the retinal ganglion cell layer (I–L). GFAP expression is absent in the oligodendrocytes and 
astrocytes of the optic nerve (I, K arrow). In contrast, GFAP was readily detected in long streaks 
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throughout the tumor tissue (M, N, P), and was expressed by cells in the mutant optic nerve (O, 
arrow). BLBP is present at the ciliary marginal zone of wild type retina (L) and appeared present 
throughout the tumor mass (P). A, E, I, M, Differential interference contrast (DIC) overlay on 
immunofluorescence labeling images. CMZ, ciliary marginal zone; GCL, ganglion cell layer; 
INL, inner nuclear layer; ON, optic nerve; ONH, optic nerve head; ONL, outer nuclear layer. All 
scale bars represent 50 µm, except in panels K and O scale bars represent 100 µm. 
 
Differential gene expression analysis of Tg(flk1:RFP)is18 retinal tumor progression 
 
 To identify the molecular signatures that correlate with onset and tumorigenesis of 
Tg(flk1:RFP)is18 tumors we performed differential gene expression analysis by RNA-Seq. 
Libraries were prepared from 6 month old age-matched wild type retina (Wild Type), pretumor 
retina from heterozygous Tg(flk1:RFP)is18 adults (Pretumor), and advanced tumor tissue from 
heterozygous Tg(flk1:RFP)is18 adults (Tumor) (S6 Table). The data was mapped to the 
zebrafish v9 genome, gene model assembly version 71 (S7 Table). The gene models included 
1133 recently identified lincRNAs expressed during early zebrafish development (Pauli A et al., 
2012). Genes with FPKM (Fragments Per Kilobase per Million sequenced reads) value of > = 1 in 
Wild Type retina were examined for significant changes in expression level in Pretumor and 
Tumor samples (S7 Table). GO term analysis (Table 2) indicated translational activity was 
elevated in Pretumor and Tumor tissue. In Pretumor and Tumor tissue cellular respiration was 
decreased; photoreception and ion transport processes were also decreased in tumor. Consistent 
with the GO term analysis, the gene set that showed the greatest down-regulation between Wild 
Type and Tumor was enriched for genes that function in photoreceptor maintenance and 
photoreception (S8 Table), indicating that in the Tg(flk1:RFP)is18 tumors, normal 
photoreception and synaptic transmission are disrupted. As expected for proliferating tumor, 
mitosis and cell division processes were increased in Tg(flk1:RFP)is18 tumors. 252 of the 1133 
lincRNAs identified in the zebrafish embryonic transcriptome were expressed in wild type retina 
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(S7 Table). 11 of the 252 lincRNAs were significantly increased or decreased in expression level 
in Pretumor and/or Tumor tissue (S9 Table). 
 We examined the expression levels of genes that map in the region of the 
Tg(flk1:RFP)is18 transgene integration in order to determine if the array influenced expression 
of nearby genes. Only 5 reads in the wild type retina transcriptome mapped to lincRNAis18, 
indicating the majority of lincRNAis18 mRNA was lost during isolation of polyadenylated RNA 
for RNA-Seq library construction. We confirmed this by RT-PCR using the input RNA for 
library construction and samples of the resulting libraries. The presence of lincRNAis18 mRNA 
was detected by RT-PCR in the total RNA input sample, but was only detectable in the wild type 
RNA-Seq library after nested RT-PCR (S9 Figure). The lincRNA si:ch211-84g22.1, located in 
intron 2 of lincRNAis18 and positioned 14 kb 3′ to the Tg(flk1:RFP)is18 transgene integration 
site, was only represented by 4 reads in wild type retina. Expression levels of si:ch211-84g22.1 
in Tg(flk1:RFP)is18 Pre-Tumor and Tumor tissue were increased (98 and 132 reads total), but 
did not significantly change between the two samples. These results raise the possibility that the 
dominant nature of the Tg(flk1:RFP)is18 transgene to induce tumors could be the result of 
activation of expression of the nearby lincRNA si:ch211-84g22.1. Other genes located in the 
region of the Tg(flk1:RFP)is18 transgene integration were examined for altered expression. No 
significant change in expression level was detected for genes that map within 1 Mb upstream or 
downstream of the transgene integration, including the HoxBa cluster and cbx1a genes. Overall, 
the analyses indicate the Tg(flk1:RFP)is18 transgene integration is responsible for inducing 
tumor formation, but the mechanism does not involve altering the expression level of genes in cis 
other than the lincRNA si:ch211-84g22.1. 
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Table 2. Categories of biological processes altered in Tg(flk:RFP)is18/+  Pre-tumor and Tumor tissues. 
 
 
*DGE Group: Differential Gene Expression Group. Genes were grouped according to direction of change in expression level 
in Pretumor and Tumor tissue. 
DGE Group* GO Process p-value 
Increased in Pretumor      translation                                                                                                        4.50e-13 
ribonucleoprotein complex  biogenesis                                 9.59e-8 
regulation  of translational initiation                                        5.62e-5 
ribosome biogenesis                                                            9.28e-5 
Decreased in Pretumor     cellular respiration                                                                       9.38e-7 
energy  derivation  by oxidation of organic  compounds        4.53e-5 
ATP metabolic  process                                                       9.01e-5 
Increased in Tumor                ribonucleoprotein complex  biogenesis                                1.99e-13 
translation                                                                                     3.86e-12 
mitotic cell cycle                                                                          9.48e-9 
cell division                                                                                 5.02e-7 
Decreased in Tumor             sensory perception of light stimulus                                         2.00e-4 
cellular respiration                                                                       3.11e-3 
ion transport                                                                        3.67e-3 
 
4
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Human Mutation-Driver and Glioma Marker Genes 
 We examined the Tg(flk1:RFP)is18 tumor differentially expressed gene set for changes 
in tumor suppressors and oncogenes that identify disrupted signal transduction pathways in 
cancer. Although the ocular tumors showed features of retinoblastoma tumors, the expression 
level of the rb1 tumor suppressor was unchanged in pretumor and elevated ∼3 fold in tumor 
tissue (S7 Table), indicating the tumors do not arise due to deletion of the rb1 locus. 62 of the 
138 designated Mutation-Driver human cancer genes (Vogelstein B et al., 2013) showed at least 
a 2-fold change in expression (Fig. 5A). In the Wnt signaling pathway, two direct molecular 
targets of ß-catenin transcriptional activation, the myc oncogene (He TC et al., 1998) and cell 
cycle regulator cyclinD1 (Tetsu O et al., 1999), showed significant increases in expression in 
Tg(flk1:RFP)is18 tumor tissue. Two tumor suppressors in the PI3K-mTOR pathway altered in 
the majority of human gliomas (Banerjee S et al., 2011, Kaul A et al., 2012, Rodrigues EF et al., 
2011), PI3K regulatory subunit pi3kr1 and the tsc1 repressor of mTOR, were decreased in 
expression level in the Tg(flk1:RFP)is18 tumors (Fig. 5A and S7 Table). The tumors showed a 
significant increase in expression of glioma diagnostic markers (Rodriguez FJ et al., 2013, Chen 
YH et al., 2013, Brennan CW et al., 2013) vimentin (vim), S100ß (s100ß) and the matrix 
metalloprotease mmp9 (Table 3). The zebrafish homolog of the putative tumor suppressor ajap1 
(Lin N et al., 2012) was also significantly decreased in expression in Tg(flk1:RFP)is18 tumor 
tissue (Table 3). qRT-PCR confirmed ajap1 decreased in expression 4-fold (Fig. 5C). These data 
are consistent with the histological and immunohistochemical data that suggests 
Tg(flk1:RFP)is18 retinal tumors express a glial gene signature. 
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Figure 5. Differential gene expression analysis of retina RNA-Seq from wild type, pre-
tumor, and retinal tumor tissues. 
A, B Heat map representations of differentially regulated transcripts associated with tumor 
initiation and progression. (A) Differential gene expression of 62 Mutation-Driver genes. Tumor 
suppressors are in green, oncogenes are in red. (B) Differential gene expression of genes required 
for photoreceptor and neural function, neural progenitor proliferation, and injury induced 
regeneration. Scale represents log2 fold change in gene expression. (C) Comparison of absolute 
fold change in gene expression levels for ajap1, ascl1a, atf3, bysl, hbegfa, and insm1a measured 
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by RNA-Seq (upper panel) and qRT-PCR (lower panel). Tg(flk1:RFP)is18/+ Pretumor (red bars) 
and Tg(flk1:RFP)is18/+ Tumor (blue bars). 
 
 
Glial activation and Neuronal Progenitors 
 
 Two populations of glia cells in the retina may contribute progenitor cells that give rise to 
the Tg(flk1:RFP)is18 tumors. The Müller glia reside within the neural retina and in the mature 
retina function as late retinal progenitors that produce the rod photoreceptor lineage. The nerve 
fiber layer contains astrocytes that migrate into the retina from the optic nerve during 
embryogenesis. We examined the transcriptome data for changes in gene expression of markers 
for glia, glial progenitors, reactive astrocytes and activated Müller glia. Glutamate transporter 
GLAST/SLC1A3 has been identified as a marker of radial glia, glial progenitor cells, and glial 
progenitor-derived astrocytes (Shibata T et al., 1997). Zebrafish slc1a3a and -b were both 
significantly increased in expression in the Tg(flk1:RFP)is18 tumors (Table 3). Activating 
transcription factor 3 (ATF3) is a member of the cAMP-response element binding protein family 
of transcriptional activators that bind the CRE (cAMP response element) enhancer and are 
activated in response to a rise in cytosolic cAMP levels. atf3 expression increases in the retinal 
ganglion and nerve fiber layers of the retina and the optic nerve after injury to the optic nerve in 
adult zebrafish (Saul KE et al., 2010). In the Tg(flk1:RFP)is18 transcriptome atf3 expression 
levels increased significantly in Pretumor and Tumor tissue (Table 3). In contrast, bystin (bysl), 
whose expression increases substantially after optic nerve injury and marks reactive astrocytes 
(Neve LD et al., 2012), remained unchanged (S7 Table). Changes in expression levels of atf3 
and bysl were confirmed by qRT-PCR (Fig. 5C). These data indicate reactive gliosis was not 
solely responsible for the increased expression of glial progenitor markers in the 
Tg(flk1:RFP)is18 ocular tumors. 
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 Many of the genes required for proliferation of neuroglial progenitor cells were increased 
in expression level in the Tg(flk1:RFP)is18 tumor tissue. This included nerve growth associated 
factor gap43, neural stem cell intermediate filament protein nestin, and neural cadherin 2 cdh2 
(Table 3). Transcription factors required in neural stem cells (foxd3, sox21b, sox4a, sox4b, 
sox11a and sox11b) were also increased in Tg(flk1:RFP)is18 Tumor tissue (Fig. 5B; Table 2). In 
response to photoreceptor degeneration after retinal injury, the Müller glia become activated to 
reenter the cell cycle and produce retinal progenitors. The gene expression pattern that defines 
proliferating Müller glia (apoeb, blbp, cdh2, hes1, rlbp1a and –b) also showed increased 
expression in the Tg(flk1:RFP)is18 tumors. Reprogramming of Müller glia is mediated by 
activation of multiple signal transduction pathways (Lenkowski JR et al., 2014). The JAK/Stat 
cytokine signal transduction pathway transcription factor stat3, which is required for 
proliferation after light dependent retinal injury and regeneration (Nelson CM et al., 2012, 
Kassen SC et al., 2009) was elevated nearly 3-fold in the tumor (Table 3). Wnt-ß-catenin signal 
transduction is activated in Müller glia derived progenitors via a network involving heparin 
binding epidermal growth factor hbegf, the transcriptional activator ascl1a, and the 
transcriptional repressor insm1a (Wan J et al., 2012, Ramachandran R et al., 2012). Each of these 
genes was significantly increased in the Tg(flk1:RFP)is18 Tumor, while the wnt antagonist 
dkk1b was significantly decreased in expression (Table 3). We confirmed the differential gene 
expression of hbegfa, ascl1a, and insm1a by qRT-PCR (Fig. 5C). Together, these data are 
consistent with the hypothesis that Tg(flk1:RFP)is18 retinal tumors might arise from neural 
progenitors derived from Müller glia and/or astroglia. 
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Table 3. Differential Expression of Neural Progenitor, Müller glia Regeneration, and Glioma Genes in 
Tg(flk1:RFP)is18/+ tumor progression. 
      Fold change 
Gene Gene Name Zebrafish Gene ID and Symbol 
WT--> 
Pretumor 
WT--> 
Tumor 
Neuroglial 
Progenitors         
atf3 activating transcription factor 3 ENSDARG00000007823_atf3 7.7 63.1 
foxd3 forkhead box D3 transcriptional activator ENSDARG00000021032_foxd3 17.7 177.7 
gap43 growth associated protein 43, nerve growth factor ENSDARG00000015775_gap43 3.1 52.8 
nestin neural stem cell intermediate filament protein ENSDARG00000088805_nes 8.7 162.1 
slc1a3a glutamate transporter GLAST/SLC1A3 ENSDARG00000026218_slc1a3a 2.1 3.4 
slc1a3b glutamate transporter GLAST/SLC1A3 ENSDARG00000043148_slc1a3b 1.3 43.6 
sox4a SRY-box-related 4a transcriptional activator ENSDARG00000004588_sox4a 2 5.4 
sox4b SRY-box-related 4b transcriptional activator ENSDARG00000043235_sox4b 1.6 6.1 
sox11a SRY-box-related 11a transcriptional activator ENSDARG00000077811_sox11a 1.2 4.4 
sox11b SRY-box-related 11b transcriptional activator ENSDARG00000095743_sox11b 2.3 18.5 
sox21b SRY-box-related 21b transcriptional activator ENSDARG00000008540_sox21b 13 469 
Muller glia*         
apoeb apolipoprotein Eb ENSDARG00000040295_apoeb 10.7 13.7 
blbp brain lipid binding protein ENSDARG00000007697_fabp7a 2.2 17.7 
cdh2 neuronal cadherin 2 ENSDARG00000018693_cdh2 1.2 3.4 
hes1 hairy/enhancer of split 1 transcriptional repressor ENSDARG00000056438_her9 1.3 12.6 
gfap glial fibrillary acid protein ENSDARG00000025301_gfap 2.3 2.5 
rlbp1a retinaldehyde binding protein 1 ENSDARG00000012504_rlbp1a 1.9 1.3 
rlbp1b retinaldehyde binding protein 1 ENSDARG00000045808_rlbp1b 2.4 2.1 
4
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Table 3 Cont. Differential Expression of Neural Progenitor, Müller glia Regeneration, and Glioma Genes in 
Tg(flk1:RFP)is18/+ tumor progression. 
      Fold change 
Gene Gene Name Zebrafish Gene ID and Symbol 
WT--> 
Pretumor 
WT--> 
Tumor 
Muller glia 
regeneration#         
ascl1a achaete-scute like 1a transcriptional activator ENSDARG00000038386_ascl1a 4.6 13.8 
dkk1b dickkopf 1, wnt antagonist ENSDARG00000045219_dkk1b 0.9 0.2 
hbegfa heparin binding epidermal-like growth factor ENSDARG00000075121_hbegfa 24.4 48.8 
hbegfb heparin binding epidermal-like growth factor ENSDARG00000031246_hbegfb 2.4 9.4 
insm1a insulinoma 1a transcriptional repressor ENSDARG00000091756_insm1a 2.3 12.7 
stat3 signal transduction and activator of transcription 3 ENSDARG00000022712_stat3 1.9 2.9 
Glioma genes$         
ajap1 Adherens Junction Associated Protein 1 ENSDARG00000038655_ajap1 1 0.2 
mmp9 matrix metalloprotease 9 ENSDARG00000042816_mmp9 2 7.4 
S100ß neural calcium binding protein ENSDARG00000057598_s100b 1.6 5 
vim vimentin ENSDARG00000010008_vim 2.8 9.6 
4
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Discussion 
 In this report we describe the isolation and characterization of a zebrafish optic pathway 
tumor line that is linked to integration of a Tol2<flk1:RFP-CAAX> transgene concatemer in line 
Tg(flk1:RFP)is18. By 1 year, greater than 80% of heterozygous Tg(flk1:RFP)is18 adults develop 
tumors in the retina, optic nerve and optic tract with features of retinoblastoma and fibrous 
glioma. Histological, immunohistochemical, and transcriptomic analyses of Tg(flk1:RFP)is18 
ocular tumors are consistent with the tumor originating in part from a glial cell population in the 
retina that includes the Müller glia. Astrocytes residing within the optic nerve fiber layer may 
also contribute to the retinal tumor cell progenitor population. The dominant pattern of 
inheritance indicates the presence of the transgene results in an oncogenic mechanism that 
induces tumor onset. The Tg(flk1:RFP)is18 transgene integration is homozygous lethal, and 
animals die between 1 and 4 weeks of age. The transgene disrupts expression of the lincRNA 
gene, lincRNAis18 (Zv9_00007276) but elevates expression of the opposite strand lincRNA 
si:ch211-84g22.1 ∼25 fold. A second deletion allele generated using TALEN genome editing 
that removes exons 2–5 of lincRNAis18 and the entire lincRNA si:ch211-84g22.1 locus did not 
result in a tumor or lethal phenotype. This suggests that in line Tg(flk1:RFP)is18 the presence of 
the Tol2<flk1:RFP-CAAX> array is responsible tumor formation and lethality, however, the 
mechanism underlying tumor onset is not known. 
 Our study provides several pieces of evidence that the Tg(flk1:RFP)is18 retinal tumors 
likely originate from glial-derived neural progenitors in the retina. The Tg(flk1:RFP)is18 
phenotype is very similar to the previously reported zebrafish optic pathway glioma model in 
which activation of Sonic hedgehog signaling in neural progenitors induces tumors (Ju B et al., 
2014). Radial glia in the CNS are the source of neural stem cells and glial progenitors during 
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development and in adult neurogenesis (Rowitch DH et al., 2010). The dramatic increase in 
expression of the radial glial marker GLAST/slc1a3b (Shibata T et al., 1997) and the neural stem 
cell markers foxd3, nestin, sox4, sox11, and sox21 in Tg(flk1:RFP)is18 tumor tissue supports a 
neuroglial progenitor population. The CREB transcriptional activator ATF3 and the reactive 
astrocyte marker Bystin are associated with reactive gliosis and are upregulated in the optic 
nerve in response to injury (Saul KE et al., 2010, Neve LD et al, 2012). While atf3 was 
dramatically increased in expression in the Tg(flk1:RFP)is18 retinal tumors, zebrafish bystin-like 
(bysl) showed no change in expression level. Consequently, the activation of glia in the 
Tg(flk1:RFP)is18 model is not merely a result of reactive gliosis due to insult or injury in the 
retina. ATF3 is a member of the cAMP-response element binding protein family of 
transcriptional activators that bind the CRE (cAMP response element) enhancer and are activated 
in response to a rise in cAMP levels. In fetal brain, synergism between the cytokine LIF and 
BMP signal transduction pathways is mediated by CREB, which acts as a bridge between 
STAT3 and smad1 to promote astrocyte formation from neural progenitors (Nakashima K et al., 
1999). Consistent with increase in CREB family member ATF3, both zebrafish smad1 and stat3 
expression levels were elevated in Tg(flk1:RFP)is18 tumors, indicating a role for cAMP signal 
transduction in tumor growth. 
 Activation of multiple signal transduction pathways required for inducing Müller glia 
proliferation and progenitor production was observed in the Tg(flk1:RFP)is18 ocular tumors. 
Müller glia markers, such as apolipoprotein Eb, apoeb, brain lipid binding protein, blbp, and 
hairy/enhancer of split 1 transcriptional repressor, hes1 (Raymond PA et al., 2006), were 
significantly increased in the tumors. The JAK/Stat signal transduction and transcriptional 
activator stat3, which is required to stimulate Müller glia proliferation in the injured zebrafish 
49 
 
retina (Nelson CM et al., 2012, Kassen SC et al., 2009), was elevated as well in tumor tissue. 
The insm1a, ascl1a/dkk1b, and hbegf pathways that active wnt signaling to induce Müller glia 
proliferation (Wan J et al., 2012, Ramachandran R et al., 2011, Ramachandran R et al., 2012) 
were also significantly altered. Together these data support the hypothesis that the Müller glia in 
the Tg(flk1:RFP)is18 retinas dedifferentiate and produce transformed neuroglial progenitors. 
Retinal tumor progenitors might also arise from astrocytes located in the nerve fiber layer. 
Overall, the transcriptome data, histological analyses, and immunohistochemical labeling of 
tumor tissue provides significant support for the conclusion that transformed glia give rise to the 
Tg(flk1:RFP)is18 tumors. Identifying the mechanism that initiates glial progenitor proliferation 
in the Tg(flk1:RFP)is18 retina will require additional studies. The zebrafish Tg(flk1:RFP)is18 
line presents a highly penetrant and consistent retinal tumor model that will be useful for 
investigating the mechanisms driving glia activation and reprogramming in the vertebrate central 
nervous system. 
 
Ongoing and Future Studies 
 Recent Tg(flk1:RFP)is18 studies have focused on investigation of the mechanisms 
underlying tumor initiation.  Differential gene expression analysis on 6 month old age-matched 
wild type retina, pretumor retina from Tg(flk1:RFP)is18 heterozygotes and advanced retinal 
tumor tissue from Tg(flk1:RFP)is18 heterozygotes has yielded potential insights.  GO Term and 
Ingenuity Pathway Analysis suggests that tumor initiation correlates with activation of hypoxia, 
growth factor, and cytokine signaling pathways. GO Term analysis of the differential gene 
expression data demonstrates down-regulation of genes associated with cellular respiration and 
ATP-dependent metabolism in the pretumor, processes indicative of a hypoxic response 
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Wheaton WW et al., 2011).  In support of these findings, significant upregulation of hypoxia-
inducible factor 1 alpha (hif1a) downstream targets including vascular endothelial growth factor 
VEGF and the cytokine leptin, was observed in the pretumor transcriptome (Forsythe JA et al., 
1996, Grosfeld A et al., 2002).  The VEGF and leptin signaling pathways play a role in 
regulating proliferation of neural progenitors suggesting a potential function for these pathways 
in Tg(flk1:RFP)is18 retinal tumor initiation (Hashimoto T et al., 2006, Perez-Gonzalez R et al., 
2011).  Our data suggests that within the Tg(flk1:RFP)is18 retina a hypoxic environment induces 
a chronic inflammatory response that leads to activation of pathways that promote sustained 
proliferation of progenitors and tumor initiation and growth.  To further explore the relationship 
between the hypoxic response and Tg(flk1:RFP)is18 tumor initiation and growth, we are 
currently using double in situ hybridization to identify the cell populations within the wild type 
and pretumor retinas that may be responding to the hypoxic environment by increased expression 
of VEGF, leptin and other genes within these pathways.  In the future, RNA-seq analysis of 
retinas from younger Tg(flk1:RFP)is18 heterozygotes and from Tg(flk1:RFP)is18 homozygous 
larvae may provide further insights into the mechanisms of tumor initiation.  The 
Tg(flk1:RFP)is18 retinal tumor model provides an opportunity for examining the relationship 
between inflammation, injury, and cancer. 
 
Materials and Methods 
Zebrafish husbandry and genetics 
 Zebrafish were reared in an Aquatic Habitat system (Aquatic Ecosystems, Inc., Apopka, 
FL). Fish were maintained on a 14-hr light/dark cycle at 27°C. Transgenic lines were established 
in a WIK wild type strain obtained from the Zebrafish International Research Center 
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(http://zebrafish.org/zirc/home/guide.php). For in situ hybridization experiments, embryos were 
collected and maintained at 28.5°C in fish water (60.5 mg ocean salts/l) containing 0.003% 1-
phenyl-2-thiourea (PTU) until harvesting. Embryos were staged according to published 
guidelines (Kimmel CB et al., 1995). All experimental protocols were approved by the Iowa 
State University Institutional Animal Care and Use Committee (Log # 11-06-6252-I) and are in 
compliance with American Veterinary Medical Association and the National Institutes of Health 
guidelines for the humane use of laboratory animals in research. Adult fish were anesthetized 
and euthanized in MS-222 Tricaine Methanesulfonate prior to sacrifice and tissue dissection for 
histopathology and immunolabeling. 
 
Animal Care and Humane Endpoint Establishment 
 Transgenic fish predisposed to tumor formation were raised side by side with non-
transgenic siblings. Heterozygous and homozygous transgenic fish and sibling fish were 
monitored daily during routine feeding for viability and morbidity, and monitored bi-weekly for 
gross presentation of ocular tumors. 50% of each generation of transgenic fish developed 
pericardial edema. All homozygous transgenic fish presented with pericardial edema beginning 
at 2-7 dpf and developing through 4 weeks of age. Fish presenting with edema were sacrificed 
before swimming and feeding behavior were adversely affected. Juvenile and adult fish were 
anesthetized and euthanized in MS-222 Tricaine Methanesulfonate according to experimental 
protocols approved by the Iowa State University Institutional Animal Care and Use Committee 
(Log # 11-06-6252-I) in compliance with the American Veterinary Medical Association and the 
National Institutes of Health guidelines for the humane use of laboratory animals in research. 
 NIH/Office of Animal Care and Use/Animal Research Advisory committee (ARAC) 
52 
 
Guidelines for endpoint in neoplasia studies (oacu.od.nih.gov/ARAC/Guidelines for Endpoints in 
Animal Study Proposals) were used to establish a humane endpoint in the zebrafish heterozygous 
Tg(flk1:RFP)is18 glioma tumor model. Adult fish were monitored bi-weekly for general 
appearance and assessed for size and length relative to non-transgenic siblings. Fish were 
sacrificed before tumor burden reached 3 mm in size/25mg in weight, constituting less than 10% 
of the total body weight of an adult fish (300-500mg), as outlined for mouse and rat studies 
(Workman P et al., 2010). No adverse effect on growth rate, feeding behavior or fertility was 
detected in Tg(flk1:RFP)is18 fish with a tumor burden less than 3mm/10% of body weight. For 
transcriptome studies age matched 6 month old fish with tumor size ranging from undetectable to 
2 mm in size were anesthetized and euthanized in MS-222 Tricaine Methanesulfonate. Retinal 
and tumor tissue was dissected for isolation of total RNA. In each generation of 
Tg(flk1:RFP)is18 fish, individuals presenting with ocular tumors were sacrificed when tumor 
burden reached 3mm/25mg of total body weight, or by 1 year of age, whichever endpoint was 
first reached. 
 
Isolation of transgenic line Tg(flk1:RFP)is18 
 The endothelial specific membrane targeted RFP reporter construct flk1:RFP-CAAX was 
assembled using standard PCR cloning methods. The zebrafish promoter for the flk1 gene was 
amplified from WIK genomic DNA. The construct was cloned into the minipTol2 transgenesis 
vector (Balciunas D et al., 2006). Transgenics were isolated by co-injection of in vitro 
transcribed, capped, polyadenylated Tol2 transposase mRNA (Balciunas D et al., 2006) and the 
pTol2<flk1:RFP-CAAX> construct into 1 cell zebrafish WIK embryos, as described previously 
(Laio HK et al., 2012). Three independent lines expressing RFP in the endothelial cells of the 
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vasculature were isolated. Line Tg(flk1:RFP)is18 contains a high copy number array 
Tol2<flk1:RFP-CAAX>. The Tg(flk1:RFP)is18 line is available upon request. 
 
Tol2<flk1:RFP>is18 transgene integration site cloning 
 A custom RNA bait library (Agilent) was used for capture of the Tol2<flk1:RFP> 
transgene concatemer and flanking genomic DNA sequences following the Agilent SureSelect 
Targeted Capture protocol. Briefly, a panel of overlapping biotin-labeled RNA baits (Table S1) 
complementary to the pTol2<flk1:RFP> construct was synthesized.  Genomic DNA from 5 
samples was subjected to shearing, hybridization capture, library amplification, and index 
barcoding as outlined in the Custom SureSelect Target Enrichment protocol (Agilent). Genomic 
DNA was isolated from muscle tissue from one Tol2<flk1:RFP>is18/+ heterozygous adult from 
the F2, F3 and F4 generation of the is18 pedigree was isolated. Genomic DNA was also isolated 
from the tumor tissue from the F3 and F4 individuals. The genomic DNA was isolated with the 
Agilent SureSelect gDNA Extraction kit (Agilent). 3 g of genomic DNA from each of the 5 
samples was sheared to ~250bp (Covaris, Inc., Woburn, MA). The SureSelect Captured Libraries 
were 75 bp paired end multiplex sequenced in one lane on an Illumina GA II instrument at the 
Iowa State University DNA Facility. The number of reads per sample was: Sample 1, 1519937; 
Sample 2, 4790568; Sample 3, 6396525; Sample 4, 10262541; Sample 5, 23644059. Each pair of 
PE fastq files was aligned using GSNAP (Wu TD et al., 2010) to the Danio rerio reference 
genome (Zv9 64) amended with the pTol2<flk1:RFP> construct sequence as a separate scaffold. 
Reads were filtered to remove those that failed to map to both the transgene and a unique 
location in the zebrafish genome. The remaining reads were used to identify 1000 bp intervals in 
the genome that had a higher level of mapped reads than expected by random chance using a 
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modification of a previously published bootstrap method written in the R programming language 
(Severin AJ et al., 2010). 4 locations were identified in which paired end sequences had one end 
mapped to the pTol2<flk1:RFP> construct and the other end mapped to a unique, non-repetitive 
sequence in the genome (Table S3). Each site was tested for confirmation by PCR amplification 
of the predicted transgene-chromosome junction fragment with primers complementary to the 
pTol2<flk1:RFP> construct and the flanking genomic DNA (Table S4). Only one of the 4 sites, 
chromosome 3:24,212,813-24,212,885, was validated by amplification in all 5 samples (Figure 
S1 B, C). A total of 81 sequences in the 5 samples mapped to the transgene and to genomic DNA 
flanking either the 5’ or 3’ sides of the integration site at 24,212,944 on chromosome 3 (Figure 
S1 D).  
 
Genomic Southern blot analyses 
 Genomic DNA was isolated from adult zebrafish using a Qiagen midiprep kit and 
chemiluminescent non-radioactive Southern blot analyses performed as described previously 
(McGrail MM et al., 2011). Sequences of primers for probes for genomic Southern analyses: 450 
bp probe complementary to chr 3 position 24,214,849 - 24,215,303; forward 5' 
CTCATTCTGTCCATGTGTTCACAG 3', reverse 5' CTTCTTGCCTGACTTTCACAGCC 3’: 
450 bp probe complementary to chr 3 positions 24,211,859 - 24,212,364; forward 5' 
CTGACAAGCAGCTGACAGATTGG 3', reverse 5' GGAAGTTGCTCTCATAATTCACG 3': 
450 bp probe complementary to RFP cDNA; forward 5' CTTCAGGGCCATGTCGCTTCTG 3', 
reverse 5' CATGGAGGGCACCGTGAACAA 3': 477 bp probe complementary to lactamase 
cDNA in pTol2 vector backbone; forward 5' ATCAGTGAGGCACCTATCTCAGC 3', reverse 5' 
CATAACCATGAGTGATAACACTGC 3'.   
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Imaging, histopathology and immunohistochemistry 
 Living 3 dpf embryos were anesthetized in Tricaine, mounted in 1% low melt agarose, and 
imaged on a Zeiss LSM700 Confocal microscope. Whole heads dissected from adult zebrafish 
were fixed in 10% Formalin (Fisher) or Davidson’s fixative (2:3:1:3 Formalin:Ethanol:Glacial 
Acetic Acid:Water) for 16 hr at 4oC, decalcified in Cal-Ex (Fisher) for 2 days at 4oC, then 
processed and embedded in paraffin at the Iowa State University Clinical Histopathology 
Laboratory. Paraffin blocks of head tissue were serial sectioned at 6um on a Shandon Finesse 
325 microtome, stained with Hematoxylin 7211 Richard-Allan Scientific (Fisher) and 3% Eosin 
Y (Argos Organics), and mounted with Permount (Fisher). Sections were imaged on a Zeiss 
Axioskop II using Nikon Coolpix and Nikon Rebel cameras. 
 For immunohistochemistry heads were removed from anesthetized adults and fixed in 4% 
paraformaldehyde overnight at 4oC, decalcified in Cal-Ex for 2 days at 4oC, then processed for 
embedding in optimal cutting temperature (OCT) medium (Fisher). Heads were serial sectioned 
at 12 m on a Microm HM 550 cryotstat at 25oC. For BrdU labeling experiments, adults were 
incubated in 5 M BrdU (Sigma) in fish water (60.5mg ocean salts/l) for 2 hours, placed in fresh 
fish water for 4 hours, then sacrificed and processed as above for immunohistochemical labeling 
experiments. Antibody labeling of cryosectioned tissue was as described previously (Nelson CM 
et al., 2012, Blong CC et al., 2010). Dilutions and primary antibodies used for labeling sectioned 
tissue were as follows: rabbit polyclonal anti-recoverin 1:1000 (Millipore); mouse monoclonal 
anti-glial fibrillary acid protein GFAP 1:1000 obtained from the Zebrafish International Research 
Center (ZIRC); rabbit polyclonal anti-Brain Lipid Binding Protein BLBP 1:200 (Abcam); mouse 
monoclonal anti-SV2 1:100 (Developmental Studies Hybridoma Bank); mouse monoclonal anti-
RT97 1:250 (Developmental Studies Hybridoma Bank); anti-BrdU 1:500 (Bio-Rad). Alexa-594 
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and Alexa-697 conjugated secondary antibodies (Invitrogen) and Cy3 and Cy5 conjugated 
secondary antibodies (Jackson Immunoresearch Labs) were used at a dilution of 1:500. Tissues 
were counterstained with 5 g/ml DAPI (Sigma) and mounted in Fluorogel (EMS). To aid 
antigen retrieval tissues were pretreated with 2M HCl (for anti-BrdU labeling). 
Immunofluorescent labeling of cryosections was imaged on a Nikon Microphot-FXA microscope 
and captured using a QImaging Retiga 2000R Fast 1394 camera and QCapture software. All 
images were edited and assembled in Adobe Photoshop CS2. 
 
RT-PCR and in situ hybridization 
 Total RNA for staged developmental series, tissue panel, and analysis of homozygous 
embryos, was isolated with a Qiagen RNeasy Isolation Kit. RT-PCR was carried out using a 
One-Step RT-PCR Kit (Invitrogen). cDNA for lincRNAis18 was amplified by RT-PCR out of 
total RNA isolated from wild type 48 hpf embryos or adult retina. cDNAs were cloned into 
pBluescript or the pCR4-TOPO vector (Invitrogen). Primers for amplification were as follows: 
lincRNAis18 forward1 5' TCACTGTCTGCTGCTGACGATC 3’, lincRNAis18 nested forward 5’ 
GACAGACTCTGGCACAATCTCTG 3’, lincRNAis18 forward2 5’ 
CAACAGTTTCCTGAACACGC 3’, lincRNAis18 reverse 5’ 
CAACGCTTTAACAGAACAGACTTC 3’, lincRNAis18 nested reverse 5’ 
TGACATACTCACATAAACTCCACGC 3’; cbx1a forward 5’ 
TCGATGAGCATGAGCCAACC 3’, cbx1a reverse 5’ CCAAGCCTAGTTCTTGTCATCTTTC 
3’. 
 Primers complementary to the ribosomal protein S6 kinase b, rps6kb1 gene were used as 
control for RT-PCR reactions. forward rps6kb1 forward 5’ CATGGCGACGGTGCGTTCAT 3’; 
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rps6kb1 reverse 5’ AGCTTGCCGCCCGTCTGAAA 3’. Digoxygenin-labeled antisense and 
sense probes for in situ hybridization were synthesized using the T3 Dig labeled RNA synthesis 
kit (Roche). In situ hybridization on 12-16 m cryosections of head and eye tissue was 
performed as described (Trimarchi JM et al., 2007). Probes were purified over Biorad Biospin or 
Qiagen RNeasy MinElute Cleanup Kit columns following the manufacturer’s instructions and 
stored in 50% formamide at -20oC.  
  
TALEN directed isolation of lincRNAis18 deletion allele 
 TALEN pairs targeting sequences in exon 2 and exon 5 of lincRNAis18 were designed 
using TAL Effector-Nucleotide Targeter 2.0 (Doyle EL et al., 2012) and synthesized using the 
modified GoldyTALEN scaffold (Bedell VM et al., 2012). 1-cell stage WIK embryos were co-
injected with 30 or 60 pg in vitro transcribed TALEN mRNA targeting sequences in exons two 
and exons five of lincRNAis18. Individual injected embryos were assayed for mutation efficiency 
by disruption of restriction enzyme sites in an amplicon spanning the targeted region. Genomic 
DNA was extracted from embryos and adult fin clips by placing tissue in 50 µl 50mM NaOH 
and heating at 95oC for 10 minutes. Primers to amplify lincRNAis18 exon two: exon2F 5’ 
GGTCATGTCCTTGTGTTTTG 3’; exon2R’ CTCCAGCTCCTGTGTATTCATTG 3’. Primers 
to amplify lincRNAis18 exon five: exon5F 5’ CCACAAGTTTCATGTGGCTCT 3’; exon5R 5’ 
TGGATTACTCGTAACTGAGGAAAAAC 3’. Founders were raised to adulthood and screened 
for germline transmission of the deletion allele. 20 individual embryos from 27 F0 adults were 
tested by PCR amplification across the exon two – exon five junction using primers exon2F 5’ 
GGTCATGTCCTTGTGTTTTG 3’ and exon5R 5’ TGGATTACTCGTAACTGAGGAAAAAC 
3’. 
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RNA-Seq, real time PCR and differential gene expression analyses 
 RNA-Seq data are available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress) 
under accession number E-MTAB-2886. Tissues for isolation of total RNA for RNA-Seq 
libraries were dissected from three age-matched genotypes. Total RNA was isolated using 
Qiagen RNeasy RNA Isolation Kit (Qiagen). The first sample, “Wild Type”, contained three 
pooled retinas from 6-month-old wild type adults. The second sample, “Pretumor”, consisted of 
three pooled retinas from age-matched heterozygous Tg(flk1:RFP)is18/+ adults that did not show 
obvious gross ocular tumors. The third sample, “Tumor”, consisted of tumor tissue dissected 
from the eyes of two age-matched heterozygous Tg(flk1:RFP)is18/+ adults that had advanced, 
large tumors that filled the vitreous and distorted the ocular cavity. RNA-Seq libraries from each 
sample were 100 bp paired-end sequenced in individual lanes on an Illumina HiSeq 2000 
instrument at the Genome Sequencing and Analysis Core Resource, Duke Institute for Genome 
Sciences and Policy, Duke University. Mapping of the RNA-Seq data was performed at the 
Genome Informatics Facility, Iowa State University. To map the RNA-Seq data the Danio rerio 
reference genome v9 and gene models (release 71) were downloaded from ensemble. Sequences 
were mapped using GSNAP version 2012-07-20 (Wu TD et al., 2010). Raw read counts per gene 
were determined using the program HTSeq-count (http://www-
huber.embl.de/users/anders/HTSeq/) (Anders S et al., 2010) to identify unique reads that mapped 
within a gene model.  Upper quartile normalization was applied to the raw reads across the three 
samples. The Fisher’s exact test was performed to determine differential expression of a gene 
between samples. Q-value estimation for false discovery rate was performed in R using open 
source software qvalue at bioconductor (http://bioconductor.org/biocLite.R ; Alan Dabney, John 
D. Storey and with assistance from Gregory R. Warnes. qvalue: Q-value estimation for false 
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discovery rate control. R package version 1.32.0). Heat maps representing log2(fold change) in 
gene expression were created in Excel. GO Term analysis was done at the Gene Ontology (GO) 
Tools website http://go.princeton.edu. 
 Two-Step real time PCR was performed on a Roche LightCycler 480 instrument using 
SYBR green reaction mix (Fisher). RNA isolation from Wild Type, Pre-tumor, and Tumor 
tissues was as described above. cDNA template was synthesized with SuperScript II 
(Invitrogen). qRT-PCR reactions were run in triplicate for each tissue template and primer pair. 
Primers for qRT-PCR are listed in Table S4.  
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Supplemental Tables and Figures 
 
Figure S1  
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Figure S1. Molecular mapping of the Tol2<flk1:RFP> concatemer transgene in zebrafish 
line Tg(flk1:RFP)is18 to chromosome 3. 
 
(A)  Schematic of Agilent Sure Select Target Enrichment mapping technique.  Tg(flk1:RFP)is18 
and flanking genomic sequences were captured with complementary biotin-RNA probes 
followed by Illumina GAIIx sequencing of barcoded libraries and mapping to the zebrafish 
genome (B) Snapshot of alignment to chromosome 3 in the zebrafish genome of genomic DNA-
transgene junction fragments captured with a custom SureSelect Target Enrichment kit. (C) 
Diagram illustrating integration site of the Tol2<flk1:RFP> concatemer at position 24, 212, 944 
on chromosome 3. The sequence flanking the transgene, containing an 8bp duplication at the 
integration site, is shown below. Primers used for PCR amplification of the junction fragments at 
the integration site are shown. Chr3F and chr3R, position of primers on chromosome 3. Tol2-5’R 
and Tol2-3’F sit within the left and right inverted repeats of the Tol2<flk1:RFP> transposon. (D) 
PCR products verify the location of the transgene integration in the 5 genomic samples used for 
SureSelect Target Enrichment. *, amplification of the 350 bp 5’ genomic-transgene junction 
fragment. **, amplification of the 200bp 3’ genomic-transgene junction fragment. 
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Figure S2 
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Figure S2. RFLP caused by integration of Tol2<flk1:RFP> concatemer at position 24, 212, 
944 on chromosome 3. 
 
(A) Diagram of Tol2<flk1:RFP> transposon construct with position of probe complementary to 
RFP cDNA (red box). (B) BamHI/BglII restriction map of region surrounding Tol2<flk1:RFP> 
concatemer integration on chromosome 3. Blue box shows position of probe complementary to 
region on chromosome 3 just 5’ to integration site. (C) Genomic Southern blots of BamH1/BglII 
double digested genomic DNA from wild type WIK, 6th generation Tg(flk1:RFP)is18, and 6th 
generation non-transgenic +/+ siblings. BamHI cuts once within the Tol2<flk1:RFP> 
transposon, releasing each copy from the concatemer. Left panel shows chromosome 3 RFLP 
due to transgene integration (blue asterisk) present only in Tg(flk1:RFP)is18 transgenic fish. 
Right panel shows an intense band at the expected size for the Tol2<flk1:RFP> transposon 
construct and many other bands of varying sizes. This confirms the identity of the 
Tg(flk1:RFP)is18 transgenic fish and reveals the complex nature and disorganization of the 
transgenes in the high copy number array. 
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Figure S3 
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Figure S3. RFLP caused by integration of Tol2<flk1:RFP> concatemer at position 24, 212, 
944 on chromosome 3.  
 
(A) Diagram of Tol2<flk1:RFP> transposon construct with position of probe complementary to 
lactamase cDNA (orange box) in the vector backbone. (B) BstEII restriction map of region 
surrounding Tol2<flk1:RFP> concatemer integration on chromosome 3. BstEIII does not cut in 
the Tol2<flk1:RFP> concatemer. Blue box shows position of probe complementary to region on 
chromosome 3 just 5’ to integration site. (C) Genomic Southern blots of BstEIII digested 
genomic DNA from wild type WIK, 5th generation Tg(flk1:RFP)is18, 6th generation 
Tg(flk1:RFP)is18, and 6th generation non-transgenic +/+ siblings. Left panel shows blot of linear 
digested plasmids of known size for comparison. Panel second from left shows high molecular 
weight band (blue asterisk) corresponding to chromosome 3 RFLP caused by concatemer 
integration. Right panels show blots hybridized with a probe specific to the transgene construct 
in the concatemer. The intense band (orange asterisk) corresponds to the concatemer integrated 
in chromosome 3. The band runs at the same position as the band recognized by the chromosome 
3 probe. Far right panel represents longer exposure of blot shown in second panel from right. 
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Figure S4  
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Figure S4. STR marker linkage analysis of the Tol2<flk1:RFP> concatemer in line 
Tg(flk1:RFP)is18.   
 
Upper panel. Genomic position and name of Short Tandem Repeat markers in the region of the 
transgene integration site on chromosome 3. Representative images of marker PCR products 
show genotype of an F5 generation Tg(flk1:RFP)is18 and a wild type WIK fish used for linkage 
analysis. Lower panel. Analysis in 20 offspring from a cross between the genotyped 
Tg(flk1:RFP)is18 and wild type WIK adults shows linkage of the chromosome to the long allele 
of Z7419, the short allele of G39247, the long allele of Z5197, and the long allele of cbx1aSTS. 
Further analyses of 200 progeny (Table 1) confirmed tight linkage of the concatemer integration 
site to the Z7419, G3927, Z5197 and cbx1aSTS markers. 
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Figure S5  
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Figure S5. Examination of zebrafish lincRNAis18 expression in early development and 
adult tissues.  
 
(A) Nested RT-PCR showing expression of lincRNAis18 within the adult zebrafish retina. (B) In 
situ hybridization using non-radioactive DIG-labeled lincRNAis18 probes on adult zebrafish 
retina cryosections.  lincRNAis18 expression is detected in the ganglion cell layer (GCL) and a 
subset of cells at the vitreal side of the inner nuclear layer (INL) (left, middle).  Negative control, 
lincRNAis18 sense DIG-labeled probe (right). (C, D) RT-PCR showing relative levels of 
lincRNAis18 expression throughout development and in adult tissues.  Control, expression of 
ribosomal protein S6 kinase b, polypeptide 1, rps6kb1. Blue bracket and asterisks indicate 
lincRNAis18 cloned and sequence confirmed products.  Red bracket and asterisks indicate 
nonspecific products cloned and confirmed by sequencing. GCL, ganglion cell layer; INL, inner 
nuclear layer; ONL, outer nuclear layer; RPE, retinal pigmented epithelium. Scale bars 100 µm. 
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Figure S6  
 
 
 
 
Figure S6. Genotyping of progeny from Tg(flk1:RFP)is18 incross.   
 
(A-C) Five individual larvae from each progeny class were genotype confirmed by PCR. Primer 
pair 1, chr3F and chr3R, amplify a fragment of the wild type chromosome 3 spanning the 
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concatemer integration site. Primer pair 2, chr3F and Tol2R, amplify a genomic DNA-transgene 
junction fragment.  Primer pair 3, control primers for amplification of a fragment of the flh gene. 
(A) Wild type +/+ sibling larvae. As expected primer pair 1 amplifies the wild type fragment of 
chromosome 3, while the concatemer genomic junction fragment that would be amplified by 
primer pair 2 is absent. (B) Homozygous mutant Tg(flk1:RFP)is18/Tg(flk1:RFP)is18 larvae. As 
expected, the wild type fragment of chromosome 3 is absent, while the concatemer genomic 
DNA junction fragment is present. (C) Heterozygous Tg(flk1:RFP)is18/+ genotyped larvae. Both 
the wild type chromosome 3 fragment and the concatemer genomic DNA junction fragment 
amplify. 
 
 
Figure S7  
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Figure S7. TALEN directed mutagenesis of lincRNAis18 exons two and five.  
 
(A) TALEN pairs targeting exon 2 and exon 5 of lincRNAis18. TALEN spacers are shown in red. 
/ marks location of FOK1 endonuclease cut site. HincII restriction enzyme site (exon 2) and MseI 
restriction enzyme site (exon 5) are underlined. (B) Individual embryos injected with TALENs 
targeting lincRNAis18 exon 2 (left panel) or exon 5 (right panel). The presence of HincII and 
MseI digestion resistant amplicons demonstrates mutation of the targeted site.  
 
 
Figure S8  
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Figure S8. The lincRNAis18e2e5del deletion allele is homozygous viable.  
 
(A) Diagram of lincRNAis18 gene structure and exon 2- exon 5 deletion allele. Primers e2F and 
e2R flank exon 2; primers e5F and e5R amplify exon 5. The genetic marker G38247 is located 
between exons 2 and 3. The genetic marker Z7419 is located 1 Mb downstream of the 3’ end of 
lincRNAis18. (B) Genotyping of fin clips from 10 adult progeny of a lincRNAis18e2e5del/+ 
incross. Genomic DNA was amplified with primer pairs listed. The exon 2- exon 5 fusion 
amplicon was detected in 4/10 adults, indicating they were homozygous for the 
lincRNAis18e2e5del chromosome (top panel). As expected these 4 adults lacked the G39247 
marker (4th panel).  
 
 
Figure S9  
 
 
 
Figure S9. Loss of lincRNAis18 mRNA at polyA selection step during RNA-Seq library 
preparation.  
 
RT-PCR shows presence of cbx1a and lincRNAis18 in the total RNA from wild type retina 
sample used for RNA-Seq cDNA library preparation.  The cbx1a transcript was detected 
following a single round of RT-PCR amplification in the total RNA sample (T) and in the 
Illumina RNA-Seq cDNA library sample (L). The lincRNAis18.v1 and .v2 transcripts were 
present in the total RNA sample (blue asterisks). However, only nonspecific products amplified 
from the cDNA library sample after one round of RT-PCR (red asterisks).  Nested PCR resulted 
in amplification of multiple alternatively spliced transcripts from both samples (Right panel, blue 
asterisks). Bands marked with asterisks were cloned and sequence verified. 
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Table S1. SureSelect Target Enrichment Antisense 120nt Bait Library tiled across 
pTol2<flk1:RFP> plasmid vector 
Bait  
ID Bait sequence 5'--> 3' 
v1 gggcgaattgggcccagaggtgtaaagtacttgagtaattttacttgattactgtacttaagtattatttttggggatttttactttacttgagtacaattaaaaatcaatacttttact 
v2 agtattatttttggggatttttactttacttgagtacaattaaaaatcaatacttttacttttacttaattacatttttttagaaaaaaaagtactttttactccttacaattttattta 
v3 tttacttaattacatttttttagaaaaaaaagtactttttactccttacaattttatttacagtcaaaaagtacttattttttggagatcacttcattctattttcccttgctattacca 
v4 cagtcaaaaagtacttattttttggagatcacttcattctattttcccttgctattaccaaaccaattgaattgcgctgatgcccagttgcggccgcgttaacgctaccatggagctcca 
v5 aaccaattgaattgcgctgatgcccagttgcggccgcgttaacgctaccatggagctccaaataatgattttattttgactgatagtgacctgttcgttgcaacaaattgataagcaatg 
v6 aataatgattttattttgactgatagtgacctgttcgttgcaacaaattgataagcaatgcttttttataatgccaactttgtataataaagttggaaaaaacctcccacacctccccct 
v7 cttttttataatgccaactttgtataataaagttggaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataa 
v8 gaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca 
v9 tggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggatctacgtaat 
v10 ttctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggatctacgtaatacgactcactatagttctagaggcgcgcctcaggagagcacacacttgcagctcatgcag 
v11 acgactcactatagttctagaggcgcgcctcaggagagcacacacttgcagctcatgcagccggggccactctcatcaggagggttcagcttattaagtttgtgccccagtttgctaggg 
v12 ccggggccactctcatcaggagggttcagcttattaagtttgtgccccagtttgctagggaggtcgcagtatctggccacagccacctcgtgctgctcgacgtaggtctctttgtcggcc 
v13 aggtcgcagtatctggccacagccacctcgtgctgctcgacgtaggtctctttgtcggcctccttgattctttccagtctgtggtccacatagtagacgccgggcatcttgaggttctta 
v14 tccttgattctttccagtctgtggtccacatagtagacgccgggcatcttgaggttcttagcgggtttcttggatctgtatgtggtcttgaagttgcagatcaggtggcccccgcccacg 
v15 gcgggtttcttggatctgtatgtggtcttgaagttgcagatcaggtggcccccgcccacgagcttcagggccatgtcgcttctgccttccaggccgccgtcagcggggtacagcatctcg 
v16 agcttcagggccatgtcgcttctgccttccaggccgccgtcagcggggtacagcatctcggtgttggcctcccagccgagtgttttcttctgcatcacagggccgttggatgggaagttc 
v17 gtgttggcctcccagccgagtgttttcttctgcatcacagggccgttggatgggaagttcacccctctgatcttgacgttgtagatgaggcagccgtcctggaggctggtgtcctgggta 
v18 acccctctgatcttgacgttgtagatgaggcagccgtcctggaggctggtgtcctgggtagcggtcagcacgcccccgtcttcgtatgtggtgactctctcccatgtgaagccctcaggg 
v19 gcggtcagcacgcccccgtcttcgtatgtggtgactctctcccatgtgaagccctcagggaaggactgcttaaagaagtcggggatgccctgggtgtggttgatgaaggttctgctgccg 
v20 aaggactgcttaaagaagtcggggatgccctgggtgtggttgatgaaggttctgctgccgtacatgaagctggtagccaggatgtcgaaggcgaaggggagagggccgccctcgaccacc 
v21 tacatgaagctggtagccaggatgtcgaaggcgaaggggagagggccgccctcgaccaccttgattctcatggtctgggtgccctcgtagggcttgccttcgccctcggatgtgcacttg 
v22 ttgattctcatggtctgggtgccctcgtagggcttgccttcgccctcggatgtgcacttgaagtggtggttgttcacggtgccctccatgtacagcttcatgtgcatgttctccttaatc 
v23 aagtggtggttgttcacggtgccctccatgtacagcttcatgtgcatgttctccttaatcagctcttcgcccttagacaccataggaccggggttttcttccacgtctcctgcttgcttt 
v24 agctcttcgcccttagacaccataggaccggggttttcttccacgtctcctgcttgctttaacagagagaagttcgtggctccggatcccccgggctgcaggaattcgatatcaagctta 
v25 aacagagagaagttcgtggctccggatcccccgggctgcaggaattcgatatcaagcttatcgatatccgcggtttgtctgttaaaataacgtcccgaatgatactccgtatgtcacttc 
v26 tcgatatccgcggtttgtctgttaaaataacgtcccgaatgatactccgtatgtcacttcacgttcggatgcggctgcagtagtccagaacttaatttctcttgatgtatgataatatgc 
v27 acgttcggatgcggctgcagtagtccagaacttaatttctcttgatgtatgataatatgcttatagttcctgttgatatgatagagatggttcttcggtgacgtgttaatagttaaacac 
v28 ttatagttcctgttgatatgatagagatggttcttcggtgacgtgttaatagttaaacacctctcagtgactgtaaagtatcgcgcaggactgcgcctgccccggtactaagacgaatgg 
v29 ctctcagtgactgtaaagtatcgcgcaggactgcgcctgccccggtactaagacgaatggagaaactccactgactccacaactcccgagggcaggtgcgaccgctgtccgtccttccta 
v30 agacgaatggagaaactccactgactccacaactcccgagggcaggtgcgaccgctgtccgtccttcctaaaaccgaatgaatgaaatttccaaaactacactatgtagtgaaggtgtaa 
v31 gtccttcctaaaaccgaatgaatgaaatttccaaaactacactatgtagtgaaggtgtaacagccatttatctatcttcacaccatcccactatacctctgacttttctactgggctttt 
v32 cagccatttatctatcttcacaccatcccactatacctctgacttttctactgggcttttccctctcgaaggctttatatgagtgaagcgaggacggaaggacgcaacgtcaccatagta 
v33 ccctctcgaaggctttatatgagtgaagcgaggacggaaggacgcaacgtcaccatagtaaccctgcagcgatactcgtaaagctacgtgtactgatttaacttaatcgataggctatct 
v34 accctgcagcgatactcgtaaagctacgtgtactgatttaacttaatcgataggctatctacttattcaggctaaatgacttgcatagagttattaggaacataccaacacaagaccaac 
v35 acttattcaggctaaatgacttgcatagagttattaggaacataccaacacaagaccaacagaaacaagaaatacatcataacatttttatacccatcaaagaaaaaaacatgaaatatg 
v36 agaaacaagaaatacatcataacatttttatacccatcaaagaaaaaaacatgaaatatgcactatagtagactgaaaatacagaactctggtcacactttataataaggttttattgtt 
v37 cactatagtagactgaaaatacagaactctggtcacactttataataaggttttattgttgactgtatttactaacataaacaaaaccaatacagcatttactaatcagttcaacattta 
v38 gactgtatttactaacataaacaaaaccaatacagcatttactaatcagttcaacatttactaatgcataagacacaaattcctcttttttaacattacttaattcagagttaattaact 
v39 ctaatgcataagacacaaattcctcttttttaacattacttaattcagagttaattaactaagaatgaacaactgtattttcactaactagcataaacaaacaattaaatgtattgttca 
v40 aagaatgaacaactgtattttcactaactagcataaacaaacaattaaatgtattgttcatggtctgttcgtgttagtgaatgcattactaatacaactttattgtaaagttttacttga 
v41 tggtctgttcgtgttagtgaatgcattactaatacaactttattgtaaagttttacttgaactgctattaaaaagtatggcctactataataagaatatgatcgatttaataagaattta 
v42 actgctattaaaaagtatggcctactataataagaatatgatcgatttaataagaatttactggaaatttgatttaaaaagagttaatacatatcatacatcacatacatcatgggttga 
v43 ctggaaatttgatttaaaaagagttaatacatatcatacatcacatacatcatgggttgatttttttaagttacataactcattccaagtgtttttaaattactgcacatattatctctc 
v44 tttttttaagttacataactcattccaagtgtttttaaattactgcacatattatctctctttctctctttctcacacacacacacacacacacacacacacacacacacacacacacac 
v45 tttctctctttctcacacacacacacacacacacacacacacacacacacacacacacacacacacacacacacacacacacacacacacacacacactctctcacacacacacacacac 
v46 acacacacacacacacacacacacacacacacacacactctctcacacacacacacacactctctcacacacacacacacacacacgcacagtactattatctcttctacaacaaataaa 
v47 tctctcacacacacacacacacacacgcacagtactattatctcttctacaacaaataaaaatatttgtaatgtatttattgaagagggttcattccgctgtagcgaacccttataaata 
v48 aatatttgtaatgtatttattgaagagggttcattccgctgtagcgaacccttataaataaggtagtaagctaaagggaaattaatgaatgaatatttattaaaatatttaagatattat 
v49 aggtagtaagctaaagggaaattaatgaatgaatatttattaaaatatttaagatattattttatcttgtttattatagacttaatatctgcacaacatcacttaaactagaatcacttt 
v50 tttatcttgtttattatagacttaatatctgcacaacatcacttaaactagaatcactttagcatagcctttctagcaaaaatcagatttagtgttagaaaatgaatgaatgaatcaata 
v51 agcatagcctttctagcaaaaatcagatttagtgttagaaaatgaatgaatgaatcaatatttgctttttggcttagtccctttattaatctggggtcgcaaaagtggaatgaacccgca 
v52 tttgctttttggcttagtccctttattaatctggggtcgcaaaagtggaatgaacccgcaacttatccttattatactctaagaaaaaaaaagatgaattatgcactacatcaaaatata 
v53 acttatccttattatactctaagaaaaaaaaagatgaattatgcactacatcaaaatataaagtagactaaaagtattccatatcaaaacaaactgtaaaaaaaaacaatattttttatt 
v54 aagtagactaaaagtattccatatcaaaacaaactgtaaaaaaaaacaatattttttattatatattttttttaaaatttaagatactgtacgcaaaaatattgcacagtccaataatct 
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pTol2<flk1:RFP> plasmid vector 
Bait  
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v55 atatattttttttaaaatttaagatactgtacgcaaaaatattgcacagtccaataatctcttcttgatcacaaaaataatttttattgtatcacaaaaacttatttttaatatatttat 
v56 cttcttgatcacaaaaataatttttattgtatcacaaaaacttatttttaatatatttattgagtaaactgtaacattaatagcatttggtactatttaaaagtgtcttcttttgtcttg 
v57 tgagtaaactgtaacattaatagcatttggtactatttaaaagtgtcttcttttgtcttgtttattatagacttaatatctggacaatataactacgatcactttagaatcacacttcta 
v58 tttattatagacttaatatctggacaatataactacgatcactttagaatcacacttctagcaagaaatcaggcttattgtgttagtgtttaattaacagaaaattaatatgaaatattt 
v59 gcaagaaatcaggcttattgtgttagtgtttaattaacagaaaattaatatgaaatatttcttagtaaatttttgcatcacaatttttttaaatcaaggtgcaacgttgcattgtctgat 
v60 cttagtaaatttttgcatcacaatttttttaaatcaaggtgcaacgttgcattgtctgattacatagcattcaaaatacactggaaaaatatttacagttttttttttacttcagaaaca 
v61 tacatagcattcaaaatacactggaaaaatatttacagttttttttttacttcagaaacaggatgtgcagctaattttatatcagagtaaataatcatggggcttctttcaccttccagc 
v62 ggatgtgcagctaattttatatcagagtaaataatcatggggcttctttcaccttccagcaccccatggtgtgtggatgcaccacagactgtttgtctttttgatgctacaaacgtggat 
v63 accccatggtgtgtggatgcaccacagactgtttgtctttttgatgctacaaacgtggatatgctccccgcaacgtacagcaatgcattgtccattcatatccttttatctacacagtgc 
v64 atgtttggtgactaaaatatttttattgtaaaataatttattgtcctctcctaacattccttccatcaatatgtggataaatcagattgccattttcttacccttagaaaaactgactta 
v65 ttccatcaatatgtggataaatcagattgccattttcttacccttagaaaaactgacttaggacttaagtcttatgattagatatgatttctggtatatctgaaaccctctatgagaagt 
v66 ggacttaagtcttatgattagatatgatttctggtatatctgaaaccctctatgagaagtttggagaatgtatcttgaaagactatttttattattattttgttcattttacccttcaca 
v67 ttggagaatgtatcttgaaagactatttttattattattttgttcattttacccttcacaaaagacttgaattactacccgatggacgaaagtataataaatagttatattattgtatat 
v68 aaagacttgaattactacccgatggacgaaagtataataaatagttatattattgtatatgatgaaatgagacacttataccactgttctgtcattgcaaatctttaaataaatgtttaa 
v69 gatgaaatgagacacttataccactgttctgtcattgcaaatctttaaataaatgtttaaaataaataaataactaatttaaatgtgggcgaagcagtggtgcagtagatagtgctgttg 
v70 aataaataaataactaatttaaatgtgggcgaagcagtggtgcagtagatagtgctgttgcctcacaacaagaaggttgctgggtcgctggttcgattctcggctcagttggcgtttttg 
v71 cctcacaacaagaaggttgctgggtcgctggttcgattctcggctcagttggcgtttttgtgtggagtttgcatgttctccctgcattcgcgtgggtttactccgggtgctacggtttcc 
v72 tgtggagtttgcatgttctccctgcattcgcgtgggtttactccgggtgctacggtttcccccacaatccaaagacatgcggtacaggtgaattgggttggctaaattgtccatagtgtc 
v73 cccacaatccaaagacatgcggtacaggtgaattgggttggctaaattgtccatagtgtctgagtgtgtgtgaatgagtgtttgtggatgtttcccagagatgggttgcatctggaaggg 
v74 tgagtgtgtgtgaatgagtgtttgtggatgtttcccagagatgggttgcatctggaagggcatccgctgcgtaaaaatgtgctggataagttggcggttcattccgctgtggcgaaccta 
v75 catccgctgcgtaaaaatgtgctggataagttggcggttcattccgctgtggcgaacctagattaataaagggactaagccaacaagaaaatgaatgaattaataatttaaaggatttat 
v76 gattaataaagggactaagccaacaagaaaatgaatgaattaataatttaaaggatttatttttattaggtttttaaataaataggtcttacactttatattttctgatttttcatagta 
v77 ttttattaggtttttaaataaataggtcttacactttatattttctgatttttcatagtatatgtattaattctgttacttttaccatatcaaccatttggtagtggctgatattttaga 
v78 tatgtattaattctgttacttttaccatatcaaccatttggtagtggctgatattttagaaataatgggatgtgttgaaaaaaatgcattgaatttgttaactaggaatgcaatccaaag 
v79 aataatgggatgtgttgaaaaaaatgcattgaatttgttaactaggaatgcaatccaaagtaattgatccctgattttttttcattgaagtatataattttagattacagatgttcattg 
v80 taattgatccctgattttttttcattgaagtatataattttagattacagatgttcattggtatttaatgttaacagatttaaatgcagatttaaatgctgataaaagccaccatgtaaa 
v81 gtatttaatgttaacagatttaaatgcagatttaaatgctgataaaagccaccatgtaaagtgtattatgcagtaaattgcaacatttagtttttgaattagaaagattaagagataaat 
v82 gtgtattatgcagtaaattgcaacatttagtttttgaattagaaagattaagagataaattcttgtaaaataaaagctagtcattttttacctttttctttttttcccaaagcatttata 
v83 tcttgtaaaataaaagctagtcattttttacctttttctttttttcccaaagcatttatagacaatacatttcaggttatgtcttcaggtttggcagcagatgttttacagagatatttc 
v84 gacaatacatttcaggttatgtcttcaggtttggcagcagatgttttacagagatatttctcgaatacacaatattcggcctagcattgacctttcatacccaagtctaactgtgagatg 
v85 tcgaatacacaatattcggcctagcattgacctttcatacccaagtctaactgtgagatgaaatatttttaaacctggcacagatgtataaatacgcctgtttattattattttaatatt 
v86 aaatatttttaaacctggcacagatgtataaatacgcctgtttattattattttaatattatttatgttgcagactttaggaaatcttgtgtccatctctctgaccgcatgtcacaagga 
v87 atttatgttgcagactttaggaaatcttgtgtccatctctctgaccgcatgtcacaaggatcatgtttgtttttttcgttctcctgtgcaatcaagccctctgaactgatcacatttccc 
v88 tcatgtttgtttttttcgttctcctgtgcaatcaagccctctgaactgatcacatttccctcagaccagtacggtggctagataagactcaggcagaaacaattgctggaagccgagcat 
v89 tcagaccagtacggtggctagataagactcaggcagaaacaattgctggaagccgagcatgcagaggagtgggcttttaagacatcttatttttgaatctagtgccgtgaacacaataag 
v90 gcagaggagtgggcttttaagacatcttatttttgaatctagtgccgtgaacacaataagagacttcacaaaccattctgtgtacgcagcttgagctctttccttcagctcaacaatgac 
v91 agacttcacaaaccattctgtgtacgcagcttgagctctttccttcagctcaacaatgacctcccctgttaaaacaaaaagctcagcgttatcagcacatactttctttggggtgaatga 
v92 ctcccctgttaaaacaaaaagctcagcgttatcagcacatactttctttggggtgaatgaggttttaactagcagaaggtgatgaatattatgtttaaacaatgctattatactatgtaa 
v93 ggttttaactagcagaaggtgatgaatattatgtttaaacaatgctattatactatgtaatgggccagacctttcaacacggaaattctgaatatcaaaagagcaggcctagttctccat 
v94 tgggccagacctttcaacacggaaattctgaatatcaaaagagcaggcctagttctccatttatcttaaaatattatttagagcgcttgtttctgaggcttttatatttcatttttatat 
v95 ttatcttaaaatattatttagagcgcttgtttctgaggcttttatatttcatttttatattctattactatttataataaaagtgcatttaatatagtggaaattgtgcgctataatgta 
v96 tctattactatttataataaaagtgcatttaatatagtggaaattgtgcgctataatgtaactaaatattaaatttaagtttatttgtacagagctttttacagtaattattgtttcaat 
v97 actaaatattaaatttaagtttatttgtacagagctttttacagtaattattgtttcaatgcagctttacaaaagatgcacatttttgcattacaatcacataattgcattactttaatt 
v98 gcagctttacaaaagatgcacatttttgcattacaatcacataattgcattactttaattaagtaaacctcagttacttaagttacaatcaaatagcagttattatatacagacacatgc 
v99 aagtaaacctcagttacttaagttacaatcaaatagcagttattatatacagacacatgcaattttatagcatatgagtgatgtccaaatagcaaaatgattgtagttgttaatattaat 
v100 aattttatagcatatgagtgatgtccaaatagcaaaatgattgtagttgttaatattaatgaggctggattattaatcttggcttcaccacgccaaataaattgtgtgaacctgaatgaa 
v101 gaggctggattattaatcttggcttcaccacgccaaataaattgtgtgaacctgaatgaaatattttagggagacatgatgagtaacagcaagttaaaaaccgtgtgtgagacaccacct 
v102 atattttagggagacatgatgagtaacagcaagttaaaaaccgtgtgtgagacaccaccttgcggtcactcagcggtattacactccggctgaagcgcgtcctcgtgcgtgttttggcgg 
v103 tgcggtcactcagcggtattacactccggctgaagcgcgtcctcgtgcgtgttttggcggggagcggtcgcgaggggcagcgttggtttttttccagtcacacagaaacttcatacaaaa 
v104 ggagcggtcgcgaggggcagcgttggtttttttccagtcacacagaaacttcatacaaaatacaaccttttaaaattacttcagattttttagatacacaaaatataatatggagcagtt 
v105 tacaaccttttaaaattacttcagattttttagatacacaaaatataatatggagcagtttgctgtcgaagtaaaaggtacgtttgcggtaaaagaaagatatgtggtaccagtcaattc 
v106 tgctgtcgaagtaaaaggtacgtttgcggtaaaagaaagatatgtggtaccagtcaattcaatgtataaaagatacgctattgtgtatttactatgagatgagctattgtgtttttttac 
v107 aatgtataaaagatacgctattgtgtatttactatgagatgagctattgtgtttttttacaaaacaattatttatcttacatattttaagtgatattaatataatgacaaataacagttt 
v108 aaaacaattatttatcttacatattttaagtgatattaatataatgacaaataacagtttcaacttaccttttgtaagtaatttaacaggttatgtgaagatatttcgtggtttgacgtt 
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v109 caacttaccttttgtaagtaatttaacaggttatgtgaagatatttcgtggtttgacgttcctttcacagacctgtcagagaaactcctccacagacagagccattcagacttggatgaa 
v110 cctttcacagacctgtcagagaaactcctccacagacagagccattcagacttggatgaagtgattgattccctcttcaaggagattttaactctagatgaagctgcaaaactacaggat 
v111 gtgattgattccctcttcaaggagattttaactctagatgaagctgcaaaactacaggattcacaggtgtggaaaatacacttcttttgaaatctacggaagcccccagggatcttgtag 
v112 tcacaggtgtggaaaatacacttcttttgaaatctacggaagcccccagggatcttgtagcgttgtgttttgaagacatgacgtctttattttgttctcgacataaatatatattatttc 
v113 cgttgtgttttgaagacatgacgtctttattttgttctcgacataaatatatattatttcgtattttaagttaacatcttacacagaaatcaggtaattgtggttcaatatttaataatt 
v114 gtattttaagttaacatcttacacagaaatcaggtaattgtggttcaatatttaataatttagttgtttttgtagctggaggaaatcgccatccagttgtggaactgggctgtcaccaaa 
v115 tagttgtttttgtagctggaggaaatcgccatccagttgtggaactgggctgtcaccaaacgtgttggcacctcaattacagaagagcagaaggccaaaggtctgtccttgtattagtct 
v116 cgtgttggcacctcaattacagaagagcagaaggccaaaggtctgtccttgtattagtcttttgttttattaactttaatataaattagattttttttaaataataatacatgtattaat 
v117 tttgttttattaactttaatataaattagattttttttaaataataatacatgtattaattaggcctaataattataattaataatgattttacttgcctgtattaagtatctatttaat 
v118 taggcctaataattataattaataatgattttacttgcctgtattaagtatctatttaatactgttgggggtttcaatctgtagtctgggaaatgtagaaatgtttaataaattaaaata 
v119 actgttgggggtttcaatctgtagtctgggaaatgtagaaatgtttaataaattaaaataattggtcaatgtagttaatacaattttaaacatgtttaaattagccttttatggacgcac 
v120 attggtcaatgtagttaatacaattttaaacatgtttaaattagccttttatggacgcacaaatgaacatactagcaggagcggacttaatcaataatcaaagttagcagccgcctaggg 
v121 aaatgaacatactagcaggagcggacttaatcaataatcaaagttagcagccgcctagggccccagggaattatgggtccctgaccaatgccaagaagcctatattaatcatatatctcg 
v122 ccccagggaattatgggtccctgaccaatgccaagaagcctatattaatcatatatctcgtttatacattttttaaatcatatgttgtaaaatctgtgtatagagtctgttcaaataaaa 
v123 tttatacattttttaaatcatatgttgtaaaatctgtgtatagagtctgttcaaataaaataacattgctcagtgaaaatgaacggctgccgattcacaaacagcaattattcagttaac 
v124 taacattgctcagtgaaaatgaacggctgccgattcacaaacagcaattattcagttaacttaaatgatcgtgaattaaatttgttaaaacttttttatttacttatatcaaaatctttt 
v125 ttaaatgatcgtgaattaaatttgttaaaacttttttatttacttatatcaaaatcttttcaccaaaatggctcatttagtttaaatagttgcaaattacttgttgtttttttttatttg 
v126 caccaaaatggctcatttagtttaaatagttgcaaattacttgttgtttttttttatttgtgaatgtattacatttaattttaaataaaaaagaaaaagcttccagtaaatataaaaata 
v127 tgaatgtattacatttaattttaaataaaaaagaaaaagcttccagtaaatataaaaatatagaaaatatacttttttatatactttttatatatatttatttatttaaatactttaaca 
v128 tagaaaatatacttttttatatactttttatatatatttatttatttaaatactttaacatgctgtttatttacaataataataatctacagagaaaaaaaatgtataagagaatgtttt 
v129 tgctgtttatttacaataataataatctacagagaaaaaaaatgtataagagaatgttttgagtttcagtgctagggccccatacccagaattgcttagggcccctgaatcactaaatcc 
v130 gagtttcagtgctagggccccatacccagaattgcttagggcccctgaatcactaaatccagtatatattttaatttaatgccatgtcaccaattaaagctattgtcatggcaagaacat 
v131 agtatatattttaatttaatgccatgtcaccaattaaagctattgtcatggcaagaacatttcagttacaagtatccaatcaaatatgaacaaaaatttgtacataaattaaataagatg 
v132 ttcagttacaagtatccaatcaaatatgaacaaaaatttgtacataaattaaataagatgtttagtgtttaaccaagtctagttttaaaatgtcttaaaactttgcgtgagattttaggt 
v133 tttagtgtttaaccaagtctagttttaaaatgtcttaaaactttgcgtgagattttaggttgtatttcatacaatttgttattttccaatgcatcccactcctcttgccacttatttaaa 
v134 tgtatttcatacaatttgttattttccaatgcatcccactcctcttgccacttatttaaaatgtaaacattgataaaatgtctcatctctggcatttgttcaccacttgtttcaaagcat 
v135 atgtaaacattgataaaatgtctcatctctggcatttgttcaccacttgtttcaaagcatccttagcagccacatcagctcactcatttcctgaaagtacctcgagatggtaccttcgat 
v136 ccttagcagccacatcagctcactcatttcctgaaagtacctcgagatggtaccttcgataaacaagaatctctagttttctttcttgcttttacttttacttccttaatactcaagtac 
v137 aaacaagaatctctagttttctttcttgcttttacttttacttccttaatactcaagtacaattttaatggagtacttttttacttttactcaagtaagattctagccagatacttttac 
v138 aattttaatggagtacttttttacttttactcaagtaagattctagccagatacttttacttttaattgagtaaaattttccctaagtacttgtactttcacttgagtaaaatttttgag 
v139 ttttaattgagtaaaattttccctaagtacttgtactttcacttgagtaaaatttttgagtactttttacacctctgctcgaccatatgggagagctcccaacgcgttggatgcatagct 
v140 tactttttacacctctgctcgaccatatgggagagctcccaacgcgttggatgcatagcttgagtattctatagtgtcacctaaatagcttggcgtaatcatggtcatagctgtttcctg 
v141 tgagtattctatagtgtcacctaaatagcttggcgtaatcatggtcatagctgtttcctgtgtgaaattgttatccgctcacaattccacacaacatacgagccggaagcataaagtgta 
v142 tgtgaaattgttatccgctcacaattccacacaacatacgagccggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaattgcgttgcgctcactgcccg 
v143 aagcctggggtgcctaatgagtgagctaactcacattaattgcgttgcgctcactgcccgctttccagtcgggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcgggga 
v144 ctttccagtcgggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtttgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgctcgg 
v145 gaggcggtttgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggttatccacag 
v146 tcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaacc 
v147 aatcaggggataacgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgcccccctgacgagcatcaca 
v148 gtaaaaaggccgcgttgctggcgtttttccataggctccgcccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgt 
v149 aaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctggaagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacc 
v150 ttccccctggaagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcatagctcacgctgtaggtatc 
v151 tgtccgcctttctcccttcgggaagcgtggcgctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagc 
v152 tcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgact 
v153 ccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtg 
v154 tatcgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctacactagaagaacagtatttggta 
v155 ctacagagttcttgaagtggtggcctaactacggctacactagaagaacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggca 
v156 tctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgcagaa 
v157 aacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacg 
v158 aaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggtcatgagattatcaaaaaggatcttcacctagatcc 
v159 aaaactcacgttaagggattttggtcatgagattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctg 
v160 ttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgacagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcat 
v161 acagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctg 
v162 ccatagttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagcaa 
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Table S1 Cont. SureSelect Target Enrichment Antisense 120nt Bait Library tiled across 
pTol2<flk1:RFP> plasmid vector 
Bait  
ID Bait sequence 5'--> 3' 
v163 gccccagtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagcaataaaccagccagccggaagggccgagcgcagaagtggtcctgcaactttatccgcctcca 
v164 taaaccagccagccggaagggccgagcgcagaagtggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagctagagtaagtagttcgccagttaatagtttgc 
v165 tccagtctattaattgttgccgggaagctagagtaagtagttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttggtatggctt 
v166 gcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcgagttacatgatcccccatgttgtgcaaaa 
v167 cattcagctccggttcccaacgatcaaggcgagttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttggccgcagtgttat 
v168 aagcggttagctccttcggtcctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgct 
v169 cactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaaccaagtcattctgagaatagtgtatgcggcgaccga 
v170 tttctgtgactggtgagtactcaaccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagcagaactttaaaag 
v171 gttgctcttgcccggcgtcaatacgggataataccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttga 
v172 tgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgtgcacccaactgatcttcagcatcttttactttca 
v173 gatccagttcgatgtaacccactcgtgcacccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataaggg 
v174 ccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataagggcgacacggaaatgttgaatactcatactcttcctttttcaatattattgaagcatttatc 
v175 cgacacggaaatgttgaatactcatactcttcctttttcaatattattgaagcatttatcagggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaatag 
v176 agggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaataggggttccgcgcacatttccccgaaaagtgccacctgatgcggtgtgaaataccgcacaga 
v177 gggttccgcgcacatttccccgaaaagtgccacctgatgcggtgtgaaataccgcacagatgcgtaaggagaaaataccgcatcaggaaattgtaagcgttaatattttgttaaaattcg 
v178 tgcgtaaggagaaaataccgcatcaggaaattgtaagcgttaatattttgttaaaattcgcgttaaatttttgttaaatcagctcattttttaaccaataggccgaaatcggcaaaatcc 
v179 cgttaaatttttgttaaatcagctcattttttaaccaataggccgaaatcggcaaaatcccttataaatcaaaagaatagaccgagatagggttgagtgttgttccagtttggaacaaga 
v180 cttataaatcaaaagaatagaccgagatagggttgagtgttgttccagtttggaacaagagtccactattaaagaacgtggactccaacgtcaaagggcgaaaaaccgtctatcagggcg 
v181 gtccactattaaagaacgtggactccaacgtcaaagggcgaaaaaccgtctatcagggcgatggcccactacgtgaaccatcaccctaatcaagttttttggggtcgaggtgccgtaaag 
v182 atggcccactacgtgaaccatcaccctaatcaagttttttggggtcgaggtgccgtaaagcactaaatcggaaccctaaagggagcccccgatttagagcttgacggggaaagccggcga 
v183 cactaaatcggaaccctaaagggagcccccgatttagagcttgacggggaaagccggcgaacgtggcgagaaaggaagggaagaaagcgaaaggagcgggcgctagggcgctggcaagtg 
v184 acgtggcgagaaaggaagggaagaaagcgaaaggagcgggcgctagggcgctggcaagtgtagcggtcacgctgcgcgtaaccaccacacccgccgcgcttaatgcgccgctacagggcg 
v185 tagcggtcacgctgcgcgtaaccaccacacccgccgcgcttaatgcgccgctacagggcgcgtccattcgccattcaggctgcgcaactgttgggaagggcgatcggtgcgggcctcttc 
v186 cgtccattcgccattcaggctgcgcaactgttgggaagggcgatcggtgcgggcctcttcgctattacgccagctggcgaaagggggatgtgctgcaaggcgattaagttgggtaacgcc 
v187 attacgccagctggcgaaagggggatgtgctgcaaggcgattaagttgggtaacgccagggttttcccagtcacgacgttgtaaaacgacggccagtgaattgtaatacgactcactata 
 
 
 
Table S2. Ilumina Paired End Reads from Custom SureSelect Target Enrichment of 
Tol2<flk1:RFP>is18 transgene integration site 
Genomic DNA 
SureSelect Indexed 
Library 
Tol2<flk1:RFP>is18 
Fish Generation and ID Tissue 
No. Paired End 
Reads/Library 
Dr is18 1 F2#3 female muscle 1519937 
Dr is18 2 F3#35 female tumor 4790568 
Dr is18 3 F3#35 female muscle 6396525 
Dr is18 4 F4#1 female tumor 10262541 
Dr is18 5 F4#1 female muscle 23644059 
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Table S3. CandidateTol2<flk1:RFP>is18 transgene integration locations  
Chromosome 
Genomic Position of 
Paired End Reads * 
No. Paired End 
Reads 
Confirmation of 
Transgene-Genomic 
Junction by PCR# 
Dr 3 24212813 - 24212885 81 + 
Dr 17 53841392 – 53841417 11 - 
Dr 20 4645321 –  4645510 9 - 
Dr 24 11726450 - 11726500 17 - 
    * 75 bp Paired End reads mapping to a unique, non-repetitive sequenc of the genome and the 
Tol2<flk1:RFP>is18 transgene. 
# PCR results presented in Supplemental Figure S1 C. 
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Table S4. Primers for genotyping and qRT-PCR 
  
Marker Zebrafish gene ID Forward Primer Reverse Primer 
cbx1a Sequence 
Tagged Site 
- 5' TTGTTGCTGTTGATGAACTGTTAG 3' 5' CAGGCAATCAAAGATCACTTCATAG 3' 
chromosome 3 
integration site 
- 5' GGCATCAGTATTGGTGAGTACATGA 3' 5' GAAAGTGTGTTTAAGCAGTGCTATTTG 3' 
G39247 UniSTS: 82394 5' TTTGGAAGCAGGTGTTACCC 3' 5' TGCTCTTCCACAGAAGGACA 3' 
is18 transgene - 5' CTCAAGTAAGATTCTAGCCAGATACT 
3' 
5' AGCGCAATTCAATTGGTTTGGTAATAG 3' 
Z5197 UniSTS: 29532 5' CCAATCTGCAAATGTCACCAGG 3' 5' TGTGCACAGCCGTTCCTACA 3'  
Z7419 UniSTS: 204934 5' TGAAGTTCAAATCAGACGTCAG 3' 5' GCTTTCATTGTGGTCAGGGT 3' 
Z7486 UniSTS: 34408 5' CGAGCAGTTACATCACAGGC 3' 5' CACGCATGTGCAGCGTTACA 3' 
Gene  
  
actb2 ENSDARG00000037870_actb2 5' CGAGCTGTCTTCCCATCCA 3' 5' TCACCAACGTAGCTGTCTTTCTG 3' 
ajap1 ENSDARG00000038655_ajap1 5' GATCATCACCATCACTGTGTCC 3' 5' TTTCTCTGATGGCTGCTGTG 3' 
ascl1a ENSDARG00000038386_ascl1a 5' ATGAACTCTATGGCCGGTTC 3' 5' TAAGTTTCCTTTTACGAACGCTC 3' 
atf3 ENSDARG00000007823_atf3 5' CAGCAGCAAAATGTCGGAAC 3' 5' GCTGCTTTTGGTTCTTCAGC 3' 
bysl ENSDARG00000001057_bysl 5' CTTCTACAATCTGGTGCTGCTG 3' 5' GAGCAGGATCCCTTTGAACC 3' 
hbegfa ENSDARG00000075121_hbegfa 5' ATTTCTCTCTGCCGGTGAAG 3' 5' TGCTTGTGAAACCTGAGTGC 3' 
insm1a ENSDARG00000091756_insm1a 5' AGGTCTACCCGTGCAAATACTG 3' 5' GGCATCTGAAGCAGGATCAC 3' 
7
9
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Table S5. Alternatively spliced isoforms of nested lincRNAis18 RT-PCR 
products 
 
Isoform Sequence 
 
Exons 2-8 
GACAGACTCTGGCACAATCTCTGGACGTCGTCTCGGCTGAAGCTCCGCCATGCCTCC
TCAGCCTGACTCTACACGATCAATACACAGGAGCTGGAGAGACAGCATTTCATACC
AGCACTTTGAGGATGAAGAAGGGAGGGACAGAGGAGCAAATAAAGGAGTGACACA
GCAAAAGGAGGGGAAAAAAGAGGAAGTTGTAAAATGACAACAAACATCAAGGAG
CCCCACTTGACCACCGGGGTGAGAGGATGGAGACTGTGGGTCACAGAAAGCCAGA
GCAGGGGCAGCGTGCCAGAGGCTGGAGATGGTAGCAGGAATGCTAATGGAGCCAT
AACCACCACTAATACCTTTAACAGCATCCTGGCAGAGCTCCTCAAGCCAGGCCTCTT
AATCTCAGTTCTGGAAGCTGGCTTATTTCCTTGACCCACCACCCTTCCTCTTTGTCGT
CACTTGAGTAGCTGATGTGCGGCCGGAGCCCTCCCCACTCATATCATCAAAAAGGA
AGCTGGTGAAAAATGAAACGACGCCAACAACAGTGGATTACAGTGGACTAACAGA
TTTTATGATTTCCTGAATAAATCTGTAAAAGTCTCTTATTTGGTCATGAGGAGAAAA
AGTGACCAATTTCAGGTCCATTTGGACATGGAGTGACACGTAAATTCTGTATAGAC
ATTCTGTACGTTCCCCCGAGCGTGGAGTTTATGTGAGTATGTCA 
Exons 2-8 
GACAGACTCTGGCACAATCTCTGGACGTCGTCTCGGCTGAAGCTCCGCCATGCCTCC
TCAGCCTGACTCTACACGATCAATACACAGGAGCTGGAGAAACAGCATTTCATACC
AGCACTTTGAGGATGAAGAAGGGAGGGACAGAGGAGCAAATAAAGGAGTGACACA
GCAAAAGGAGGGGAAAAAAGAGGAAGTTGTAAAATGACAACAAACATCAAGGAG
CCCCACTTGACCACCGGGGTGAGAGGATGGAGACTGTGGGTCACAGAAAGCCAGA
GCAGGGGCAGCGTGCCAGAGGCTGGAGATGGTAGCAGGAATGCTAATGGAGCCAT
AACCACCACTAATACCTTTAACAGCATCCTGGCAGAGCTCCTCAAGCCAGGCCTCTT
AATCTCAGTTCTGGAAGCTGGCTTATTTCCTTGACCCACCACCCTTCCTCTTTGTCGT
CACTTGAGTAGCTGATGTGCGGCCGGAGCCCTCCCCACTCATATCATCAAAAAGGA
AGCTGGTGAAAAATGAAACGAAACACAGACGCCAACAACAGTGGATTACAGTGGA
CTAACAGATTTTATGATTTCCTGAATAAATCTGTAAAAGTCTCTTATTTGGTCATGA
GGAGAAAAAGTGACCAATTTCAGGTCCATTTGGACATGGAGTGACACGTAAATTCT
GTATAGACATTCTGTACGTTCCCCCGAGCGTGGAGTTTATGTGAGTATGTCA 
* 
Exons 2-8 
GACAGACTCTGGCACAATCTCTGGACGTCGTCTCGGCTGAAGCTCCGCCATGCCTCC
TCAGCCTGACTCTACACGATCAATACACAGGAGCTGGAGAAACAGGTCAGCTGATG
CGCTTCCACATTTCATACCAGCACTTTGAGGATGAAGAAGGGAGGGACAGAGGAGC
AAATAAAGGAGTGACACAGCAAAAGGAGGGGAAAAAAGAGGAAGTTGTAAAATG
ACAACAAACATCAAGGAGCCCCACTTGACCACCGGGGTGAGAGGATGGAGACTGT
GGGTCACAGAAAGCCAGAGCAGGGGCAGCGTGCCAGAGGCTGGAGATGGTAGCAG
GAATGCTAATGGAGCCATAACCACCACTAATACCTTTAACAGCATCCTGGCAGAGC
TCCTCAAGCCAGGCCTCTTAATCTCAGTTCTGGAAGCTGGCTTATTTCCTTGACCCA
CCACCCTTCCTCTTTGTCGTCACTTGAGTAGCTGATGTGCGGCCGGAGCCCTCCCCA
CTCATATCATCAAAAAGGAAGCTGGTGAAAAATGAAACGAAACACAGACGCCAAC
AACAGTGGATTACAGTGGACTAACAGATTTTATGATTTCCTGAATAAATCTGTAAAA
GTCTCTTATTTGGTCATGAGGAGAAAAAGTGACCAATTTCAGGTCCATTTGGACATG
GAGTGACACGTAAATTCTGTATAGACATTCTGTACGTTCCCCCGAGCGTGGAGTTTA
TGNGAGTNNNCA 
*^ 
Exons 2, 6, 
7, 8 
GACAGACTCTGGCACAATCTCTGGACGTCGTCTCGGCTGAAGCTCCGCCATGCCTCC
TCAGCCTGACTCTACACGATCAATACACAGGAGCTGGAGAAACAGCTCCTCAAGCC
AGGCCTCTTAATCTCAGTTCTGGAAGCTGGCTTATTTCCTTGACCCACCACCCTTCCT
CTTTGTCGTCACTTGAGTAGCTGATGTGCGGCCGGAGCCCTCCCCACTCATATCATC
AAAAAGGAAGCTGGTGAAAAATGAAACGACGCCAACAACAGTGGATTACAGTGGA
CTAACAGATTTTATGATTTCCTGAATAAATCTGTAAAAGTCTCTTATTTGGTCATGA
GGAGAAAAAGTGACCAATTTCAGGTCCATTTGGACATGGAGTGACACGTAAATTCT
GTATAGACATTCTGTACGTTCCCCCGAGCGTGGAGTTTATGTGAGTATGTCA 
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Table S5 Cont. Alternatively spliced isoforms of nested lincRNAis18 RT-PCR 
products 
 
Isoform Sequence 
 
Exons 2, 6, 
7, 8 
GACAGACTCTGGCACAATCTCTGGACGTCGTCTCGGCTGAAGCTCCGCCATGCCTCC
TCAGCCTGACTCTACACGATCAATACACAGGAGCTGGAGAAACAGCTCCTCAAGCC
AGGCCTCTTAATCTCAGTTCTGGAAGCTGGCTTATTTCCTTGACCCACCACCCTTCCT
CTTTGTCGTCACTTGAGTAGCTGATGTGCGGCCGGAGCCCTCCCCACTCATATCATC
AAAAAGGAAGCTGGTGAAAAATGAAACGAAACACGGACGCCAACAACAGTGGATT
ACAGTGGACTAACAGATTTTATGATTTCCTGAATAAATCTGTAAAAGTCTCTTATTT
GGTCATGAGGAGAAAAAGTGACCAATTTCAGGTCCATTTGGACATGGAGTGACACG
TAAATTCTGTATAGACATTCTGTACGTTCCCCCGAGCGTGGAGTTTATGTGAGTATG
TCA 
* 
Exons 2, 6, 
7, 8 
GACAGACTCTGGCACAATCTCTGGACGTCGTCTCGGCTGAAGCTCCGCCATGCCTCC
TCAGCCTGACTCTACACGATCAATACACAGGAGCCGGAGAAACAGGTCAGCTGATG
CGCTTCCACTCCTCAAGCCAGGCCTCTTAATCTCAGTTCTGGAAGCTGGCTTATTTCC
TTGACCCACCACCCTTCCTCTTTGTCGTCACTTGAGTAGCTGATGTGCGGCCGGAGC
CCTCCCCACTCATATCATCAAAAAGGAAGCTGGTGAAAAATGAAACGACGCCAACA
ACAGTGGATTACAGTGGACTAACAGATTTTATGATTTCCTGAATGAATCTGTAAAAG
TCTCTTATTTGGTCATGAGGAGAAAAAGTGACCAATTTCAGGTCCATTTGGACATGG
AGTGACACGTAAATTCTGTATAGACATTCTGTACGTTCCCCCGAGCGTGGAGTTTAT
GTGAGTATGTCA 
^ 
Exons 2, 6, 
7, 8 
GACAGACTNTGGCACAATCTCTGGACGTCGTCTNGGCTGAAGCTCCGCCATGCCTCC
TCAGCCTGACTNTACACGATCAATACACAGGAGCTGGAGAAACAGCTCCTCAAGCC
AGGCCTCTTAATNTCAGTTCTGGAAGCTGGCTTATTTCCTTGACCCACCACCCTTCCT
CTTNGTCGTCACTTGAGTAGCTGATGTGCGGCCGGAGCCCTCCCCACTCATATCATC
AAAAAGGAAGNTGGTGAAAAATGAAACGACGCCAACAACAGTGGATTACAGTGGA
CTAACAGATTTTATGATTTCCTGAATAAATCTGTAAAAGTCTCTTATTTGGTCATGA
GGAGAAAAAGTGACCAATTTCAGGTCCATTTGGACATGGAGTGACACGTAAATTCT
GTATAGACATTCTGTACGTTCCCCCGAGCGTGGAGTTTATGTGAGTATGTCAAATGT
GCATTAATGTGTGTGTGTTATTTTTTTGAAGTCTGTTCNGTTAAAGCGTG 
# 
Exons 2, 
241271554-
24127218, 
6, 7, 8 
GACAGACTCTGGCACAATCTCTGGACGTCGTCTCGGCTGAAGCTCCGCCATGCCTCC
TCAGCCTGACTCTACACGATCAATACACAGGAGCTGGAGAAACAGATGATTCCATT
TATAAGTGATTTAAGTCATTGCAGAGATGTATGGCTGCAGTCCTCCAAGCTTATCTC
CTCAAGCCAGGCCTCTTAATCTCAGTTCTGGAAGCTGGCTTATTTCCTTGACCCACC
ACCCTTCCTCTTTGTCGTCACTTGAGTAGCTGATGTGCGGCCGGAGCCCTCCCCACT
CATATCATCAAAAAGGAAGCTGGTGAAAAATGAAACGACGCCAACAACAGTGGAT
TACAGTGGACTAACAGATTTTATGATTTCCTGAATAAATCTGTAAAAGTCTCTTATT
TGGTCATGAGGAGAAAAAGTGACCAATTTCAGGTCCATTTGGACATGGAGTGACAC
GTAAATTCTGTATAGACATTCTGTACGTTCCCCCGAGCGTGGAGTTTATGTGAGTAT
GTCA 
Exons 2, 
24127154-
24127218, 
6, 7, 8 
GACAGACTCTGGCACAATCTCTGGACGTCGTCTCGGCTGAGGCTCCGCCATGCCTCC
TCAGCCTGACTCTACACGATCAATACACAGGAGCTGGAGAAACAGATGATTTCATT
TATAAGTGATTTAAGTCATTGCAGAGATGTATGGCTGCAGTCCTCCAAGCTTATCTC
CTCAAGCCAGGCCTCTTAATCTCAGTTCTGGAAGCTGGCTTATTTCCTTGACCCACC
ACCCTTCCTCTTTGTCGTCACTTGAGTAGCTGATGTGCGGCCGGAGCCCTCCCCACT
CATATCATCAAAAAGGAAGCTGGTGAAAAATGAAACGAAACACAGACGCCAACAA
CAGTGGATTACAGTGGACTAACAGATTTTATGATTTCCTGAATAAATCTGTAAAAGT
CTCTTATTTGGTCATGAGGAGAAAAAGTGACCAATTTCAGGTCCATTTGGACATGGA
GTGACACGTAAATTCTGTATAGACATTCTGTACGTTCCCCCGAGCGTGGAGTTTATG
TGAGTNNNCA 
* 
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Table S5. Alternatively spliced isoforms of nested lincRNAis18 RT-PCR 
products 
 
Isoform Sequence 
 
Exons 2, 7, 
8 
GACAGACTCTGGCACAATCTCTGGACGTCGTCTCGGCTGAAGCTCCGCCATGCCTCC
TCAGCCTGACTCTACACGATCAATACACAGGAGCTGGAGAAACAGGCCGGAGCCCT
CCCCACTCATATCATCAAAAAGGAAGCTGGTGAAAAATGAAACGACGCCAACAAC
AGTGGATTACAGTGGACTAACAGATTTTATGATTTCCTGAATAAATCTGTAAAAGTC
TCTTATTTGGTCATGAGGAGAAAAAGTGACCAATTTCAGGTCCATTTGGACATGGA
GTGACACGTAAATTCTGTATAGACATTCTGTACGTTCCCCCGAGCGTGGAGTTTATG
TGAGTATGTCA 
Exons 2, 5, 
6, 7, 8 
GACCAGACTCTGGCACAATCTCTGGACGTCGTCTCGGCTGAAGCTCCGCCATGCCTC
CTCAGCCTGACTCTACACGATCAATACACAGGAGCTGGAGAAACAGGGCAGCGTGC
CAGAGGCTGGAGATGGTAGCAGGAATGCTAATGGAGCCATAACCACCACTAATACC
TTTAACAGCATCCTGGCAGAGCTCCTCAAGCCAGGCCTCTTAATCTCAGTTCTGGAA
GCTGGCTTATTTCCTTGACCCACCACCCTTCCTCTTTGTCGTCACTTGAGTAGCTGAT
GTGCGGCCGGAGCCCTCCCCACTCATATCATCAAAAAGGAAGCTGGTGAAAAATGA
AACGACGCCAACAACAGTGGATTACAGTGGACTAACAGATTTTATGATTTCCTGAA
TAAATCTGTAAAAGTCTCTTATTTGGTCATGAGGAGAAAAAGTGACCAATTTCAGGT
CCATTTGGACATGGAGTGACACGTAAATTCTGTATAGACATTCTGTACGTTCCCCCG
AGCGTGGAGTTTATGTGAGNNNNCNA 
Exons 2, 3, 
4, 5, 8 
GACAGACTCTGGCACAATCTCTGGACGTCGTCTCGGCTGAAGCTCCGCCATGCCTCC
TCAGCCTGACTCTACACGATCAATACACAGGAGCTGGAGAAACAGCATTTCATACC
AGCACTTTGAGGATGAAGAAGGGAGGGACAGAGGAGCAAATAAAGGAGTGACACA
GCAAAAGGAGGGGAAAAAAGAGGAAGTTGTAAAATGACAACAAACATCAAGGAG
CCCCACTTGACCACCGGGGTGAGAGGATGGAGACTGTGGGTCACAGAAAGCCAGA
GCAGGGGCAGCGTGCCAGAGGCTGGAGATGGTAGCAGGAATGCTAATGGAGCCAT
AACCACCACTAATACCTTTAACAGCATCCTGGCAGAGACGCCAACAACAGTGGATT
ACAGTGGACTAACAGATTTTATGATTTCCTGAATAAATCTGTAAAAGTCTCTTATTT
GGTCATGAGGAGAAAAAGTGACCAATTTCAGGTCCATTTGGACATGGAGTGACACG
TAAATTCTGTATAGACATTCTGTACGTTCCCCCGAGCGTGGAGTTTATGTGAGTATG
TCAAATGTGCATTAATGTGTGTGTGTTATTTTTTTGAAGTCTGTTCTGTTAAAGCGTG 
# 
Exons 2, 3, 
4, 5, 6, 8 
GACAGACTCTGGCNCNNTCTCNGGACGTCGTCTCGGCTGAAGCTCCGCCATGCCTCC
TCAGCCTGACTCTACACGATCAATACACAGGAGCTGGAGAAACAGCATTTCATACC
AGCACTTTGAGGATGAAGAAGGGAGGGACAGAGGAGCAAATAAAGGAGTGACACA
GCAAAAGGAGGGGAAAAAAGAGGAAGTTGTAAAATGACAACAAACATCAAGGAG
CCCCACTTGACCACCAGGGTGAGAGGATGGAGACTGTGGGTCACAGAAAGCCAGA
GCAGGGGCAGCGTGCCAGAGGCTGGAGATGGTAGCAGGAATGCTAATGGAGCCAT
AACCACCACTAATACCTTTAACAGCATCCTGGCAGAGCTCCTCAAGCCAGGCCTCTT
AATCTCAGTTCTGGAAGCTGGCTTATTTCCTTGACCCACCACCCTTCCTCTTTGTCGT
CACTTGAGTAGCTGATGTGCGACGCCAACAACAGTGGATTACAGTGGACTAACAGA
TTTTATGATTTCCTGAATAAATCTGTAAAAGTCTCTTATTTGGTCATGAGGAGAAAA
AGTGACCAATTTCAGGTCCATTTGGACATGGAGTGACACGTAAATTCTGTATAGAC
ATTCTGTACGTTCCCCCGAGCGTGGAGTTTATGTGAGTATGTCA 
   
 * Use of alternative splice acceptor 8 bp upstream (5' end) of exon 8  
 ^ Use of alternative splice donor 19 bp downstream (3' end) of exon 2  
 # 4 bp deletion   
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Table S6. Illumina Hi-Seq RNA-Seq data from zebrafish wild type retina, 
Tg(flk1:RFP)is18/+  pretumor retina and Tg(flk1:RFP)is18/+  tumor tissue 
Sample* 
Mbases of 
Sequence# No. of Reads 
% of reads 
=>Q30 
Mean 
Quality 
Score 
MM01 tumor retina is18/+ 42, 232 422,324,454 98.83 35.49 
     MM02 pre-tumor retina is18/+ 44, 484 444,838,528 89.63 35.16 
     MM03 normal retina +/+ 43, 651 436,511,378 89.75 35.21 
     * Total RNA was isolated from retina or tumor tissue dissected from age-matched 6 month old 
wild type or heterozygous lncRNAis18/+ siblings. 
# RNA-Seq libraries were prepared and 100bp paired-end sequenced in individual lanes on an 
Illumina HiSeq instrument at the Genome Sequencing and Analysis Core Resource, Duke 
Institute for Genome Sciences and Policy, Duke University.  
 
 
 
Table S7: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259487/ 
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Table S8. Differential expression of genes required for photoreception and neurotransmisson in Tg(flk1:RFP)is18/+ pre-
tumor retina and tumor tissue 
      Fold change 
Gene 
Gene 
Name Zebrafish Gene ID and Symbol 
WT--> 
Pretumor 
WT--> 
Tumor 
arrestin arr3a ENSDARG00000056511_arr3a 0.7 - 6.0 
calcium/calmodulin-dependent protein kinase 
kinase 1 CAMKK1 ENSDARG00000015134_CAMKK1 - 1.4 - 201 
crumbs crb1 ENSDARG00000062245_crb1 - 2.0 - 8.4 
cGMP-specific phosphodiesterase 6 pde6a ENSDARG00000000380_pde6a - 1.1 - 6.5 
cGMP-specific phosphodiesterase 6 pde6b ENSDARG00000011671_pde6b 1.0 - 6.1 
cGMP-specific phosphodiesterase 6 pde6c ENSDARG00000078461_pde6c - 1.7 - 30.7 
cGMP-specific phosphodiesterase 6 pde6d ENSDARG00000074892_pde6d - 1.6 - 3.8 
cGMP-specific phosphodiesterase 6 pde6g ENSDARG00000022820_pde6g 1.0 - 2.8 
cGMP-specific phosphodiesterase 6 pde6h ENSDARG00000070439_pde6h 0.5 - 7.3 
gamma-aminobutyric acid (GABA) A receptor gabra6a ENSDARG00000075058_gabra6a - 1.4 - 19.4 
gamma-aminobutyric acid (GABA) A receptor gabra6b ENSDARG00000058736_gabra6b 0.9 - 2.2 
guanylate cyclase activator 1c guca1a ENSDARG00000043294_GUCA1A - 1.2 - 3.9 
guanylate cyclase activator 1c guca1a ENSDARG00000010454_guca1a - 4.6 - 4.0 
guanylate cyclase activator 1c guca1b ENSDARG00000013393_guca1b 1.0 - 4.8 
guanylate cyclase activator 1c guca1c ENSDARG00000030758_guca1c 0.8 - 149.8 
guanylate cyclase activator 1c guca1d ENSDARG00000044629_guca1d - 1.5 - 117.2 
guanylate cyclase activator 1c guca1e ENSDARG00000078384_guca1e - 1.8 - 18.5 
guanylate cyclase activator 1c guca1g ENSDARG00000045737_guca1g - 2.5 - 34.5 
interphotoreceptor retinoid binding protein irbp ENSDARG00000059163_irbp 0.6 - 9.7 
8
4
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Table S8 Cont. Differential expression of genes required for photoreception and neurotransmisson in Tg(flk1:RFP)is18/+ 
pre-tumor retina and tumor tissue 
      Fold change 
Gene Gene Name Zebrafish Gene ID and Symbol 
WT--> 
Pretumor 
WT--> 
Tumor 
presynaptic cytoskeletal matrix protein piccolo scn1ba ENSDARG00000060222_scn1ba - 1.2 - 4.1 
retinitis pigmentosa 1 RP1 ENSDARG00000077687_RP1 - 1.8 - 10.4 
retinitis pigmentosa 1 RP1 ENSDARG00000086360_RP1 - 1.4 - 6.4 
retinitis pigmentosa 1-like 1 RP1L1 ENSDARG00000089458_RP1L1 - 1.6 - 6.9 
retinitis pigmentosa 1-like 1 RP1L1 ENSDARG00000088377_RP1L1 - 2.8 - 83.9 
retinol binding protein 4 rbp4 ENSDARG00000077505_rbp4 0.4 - 1.5 
retinol binding protein 4-like rbp4l ENSDARG00000044684_rbp4l 0.6 - 3.19 
solute carrier family 1/glutamate transporter slc1a2a ENSDARG00000052138_slc1a2a - 3.0 - 38.2 
solute carrier family 1/glutamate transporter slc1a2b ENSDARG00000009563_slc1a2b 0.9 - 1.4 
solute carrier family 1/glutamate transporter slc1a8a ENSDARG00000034628_slc1a8a - 2.8 - 6.2 
solute carrier family 1/glutamate transporter slc1a8b ENSDARG00000032465_slc1a8b - 1.6 - 168.1 
voltage gated sodium channel scn1ba ENSDARG00000060222_scn1ba - 1.2 - 4.1 
8
5
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Table S9. Differential Expression of lncRNAs in 
Tg(flk1:RFP)is18/+ pre-tumor retina and tumor tissues 
    Fold change 
lncRNA Chromosome 
WT--> 
Pretumor 
WT--> 
Tumor 
Zv9_00015799_lnc  6 1.2 -3 
Zv9_00019217_lnc  7 -2 -3 
Zv9_00020187_lnc  8 -1.5 -4 
Zv9_00055360_lnc  25 -0.2 -5 
Zv9_00017181_lnc 7 -2 -7 
Zv9_00046367_lnc 20 -1 -20 
Zv9_00011317_lnc 5 -2 -16 
Zv9_00028216_lnc 12 1 -22 
Zv9_00033972_lnc 14 -2 -28 
Zv9_00056161_lnc  25 1 4 
Zv9_00043309_lnc 19 2 5 
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CHAPTER 3: RAPID TUMOR INDUCTION IN ZEBRAFISH BY TALEN-MEDIATED 
SOMATIC INACTIVATION OF THE RETINOBLASTOMA1 TUMOR SUPPRESSOR 
RB1 
 
Adapted from: Rapid tumor induction in zebrafish by talen-mediated somatic inactivation of the 
retinoblastoma1 tumor suppressor rb1. (2015) Sci Rep 5:13745 
 
Staci L. Solin, Heather R. Shive, Kevin D. Woolard, Jeffrey J. Essner & Maura McGrail 
 
Abstract 
 Investigating the in vivo role of tumor suppressor genes in cancer is technically 
challenging due to their essential requirement during early animal development. To address 
this bottleneck, we generated genetic mosaic adult zebrafish using TALEN genome editing 
and demonstrate somatic inactivation of the tumor suppressor retinoblastoma1 (rb1) induces 
tumorigenesis at high frequency. 11–33% of 1-cell stage embryos injected with TALEN 
mRNAs targeting rb1 exon 2 or 3 develop tumors beginning as early as 3.5 months of age. 
Lesions predominantly arise in the brain and show features of neuroectodermal-like and glial-
like tumors. Mutant allele analysis is consistent with tumor initiation due to somatic 
inactivation of rb1, revealing a conserved role for rb1 in tumor suppression across vertebrates. 
In contrast to genetic mosaics, heterozygous rb1−/+ adults show no evidence of neoplasia, 
while homozygous mutant rb1−/− are larval lethal. This is the first demonstration that 
somatic inactivation of a tumor suppressor causes cancer in zebrafish, and highlights the 
utility of site-specific nucleases to create genetic mosaic zebrafish for tumor suppressor gene 
discovery. Somatic inactivation with site-directed nucleases in zebrafish presents a rapid and 
scalable strategy to study tumor suppressor gene function in cancer.  
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Introduction 
 Targeted somatic inactivation of tumor suppressor genes in genetic mosaic animals 
enables investigation of their roles in carcinogenesis if they are embryonic lethal. Mouse and 
zebrafish models of human cancer frequently require crosses with multiple transgenic lines to 
create conditional gene knockouts in predisposed mutant backgrounds (Shive HR et al., 2012, 
White R et al., 2013, Stiedl P et al., 2015, Tschida BR et al., 2014). Genome editing nucleases 
are emerging as a highly efficient alternative strategy for inactivating gene function in 
somatic tissues. TAL effector nucleases (TALENs) were first used for somatic gene 
inactivation to study vascular system development in zebrafish embryos (Bedell VM et al., 
2012). Adult phenotypes have also been created in zebrafish and mice with CRISPR/Cas9 
nuclease genome editing. In zebrafish, tissue specific CRISPR/Cas9s have been used for 
targeted gene knockout in the hematopoietic system (Ablain J et al., 2015). Nuclease targeted 
somatic inactivation was successfully used in adult mice to investigate cooperating genes 
during liver and lung carcinogenesis (Sanchez-Rivera FJ et al, 2014, Xue W et al., 2014). 
Most recently, malignant brain tumor models were developed using CRISPR/Cas9 somatic 
inactivation of multiple tumors suppressors in embryonic and neonatal mouse brain  
(Zuckermann M et al., 2015). Multiplex gene targeting with site directed nucleases simplifies 
the process of creating complex genotypes that normally require numerous genetic crosses. In 
addition, targeting nucleases allow for introduction of a range of loss of function alleles in 
addition to complete gene knockouts (Blackburn PR et al., 2013, Joung JK et al., 2013). 
The central role of the retinoblastoma tumor suppressor Rb1 in human cancer is well 
established. The Rb protein family’s main tumor suppressive role is  in regulation of cell cycle 
entry through interaction with E2F transcription factors (Harbour JW et al., 2000). Rb1 
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function also intersects with pathways controlling cellular senescence, apoptosis, DNA repair, 
and chromosome integrity (Schaal C et al., 2014, Henley SA et al., 2012). Mutation or 
alteration of the Rb1 pathway is detected in the majority of human adult gliomas 
(Goodenberger ML et al., 2012, Brennan CW et al., 2013). The role of Rb1 in specific cancers 
has been studied in mice by germline mutation (Hu N et al., 1994, Williams BO et al., 1994) 
and somatic inactivation with conditional or tissue specific knockouts (Zhang J et al., 2004, 
Parisi T et al., 2015). Targeted and conditional knockout of Rb1 in combination with tp53, 
PTEN, or Nf1 tumor suppressors in astrocytes and neural progenitors in adult mice induces 
malignant brain tumors (Chow LM et al., 2011, Alcantara LS et al., 2009, Zheng H et al., 
2008, Wang Y et al., 2009, Xiao A et al., 2002, Jacques TS et al., 2010) consistent with the 
predicted role for these genes in preventing cellular transformation in progenitor cell 
populations in the brain. Combinatorial deletion of tumor suppressors with or 
without Rb1 was shown to influence brain tumor phenotypes, indicating genetic disruption of 
cell cycle regulation in progenitors favors formation of primitive neuroectodermal tumors 
over glioma (Jacques TS et al., 2010) 
Here we present a proof of principle study in zebrafish that shows genome-editing 
nucleases can be used to study tumor suppressor gene function by targeted somatic 
inactivation. We demonstrate that TALEN-mediated targeting of rb1 results in highly 
penetrant tumor formation in genetic mosaic adults. The zebrafish rb1 tumor suppressor is an 
essential gene that functions in retinal neural progenitor proliferation and cell fate 
specification (Gyda M et al., 2012). However, its role in cancer has not been previously 
studied in zebrafish. Heterozygous adult fish with stable germline rb1 frameshift alleles did 
not develop lesions or tumors. In contrast, genetic mosaic adults develop tumors, 
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predominantly in the brain, with varying degrees of proliferation and histological features of 
neuroectodermal-like or glial-like tumors. The majority of mutant rb1 alleles in somatic, 
germline and brain tumor tissues were frameshift mutations. In tumor tissue only one or two 
frameshift alleles were present and overrepresented compared to wild type tissue. Together, 
the data indicate that biallelic inactivation of rb1in somatic tissue underlies neoplastic 
transformation and tumor initiation. Predisposing zebrafish to brain tumors by somatic 
inactivation of rb1 with site-specific nucleases will be useful for investigating pathways 
cooperating in brain tumorigenesis. Nuclease gene targeting in zebrafish presents a rapid and 
simple method to screen potentially hundreds of candidate tumor suppressor genes that impact 
carcinogenesis. 
 
Results and Discussion 
We used TALEN targeting to isolate germline mutations in the zebrafish 
retinoblastoma1 (rb1) tumor suppressor gene. Single cell embryos were injected with 150 or 
200 pg of TALEN mRNA targeting rb1 exon 2 or 12.5 to 50 pg of TALEN mRNA 
targeting rb1 exon 3 (Supplementary Figure S1). rb1 exon 2 TALENs were highly efficient, 
obtaining up to 100% biallelic inactivation in 50% of injected embryos. Lower mutagenesis 
efficiency was observed with rb1 exon 3 TALENs, and increased doses caused high toxicity 
and mortality. We screened three adults for germline transmission and recovered four 
new rb1 alleles in exon 2, two frameshift deletions Δ4 and Δ7, and two in frame deletion Δ9 
and Δ12 (Supplementary Figure S1). Homozygous Δ4 and Δ7 larvae failed to develop a swim 
bladder and died at ~7 days post fertilization, as reported previously for the rb1 mutant space 
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cadet (Gyda M et al., 2012). Normal development and viability was observed in the in frame 
deletion Δ9 and Δ12 homozygotes. 
During the course of this study, we observed that the genetic mosaic adults generated 
by somatic inactivation of rb1 in embryos develop tumors in the head region at high 
frequency (Fig. 1). Beginning at 3.5 months of age, fish that were injected with rb1 TALENs 
as embryos presented with tissue masses protruding out over the eyes and causing 
malformation of the skull (Fig. 1b, arrows). At 1.5 years post fertilization, tumor penetrance 
in rb1 exon 2 and exon 3 TALEN injected fish was 33% (29/87 adults) and 11% (29/275), 
respectively (Table 1). The heads from 52/58 adults were dissected and revealed abnormal 
brain morphology disrupted by large masses. The remaining 6 adults with lesions in the head 
region were not further analyzed (Table 1, “unknown”). Adults often displayed abnormal 
swimming behavior before overt appearance of masses in the head region, providing an early 
indicator of brain lesions in the affected animal. In contrast, heterozygous rb1−/+ adults 
carrying either of the established rb1 frameshift alleles do not develop tumors and are 
behaviorally normal. 
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Figure 1. Somatic inactivation of rb1 predisposes adult zebrafish to central nervous system 
tumors. 
 
(a) TALEN mRNAs targeting exon 2 or exon 3 of rb1 injected into 1-cell stage zebrafish 
embryos induces genetic mosaicism in somatic tissue and brain tumors in adults. Mosaic 
embryos with variable grey shading of individual cells representing one of n possible rb1 
alleles. Adults with genetic mosaic tissue represented by grey areas. Red circles represent 
brain lesions. (b) Presentation of cranial tumors in three 8 month old adult zebrafish injected 
with rb1 TALENs as 1-cell embryos. Age matched adult wild type fish is shown for 
comparison. Arrows point to masses protruding out of the cranial cavity over the eyes and 
distorting the dorsal head region. 
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Table 1. Tumor frequency and location in adult zebrafish after somatic inactivation of rb1 
 
TALEN-targeted rb1 
exon 
Tumor number and 
frequency (%)a 
Tumor location and 
histological features 
Number 
Exon 2b 29/87 (33%) Brain 23/29 
    glial or glial/neuronal 1 
    expanded glial rests 2 
    neuroectodermal-like 5 
    not analyzed by histologyc 15 
    Unknownd 6/29 
Exon 3e 29/275 (11%) Brain 29/29 
    glial or glial/neuronal 3 
    neuroectodermal-like 3 
    not analyzed by histologyc 23 
Control un-injectedf 0/150 – – 
 
aFrequency and percentage of adult fish with tumors at 1.5 years of age.  
bFour separate injections of 150 pg or 200 pg.  
cAdults presenting with gross tumors in head region; morphology of dissected brain was 
abnormal and disrupted by mass lesion; histopathology not performed.  
dTumors located in head region; dissection and histopathology not performed.  
eThree separate injections of 12.5, 25, or 50 pg.  
fControl un-injected fish raised alongside TALEN-injected embryos. 
 
 
Serial sections of 14/52 dissected brains in eight exon 2-targeted and six exon 3-
targeted fish revealed 12 neoplastic mass lesions that infiltrated and effaced the neuropil and 
two brains with expanded glial rests (Table 1). The remaining dissected brains were not 
analyzed by histology for tumor characterization (Table 1 “not analyzed by histology)”. Most 
tumors exhibited numerous mitoses and variable numbers of individually apoptotic cells . 
Prominent vasculature was generally not a feature of individual tumors. Tumors exhibited a 
range of histological features (Fig. 2 and Table 1), but the majority (7/12) exhibited 
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histological features suggestive of neuroectodermal-like tumors, including hyperchromatic or 
oval/wedge-shaped nuclei with rosette formation (Fig. 2a,b) or multilayered tubular structures 
(Fig. 2c). Four of 12 tumors contained features more consistent with glial-like tumors (Fig. 
2d) or mixed glial-like tumors (Fig. 2e). The remaining two brains revealed proliferative cell 
populations that appeared to arise from glial rests (glial cells that are retained from embryonal 
neurogenesis), without formation of a clear mass lesion (Fig. 2f). 
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Figure 2. rb1 inactivation-induced brain lesions show features of neuroectodermal-like and 
glial-like tumors. 
 
(a–f) Histological staining of coronal sections through heads of six adult zebrafish with brain 
tumors. Insets with boxed region refer to region of tumor shown in panel. (a) Neuroectodermal-
like tumor with neoplastic cells exhibiting small hyperchromatic nuclei that form rosettes (white 
arrowhead). (b) Neuroectodermal-like tumor with neoplastic cells exhibiting oval or wedge 
shaped nuclei, finely granular chromatin, and occasionally forming poorly defined rosettes 
(black arrowheads). (c) Tumor with multilayered tubules (black arrow) formed from cells 
exhibiting oval or wedge shaped nuclei with finely granular chromatin. (d) Glial-like tumor with 
neoplastic stellate or spindloid cells exhibiting oval or irregularly shaped nuclei with granular 
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chromatin forming poorly defined streams and bundles. Numerous mitotic figures (white 
arrowhead) and apoptotic cells (black arrowhead) are present. (e) Presumed mixed glial tumor 
with two cell populations. 1. Small round blue cells with hyperchromatic nuclei frequently in 
clusters (white arrowhead); 2. Larger cells with finely granular chromatin found in small clusters 
and bands (black arrowhead). (f) Expanded glial rests. Multiple small clusters (black arrowhead) 
and cellular bands of cells (black arrow) with round to oval nuclei and finely granular chromatin. 
no overt mass lesion. Scale bars: 200 µm, inset 20 µm. 
 
 
 
Two brain tumors from exon 2 and exon 3 targeted fish were analyzed by 
immunohistochemistry for identification of proliferating cells and expression of glial and 
neuronal markers. Consistent with the observation of mitotic figures in hematoxylin and eosin 
sections (Fig. 2d), many cells expressing phospho-histone H3 were observed in different 
regions of each tumor (Fig. 3d,e; Supplementary Figure 2). In one brain, the overall structure 
appeared mostly normal, but the lateral division of the valvula cerebelli contained numerous 
proliferating cells not observed in wild type (Supplementary Figure 2). Images of glial and 
neuronal differentiation markers labeling wild type brain and a representative brain tumor are 
shown in Fig. 3. The glial marker S100 and neuronal markers HuC/D and SV2 were detected 
within less disrupted regions of the tumor positive brain including the parenchyma (Fig. 
3g,j,m), which may represent non-neoplastic cells. These regions frequently showed 
infiltration of neoplastic cells (Fig. 3g,j,m). Expression of S100 within densely cellular 
regions of the tumors was limited to a few cells with similar appearance to astrocytes (Fig. 
3h), although the presence of stellate astrocytes in the midbrain of adult zebrafish has not 
been reported (Lyons DA et al., 2015). Little to no expression of neuronal markers HuC/D and 
SV2 was observed in these tumor regions (Fig. 3k,n). The lack of expression of differentiation 
markers for glia (S100) and neurons (HuC/D and SV2) suggests the tumors may lack 
differentiated cell types, but this is not definitive. Together, the data suggest that somatic 
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inactivation of rb1 results in brain tumors that are highly infiltrative with diverse histological 
features. 
 
 
Figure 3. Expression of mitotic index, glial and neuronal markers in rb1 inactivation-
induced brain tumors. 
 
H and E staining of coronal sections through wild type brain (a) and a representative rb1 TALEN 
induced brain tumor shows disruption of brain architecture (b). Immunohistochemical analyses 
on wild type (c,f,i,l) and brain tumor tissue (d,e,g,h,j,k,m,n). Phospho-histone pH3 labeling 
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reveals regions of high mitotic index throughout the tumor (d,e). Glial marker S100 (g) and 
neuronal markers HuC/D (j) and SV2 (m) were detected within brain parenchyma infiltrated with 
abnormal cells. In the densely cellular regions of the tumor a few S100 positive cells were 
observed (h) while little to no expression of HuC/D (k) and SV2 (n) was detected. Scale bars in 
H&E panels 500 µm; immunohistochemical panels 50 µm. 
 
 The frequency of rb1 mutant alleles in tumor and adult tissues was examined to 
confirm that rb1 somatic inactivation correlated with brain tumor induction in adult fish (Fig. 
4). Targeted rb1 exons 2 and 3 were sequenced in tumor, retina, muscle and germline tissue 
from four tumor positive fish ranging in age from 3.5 months to one year. In all tumor tissues 
(4/4) the frequency of rb1 mutant alleles was consistently higher than wild type alleles (68%–
87% of cloned amplicons represented indels; Supplementary Table 1). Only one or two 
specific rb1alleles were present in 3 out of 4 tumors. Of the 10 alleles recovered in the tumor 
tissue, 8 of the 10 were frameshift mutations. In contrast, the mutation frequency in  retinal, 
muscle, and germline tissues was highly variable (3%–100%) and was as high as 7 different 
mutant rb1 alleles in one fish (Supplementary Table 1). The presence of predominantly loss of 
function alleles in genetic mosaic fish that develop tumors is consistent with biallelic 
inactivation of rb1 initiating the pathway to transformation. However, the possibility that 
additional mutations in the genome caused by off targeting contributed to tumor induction 
cannot be ruled out. The high efficiency of TALENs targeting rb1 exon 2 produced 19 
different indels, with five specific to tumor tissue (Fig. 4a). Remarkably, only two exon 3 
frameshift alleles, Δ11 and Δ19, were recovered in the normal and tumor tissues from fish 
targeted with the low efficiency exon 3 TALENs (Fig. 4b). The high degree of mutagenesis 
was consistent with tumor growth from a neoplastic cell population transformed by 
inactivation of rb1. 
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Figure 4. rb1 mutant alleles and allele frequencies in somatic, germline, and tumor tissues 
from adult genetic mosaic zebrafish.  
 
(a) 14 different indel alleles in rb1 exon 2 were identified in retina, muscle, and germline 
genomic DNA from two adults. Mutant alleles represented 33% of cloned amplicons. In tumor 
tissue 8 unique alleles were identified, representing 87% of cloned amplicons. (b) Two 
frameshift alleles that delete 11 bp and 19 bp in rb1 exon 3 were detected in two adults. 10% of 
sequenced clones were mutant in retina, muscle or germline tissue. In tumor tissue 68% of 
sequenced clones were mutant alleles. Red arrows mark TALEN cut site. 
 
In summary, we demonstrate that targeted somatic inactivation of therb1 tumor 
suppressor in zebrafish embryos using two independent TALEN pairs results in genetic 
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mosaic adults that develop tumors at high frequency, predominantly located in the brain. 
Pathological and immunohistochemical analyses of the head in affected individuals indicate 
zebrafish can be predisposed to neuroectodermal-like and glial-like tumors by somatic 
inactivation of rb1 with site-specific nucleases. In contrast to genetic mosaic animals, 
adult rb1–/+ heterozygotes with a stable germline rb1 mutation do not develop tumors. This 
suggests that nuclease targeting induces biallelic inactivation at the rb1 locus and sensitizes 
cells to transformation. It has been proposed that in the case of epithelial cancers, tumor 
initiating cells may arise from a dedifferentiating progenitor population of transit amplifying 
cells (Chaffer CL et al., 2015). Similar mechanisms may drive neoplasms derived from the 
neurogenic cell populations in the brain. In support of this, mouse models of pediatric and 
adult brain tumors have been created by targeting tumor suppressor gene knockout, oncogene 
activation and insertional transposon mutagenesis to neural stem and progenitor cells in the 
brain (Chow LM et al., 2011, Alcantara LS et al., 2009, Zheng H et al., 2008, Wang Y et al., 
2009, Xiao A et al., 2002, Jacques TS et al., 2010, Larson JD et al., 2012, Wu X et al., 2012, 
Pei Y et al., 2012, Yang Z et al., 2008). Our observations are consistent with previously 
published zebrafish models of brain cancer generated by driving overexpression of activated 
Ras (Jung IH et al., 2013, Ju B et al., 2015) in neural and glial progenitor cells. Adapting a 
tissue specific CRISPR targeting method (Ablain J et al., 2015) to inactivate genes in neural 
progenitors in combination with zebrafish brain cancer models (Ju B et al., 2015, Shin J et al., 
2012, Ju B et al., 2014) will be useful for investigating cooperating pathways promoting 
tumorigenesis. Our study demonstrates the potential for rapid large scale screening of 
candidate tumor suppressors in zebrafish using genome-editing nucleases to generate genetic 
mosaics. 
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Materials and Methods 
Zebrafish care and husbandry 
 Zebrafish were reared in an Aquatic Habitat system from Aquatic Ecosystems, Inc., 
and maintained at 27 oC on a 14 hr light/10 hr dark cycle. The WIK wild type strain used in 
this study was obtained from the Zebrafish International Research Center 
(http://zebrafish.org/zirc/home/guide.php). Experimental protocols were approved by the Iowa 
State University Institutional Animal Care and Use Committee (Log # 11-06-6252-I). The 
protocols are in compliance with American Veterinary Medical Association and the National 
Institutes of Health guidelines for the humane use of laboratory animals in research. Adult 
fish were anesthetized and euthanized in MS-222 Tricaine Methanesulfonate, and tissue 
dissection was carried out according to experimental protocols approved by the Iowa State 
University Institutional Animal Care and Use Committee (Log # 11-06-6252-I) in compliance 
with the American Veterinary Medical Association and the National Institutes of Health 
guidelines for the humane use of laboratory animals in research. NIH/Office of Animal Care 
and Use/Animal Research Advisory committee (ARAC) Guidelines for endpoint in neoplasia 
studies (oacu.od.nih.gov/ARAC/Guidelines for Endpoints in Animal Study Proposals) were 
used to establish a humane endpoint in the zebrafish rb1 TALEN injected fish. Adult fish 
were monitored for general appearance, size, length, viability and morbidity relative to control 
siblings daily during routine feeding. Fish were closely monitored bi-weekly for gross 
presentation of cranial tumors. Fish from each injection experiment were sacrificed before 
tumor burden reached 3 mm in size/25 mg in weight, constituting less than 10% of the total 
body weight of an adult fish (300–500 mg), as outlined for mouse and rat studies (Workman P 
et al., 2010), or by 1.5 year of age, whichever endpoint was reached first.  The swimming 
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behavior of some of rb1 TALEN injected fish was adversely affected before gross 
presentation of cranial tumors, possibly due to tumor location. These fish were sacrificed 
although tumor burden was less than 3 mm/10% of body weight.  
 
rb1 TALEN assembly, targeting, and allele analysis 
 TALENs targeting rb1 exon 2 or exon 3 were designed using TAL Effector Nucleotide 
Targeter 2.0 at https://tale-nt.cac.cornell.edu/node/add/talen-old (Doyle EL et al., 2012) and 
assembled in the modified GoldyTALEN scaffold5. 150–200 pg of exon 2 or 12.5–50 pg of 
exon 3 TALEN mRNA was injected into 1-cell stage wild type WIK embryos. TALEN 
efficiency was determined by assaying individual injected embryos for disruption of 
restriction enzyme sites in a PCR amplicon spanning the target site. Genomic DNA was 
extracted from embryos and adult fin clips by placing tissue in 50 μl 50 mM NaOH and 
heating at 95 oC for 30 minutes. For rb1 allele frequency analysis, genomic DNA was isolated 
from tumor, somatic and germline tissues using a DNeasy Blood and Tissue Kit (Qiagen). 
Amplicons were TOPO cloned (Invitrogen), and 50–100 individual clones sequenced per 
sample. Primers used for amplification of rb1 exons: exon 2 F-5’- 
TTTCCAGACACAAGGACAAGG-3’, R-5’-GCGGTAAAGCAGATATCAGAAGA -3’; 
exon 3 F-5’-TTTCCAGACACAAGGACAAGG-3’, R-5’-
CCTCACAAGACTGATGAACTGC-3’ or F-5’-TTACCGCACTTGTGTTTTGG-3’, R-5’-
TGCCACACATACCTCAGACC-3’. 
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Histopathology and Immunohistochemistry 
 Adult zebrafish were sacrificed and head tissue processed for histopathology and 
immunohistochemistry as described previously (Solin SL et al., 2014). For histopathology 
tissues fixed in Davidson’s or 10% Formalin (Fisher) were decalcified in Cal-Ex (Fisher), and 
paraffin embedded at the Iowa State University Clinical Histopathology Laboratory. 6 um 
sections were stained with Hematoxylin 7211 Richard-Allan Scientific (Fisher) and 3% Eosin 
Y (Argos Organics). For immunohistochemistry heads were fixed in 4% paraformaldehyde, 
decalcified in 12% EDTA, and embedded in Tissue-Tek optimal cutting temperature medium 
(Sakura). 14 um tissue sections were labeled with antibodies anti-phosphohistone-H3 (1:100, 
Upstate), anti-S100 (1:250, Dako). Secondary antibodies were conjugated with HRP. Tissues 
were counterstained with modified Mayer’s Hematoxylin (Fisher) and eosin. Slides were 
photographed on a Zeiss Axiophot using a Nikon Rebel camera and on a Zeiss confocal LSM 
700. 
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Supplemental Tables and Figures 
 
Figure S1. Design of TALENs targeting exon 2 and exon 3 of zebrafish rb1.  
 
(a) Diagram of TALEN design to target rb1 exon 2. Gel of restriction enzyme assay on exon 2 
PCR amplicon demonstrates 100% biallelic inactivation at the target site in 50% of individual 
embryos injected with 150 pg TALEN mRNA. (b) Diagram of TALEN design to target rb1 exon 
3. Gel of restriction enzyme assay on exon 3 PCR amplicon reveals relatively inefficient 
inactivation of the targeted location in individual embryos injected with 50 pg TALEN mRNA. 
Higher doses of exon 3 TALENs were not used due to toxicity. (c) Four new germline mutations 
recovered in rb1 exon2. Two frameshift and two inframe deletion alleles have been established. 
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Figure S2. Regions of high mitotic activity in rb1 inactivation-induced brain tumors.  
 
Coronal sections through wild type (a, b) two rb1 TALEN exon 2-induced tumors (c-f) and one 
rb1 TALEN exon 3-induced tumor (g,h). H and E staining reveals presence of tumor and 
disruption of brain architecture. Phospho-histone pH3 labeling reveals absence of pH3 labeling 
in wild type brain (b) compared to regions with high mitotic index in the three tumors (d, f, h). 
Scale bars in H&E panels 500 µm; pH3 panels 50 µm, inset 20 µm. 
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Supplemental Table S1. rb1 genetic mosaicism in adult tissues of TALEN targeted 
embryos 
 
 
 
Fish ID Tumor Retina Muscle Germlinea 
 
frequency
b
 alleles
c
 
 
frequency 
 
alleles 
 
frequency 
 
alleles 
 
frequency 
 
alleles 
 
Exon 2 -1 
13/15 
(87%) 
 
1 
2/16 
(13%) 
 
2 
9/12 
(75%) 
 
7 
10/10 
(100%) 
 
4 
 
Exon 2 -2 
10/16 
(63%) 
 
7 
3/16 
(19%) 
 
3 
6/22 
(27%) 
 
5 
 
1/19 (5%) 
 
1 
 
Exon 3-1 
17/21 
(81%) 
 
1 
4/30 
(13%) 
 
2 
 
2/22 (9%) 
 
2 
 
2/27 (7%) 
 
2 
 
Exon 3-2 
22/36 
(61%) 
 
2 
 
0/20 (0%) 
 
- 
 
1/27 (4%) 
 
1 
 
1/29 (3%) 
 
1 
 
a  
Ovary or Testis. 
b 
Frequency of insertion/deletion alleles in cloned amplicons from genomic DNA. 
The number of indel amplicons out of total amplicons sequenced is shown. 
c 
Number of unique mutant 
alleles. 
 
Acknowledgments 
The authors thank Dr. Stephen Ekker and Dr. Stephen Johnson for discussion of this work. 
Jordan Welker, Jennifer Groeltz-Thrush, Laura Schultz and Jasmine Linn assisted with 
experiments. This work was supported by grant #14-4418 from the Roy J. Carver Charitable 
Trust (M. McGrail). 
 
 
 
 
 
 
 
 
107 
 
CHAPTER 4:  ONGOING AND FUTURE STUDIES: RNA-SEQ ANALYSIS OF RB1 
INACTIVATION-INDUCED BRAIN TUMORS 
 
Introduction  
 Central nervous system primitive neuroectodermal tumors (CNS-PNETs) are a class of 
aggressive, embryonal brain tumors that are composed of undifferentiated neuroepithelial cells.  
CNS-PNETs occur predominantly in children and adolescents and account for 3% of pediatric 
brain and CNS tumors (Louis DN et al., 2007, Reddy AT et al., 2000).  Patients diagnosed with 
CNS-PNETs receive clinical treatment similar to that established for patients with high-risk 
medulloblastoma (MB), a histologically similar PNET arising specifically in the cerebellum 
(Reddy AT et al., 2000).  However, CNS-PNET patients have a significantly poorer outcome 
(Inda MM et al., 2006).  While considerable progress has been made in our understanding of the 
molecular characteristics and cellular origin of medulloblastoma, less is known about the 
molecular and cellular biology underlying CNS-PNETs (Northcott PA et al., 2011).  To gain a 
better understanding of the molecular and cellular biology of CNS-PNETs, animal models that 
recapitulate the human disease are needed.  
 The zebrafish has recently emerged as a system for modeling human diseases including 
cancer.   The molecular mechanisms and signaling pathways regulating developmental processes 
such as proliferation, differentiation, and apoptosis are highly conserved between zebrafish and 
humans (Santoriello C et al., 2012).  Deregulation of these fundamental cellular processes is a 
hallmark of cancer.  Thorough histological and molecular characterization of the first zebrafish 
cancer models showed that they resembled human tumors, affirming the zebrafish as a tool for 
studying cancer (Lam SH et al., 2006, Berghmans S et al., 2005, Langeneau DM et al., 2007, 
Shive HR et al., 2010).  The recent establishment and characterization of zebrafish glioma brain 
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cancer models, including an optic pathway glioma model, highlight the potential for the 
zebrafish as a brain cancer model (Shin J et al., 2012, Jung IH et al., 2013, Ju B et al., 2015, Ju B 
et al., 2014). 
 We previously identified a zebrafish brain tumor model in which TALEN-mediated 
somatic inactivation of rb1 leads to predominantly CNS primitive neuroectodermal-like brain 
tumors at a high frequency.  To comprehensively characterize this model we performed RNA-
seq analysis on rb1 somatic inactivation-induced brain tumors and wild type brains.  The average 
number of reads per library was ~15 million reads following RNA sequencing of replicate 
libraries for each sample.  High quality sequencing data with an average library Q score of 37.5 
(out of 40) was achieved from RNA sequencing.  Preliminary data suggests rb1 somatic 
inactivation-induced brain tumors resemble the oligoneural subgroup of human CNS-PNETs 
identified by Picard and colleagues.  Future studies will include differential gene expression, 
Ingenuity Pathway, GO Term, Hierarchical clustering, and principal component analyses of the 
RNA-seq data followed by qRT-PCR, in situ hybridization and immunohistochemical validation.  
This thorough characterization of rb1 inactivation-induced CNS-PNETs allows for comparative 
analysis with human CNS-PNETs.  These comparative studies have the potential to reveal the 
conserved molecular mechanisms that underlie CNS-PNET formation and aggressive 
progression. 
 
Results and Discussion 
Quality of RNA-seq data from rb1 somatic inactivation-induced brain tumors 
 To investigate the molecular similarities of zebrafish rb1 somatic inactivation-induced 
primitive neuroectodermal-like brain tumors with histologically similar human CNS-PNETs we 
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performed RNA sequencing on the zebrafish brain tumors and wild type brain.  Individual 
cDNA libraries were prepared from 10 brain tumors induced by TALEN-mediated somatic 
inactivation of rb1 and 2 pools of 3 age-matched wild type zebrafish brains ages 6.5 to 10.5 
months.  Libraries were created in replicates and analyzed for quality control prior to sequencing 
(Table 1).  A library size of approximately 260 base pairs was expected.  The libraries ranged in 
size from 264 to 277 bp with an average library size of 270 bp (Table 1).  We obtained 179 
million and 183 million reads in Lane 1 and Lane 2, respectively.  The average number of reads 
per library was ~15 million reads following RNA sequencing, a depth sufficient for differential 
gene expression in zebrafish (Liu Y et al., 2014). During RNA sequencing an average quality 
score (Q-score) was generated for each library (Table 2). The Q-score is an indicator of the 
quality of sequencing data, predicting of the probability of incorrect base call and range from 0 
to 40 with 40 being the highest quality (Ewing B et al., 1998).  For a Q score of 40 there is 
0.01% chance of a base being called incorrectly.  In the sequencing run performed an average of 
94.2% of bases had a quality score greater than or equal to the Q30 cutoff for further processing, 
and the average quality score for the libraries was 37.5 (Table 2).  These results demonstrate high 
quality sequencing data for downstream gene expression and pathway analysis. 
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Table 1. Final RNA-Seq library average fragment size 
 
cDNA Library bp Size 
   Replicate 1 Replicate 2 
 Tumor #1 270 274 
 Tumor #2 267 271 
 Tumor #3 273 272 
 Tumor #4 271 264 
 Tumor #5 271 264 
 Tumor #6 267 269 
 Tumor #7 266 267 
 Tumor #8 266 277 
 Tumor #9 269 273 
 Tumor #10 275 272 
 WT Pool #1 274 271 
 WT Pool #2 274 266 
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Table 2. Illumina Hi-Seq RNA-Seq data from rb1 inactivation-induced brain tumors and wild type brain 
 
cDNA 
Library 
Yield Mbases of 
Sequence No. of Reads % of >= Q30 Bases Mean Quality Score  
  Replicate 1 Replicate 2 Replicate 1 Replicate 2 Replicate 1 Replicate 2 Replicate 1 Replicate 2 
Tumor #1 718 785 14,080,104 15,387,623 94.03 94.34 37.46 37.56 
Tumor #2 754 735 14,787,466 14,412,119 94.11 94.41 37.47 37.59 
Tumor #3 815 826 15,976,577 16,188,958 93.93 94.29 37.42 37.55 
Tumor #4 770 740 15,096,943 14,514,689 94.11 94.38 37.47 37.58 
Tumor #5 822 812 16,117,019 15,931,174 94.02 94.34 37.46 37.57 
Tumor #6 865 840 16,965,370 16,466,627 94.04 94.40 37.46 37.58 
Tumor #7 843 893 16,524,639 17,516,572 94.00 94.35 37.44 37.57 
Tumor #8 817 713 16,020,463 13,981,005 93.95 94.34 37.43 37.57 
Tumor #9 628 702 12,305,355 13,767,340 94.00 94.30 37.45 37.57 
Tumor #10 668 778 13,101,532 15,247,837 93.82 94.14 37.39 37.5 
WT Pool #1 722 762 14,153,617 14,940,910 93.91 94.25 37.42 37.54 
WT Pool #2 721 773 14,143,448 15,158,180 94.08 94.38 37.47 37.58 
1
1
1
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Preliminary gene expression analysis of rb1 somatic inactivation-induced brain tumors 
To investigate similarities in the molecular signatures of zebrafish rb1 somatic 
inactivation-induced brain tumors with human CNS-PNETs signatures we examined expression 
of gene sets associated with each of the three identified subtypes of human CNS-PNETs (Picard 
D et al., 2012).  RNA-seq mapped read count was used for preliminary analysis.  In the primitive 
neural subtype, genes associated with stem cell pluripotency including LIN28 and CRABP1 
showed strong upregulation (Picard D et al., 2012).  In the rb1 somatic inactivation-induced 
brain tumors little to no expression of embryonic or neural stem cell- associated genes lin28a, 
lin28b, and crabp1b was detected. Human CNS-PNETs with significant upregulation of genes 
associated with oligo-neural differentiation including OLIG1/2 and SOX10 were classified as 
oligoneural (Picard D et al., 2012).  Strong expression of oligo-neural differentiation markers 
olig2, sox10, and sox8b was detected in the rb1 somatic inactivation-induced brain tumors.  The 
third CNS-PNET subtype identified by Picard and colleagues, mesenchymal, demonstrated an 
epithelial and mesenchymal differentiation expression signature.  Upregulation of genes 
associated with this subtype included COL1A, COL5A, FOXJ1, and MSX1 (Picard D et al., 
2012).  The rb1 somatic inactivation-induced brain tumors expressed epithelial and 
mesenchymal differentiation genes col1a and col5a1 while few foxj1a, foxj1b, msx1a, and msx1b 
transcripts were detected.   These preliminary data suggest that rb1 somatic inactivation-induced 
brain tumors resemble the oligoneural subtype of CNS-PNETs with some possible overlap with 
the mesenchymal subtype.  
 Although CNS-PNETs histologically resemble medulloblastoma, research suggests that 
they are distinct tumor entities with differing molecular signatures and cellular origins (Jones 
DTW et al., 2014).  To examine potential similarities between rb1 somatic inactivation-induced 
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brain tumors and human medulloblastoma we analyzed expression of genes associated with 
medulloblastoma. Phi and colleagues demonstrated that medulloblastomas express significantly 
higher levels of proneural gene NEUROG1 while CNS-PNETs express significantly higher 
levels of neural stem marker SOX2 (Phi et al., 2010).  The rb1 somatic inactivation-induced 
brain tumors showed little to no expression of neurog1 as well as atoh1a, atoh1b, and atoh1c, a 
known marker of a subset of medulloblastoma.  In contrast, strong expression of sox2 was 
detected in the rb1 somatic inactivation-induced brain tumors.  These preliminary data suggest 
that the molecular signature of the rb1 somatic inactivation-induced brain tumors is distinct from 
that of medulloblastoma. 
 
Ongoing and future studies 
 Further studies will include a combination of bioinformatics and molecular techniques to 
comprehensively characterize the rb1 somatic inactivation-induced brain tumors.  Hierarchical 
clustering and principal component analysis will be applied to compare the molecular signatures 
of the 10 rb1 somatic inactivation-induced brain tumors to each other and identify potential 
molecular similarities and differences.  The RNA-seq analysis included wild type brains 
allowing for differential gene expression between wild type brains and rb1 somatic inactivation-
induced brain tumors.  Ingenuity Pathway and GO term pathway analysis will identify the 
biological processes and signal transduction pathways that are disrupted in the rb1 somatic 
inactivation-induced brain tumors and provide potential insight to the mechanisms of tumor 
initiation and progression.  For RNA-seq analysis half of each of the 10 brain tumors was used 
for library preparation while the remaining half of the brain tumor was embedded for sectioning. 
This allows for the bioinformatic approaches to be coupled with molecular approaches including 
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histological, in situ hybridization, and immunohistochemical characterization of the remaining 
portion of the rb1 somatic inactivation-induced brain tumors.   
 Current treatments for CNS-PNETs are based on treatment for high-risk medulloblastoma 
but are significantly less effective on CNS-PNETs (Inda MM et al., 2006).   Furthermore, these 
treatments are associated with significant long-term adverse effects including neurological and 
neuroendocrine deficits (Fangusaro J et al., 2012, Reddy AT et al., 2000).  A better 
understanding of the molecular mechanisms that promote CNS-PNET initiation and aggressive 
progression will aid in the development of improved, targeted therapeutics for the treatment of 
CNS-PNETs.  The sustained, undifferentiated and proliferative phenotype of CNS-PNETs 
contributes to their highly malignant nature but the mechanisms underlying this phenotype are 
unknown.  The zebrafish rb1 inactivation-induced CNS-PNET model, coupled with data from 
human CNS-PNETs, will be useful for identifying and investigating candidate targets that may 
function in promoting the undifferentiated and proliferative aspect of these tumors.  Additionally, 
the preliminary finding of an oligoneural signature in zebrafish rb1 inactivation-induced CNS-
PNETs highlight the potential of this model for identification of CNS-PNET subgroup-specific 
biomarkers. 
 
Materials and Methods 
Zebrafish husbandry and genetics 
 Zebrafish were reared in an Aquatic Habitat system (Aquatic Ecosystems, Inc., Apopka, 
FL). Fish were maintained on a 14-hr light/dark cycle at 27°C. Transgenic lines were established 
in a WIK wild type strain obtained from the Zebrafish International Research Center 
(http://zebrafish.org/zirc/home/guide.php). All experimental protocols were approved by the 
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Iowa State University Institutional Animal Care and Use Committee (Log # 11-06-6252-I) and 
are in compliance with American Veterinary Medical Association and the National Institutes of 
Health guidelines for the humane use of laboratory animals in research.  
 
RNA Isolation, cDNA library synthesis  
 Tissues for isolation of total RNA, polyA selection and cDNA library synthesis were 
dissected from 10 brain tumor bearing and 6 age-matched wild type adult zebrafish ages 6.5 to 
10.5 months.  One sagittal half of each brain from the diencephalon to behind the cerebellum was 
isolated for RNA extraction. The remaining half was processed and embedded.  Total RNA was 
isolated using TRIzol reagent and the standard protocol.  Total RNA was DNase I (Qiagen) 
treated and cleaned up using Qiagen RNeasy MinElute Cleanup Kit (Qiagen).  RNA quality was 
analyzed using Agilent 2100 Bioanalyzer and Agilent RNA 6000 Nano Kit.  For those samples 
for which a RIN score was obtained the scores were 8.8 or above.  For cDNA library synthesis 
from wild type brain RNA, RNA isolated individually from three adult brains was pooled.  RNA 
from individual brain tumors was used for synthesis of cDNA libraries.  Replicate cDNA 
libraries were synthesized from 10 brain tumor RNA samples and 2 wild type brain RNA 
samples using Illumina TruSeq RNA Library Prep Kit v2. 1µg of total RNA input was used for 
each library preparation.   
 
Library sequencing and RNA sequencing analysis 
 Twenty four cDNA libraries were 50 bp single-end sequenced on 2 lanes (12 per lane) on 
an Illumina Hiseq 2500 instrument at the Genome Sequencing Core, Center for Molecular 
Analysis of Disease Pathways, University of Kansas.  To map the RNA-Seq data the Danio 
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rerio reference genome v10 and gene models (release 82) were downloaded from Ensembl.  
Reads were aligned and counted using the Bowtie2 (Langmead B et al., 2012) SAMtools (Li H et 
al., 2009) and featureCounts (Liao Y et al., 2014) software packages. 
 
Acknowledgments 
 
I would like to thank Laura Schultz for assistance with cDNA library synthesis and Jeff Haltom 
for preliminary analysis of the RNA-seq data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
117 
 
CHAPTER 5: SUMMARY AND CONCLUSIONS 
  
 Brain and central nervous system (CNS) tumors are the most common solid tumor 
amongst infants and children age 0-14 and are the leading cause of cancer-related death amongst 
this age group (Louis DN et al., 2007).  Advancements in tumor imaging, surgical techniques 
and chemotherapeutics have enhanced our ability to treat brain and CNS cancer.  However, the 
overall prognosis for children diagnosed with high-grade brain and CNS tumors remains dismal 
(Ostrom QT et al., 2015).  Children with high-grade brain and CNS tumors who undergo 
combinatorial treatment that includes radiotherapy and those with low-grade brain and CNS 
tumors that undergo minimal surgical resection frequently experience long-term morbidities 
(Armstrong GT et al., 2011, Fangusaro J et al., 2012, Reddy AT et al., 2000).  These findings 
highlight the need for effective, targeted treatments for pediatric brain and CNS cancers.  An 
improved understanding of the molecular biology underlying pediatric brain and CNS cancer 
tumorigenesis will assist the development of therapeutics for the treatment of pediatric brain and 
CNS cancer.  We characterized two models of pediatric brain and CNS tumors, a low-grade 
glial-like tumor and a high-grade primitive neuroectodermal-like tumor, for investigating the 
molecular mechanisms that promote brain and CNS tumor initiation and progression. 
 We identified a transgenic Tg(flk1:RFP)is18 zebrafish line in which heterozygotes 
develop glial-like tumors in the optic pathway.  The highly penetrant tumor phenotype (80-100% 
by one year) is linked to the integration of a high copy number transgene array in a novel long 
non-coding RNA gene, lincRNAis18, on chromosome 3.  Integration of the transgene array 
reduces expression of the lincRNAis18 RNA to an undetectable level.  A lincRNAis18 deletion 
allele of exons 2-5 was created using TALENs.  The deletion allele did not recapitulate the tumor 
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or homozygous embryonic lethal phenotypes observed in Tg(flk1:RFP)is18 suggesting loss of 
function of the lincRNAis18 locus is not the trigger for tumor onset.  To investigate potential 
similarities between the Tg(flk1:RFP)is18 optic pathway tumors and human optic pathway 
tumors we performed histopathological analysis in the retinal tumors. 
  Tg(flk1:RFP)is18 optic pathway tumors histologically resembled human pilocytic and 
diffuse astrocytoma.  The tumors within the retina were composed of neuroepithelial-like cells 
dispersed throughout a fibrous network.  Rosette-like structures, a hallmark feature of human 
tumors of neuroectodermal origin, were also observed. Tumors in the optic nerve and tract 
caused significant disruption of overall structure.  Infiltration beyond the optic pathway and into 
the brain disrupted normal brain structures.  Human optic pathway low-grade gliomas affecting 
the hypothalamus are associated with a poorer outcome because they are not amenable to 
surgical resection.  Similar to human low-grade glioma, the optic pathway tumors were not 
characterized by necrosis or high mitotic activity. Immunolabeling of retinal and optic nerve 
tumors with GFAP, a marker of glial cells, demonstrated strong expression throughout the retinal 
tumors.  GFAP expression was detected in the optic pathway tumors but was absent from wild 
type optic nerves.  Expression of BLBP, a marker of subset of glial cells, was also detected 
throughout the tumors of the retina.  These findings support a glial-like phenotype and 
demonstrate similarity of the Tg(flk1:RFP)is18 optic pathway tumors to human pilocytic and 
diffuse astrocytoma.  To further characterize the Tg(flk1:RFP)is18 retinal tumors we performed 
differential gene expression analysis wild type retina, pretumor retina from Tg(flk1:RFP)is18 
heterozygotes and advanced retinal tumor tissue from Tg(flk1:RFP)is18 heterozygotes 
 Differential gene expression revealed upregulation of genes that are markers of radial 
glia, glial progenitor cells, glial progenitor-derived astrocytes, and proliferating neuroglial 
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progenitor cells suggesting Tg(flk1:RFP)is18 tumors arise from neuroglial progenitors.  
Upregulation of genes involved in proliferation of Muller glia, resident retinal cells that can 
undergo dedifferentiation to produce neural progenitors, support a Muller glia origin for the 
neural progenitor signature. The tumors showed a significant increase in expression of glioma 
diagnostic markers vimentin (vim), S100ß (s100ß) and the matrix metalloprotease mmp9.  
Although the Tg(flk1:RFP)is18 glial-like tumors show strong histological and some molecular 
resemblance to human low-grade glioma the genetic lesion in the Tg(flk1:RFP)is18 line is unlike 
those associated with human low-grade gliomas.  The mechanism of Tg(flk1:RFP)is18 tumor 
initiation remains unknown.  These findings have impeded the use of the Tg(flk1:RFP)is18 line 
as a translational low-grade glioma cancer model. 
 The second pediatric brain and CNS tumor model was developed using transcription 
activator-like effector nucleases (TALENs) to target one of the most frequently disrupted 
pathways in human sporadic cancers, the RB tumor suppressor pathway (Indovina P et al., 2013).  
Mutation or alteration of the RB tumor suppressor pathway is detected in human pediatric and 
adult gliomas and pediatric CNS-PNETs (Picard D et al., 2012, Sturm E et al., 2014, 
Goodenberger, ML et al., 2012,).  Research in mouse models has demonstrated a role for RB1 
in preventing cellular transformation in progenitor cell populations in the brain tumors (Chow 
LM et al., 2011, Alcantara LS et al., 2009, Zheng H et al., 2008, Wang Y et al., 2009, Xiao A 
et al., 2002, Jacques TS et al., 2010). These findings suggested that the RB pathway would be 
an important component to the development and study of many types of cancer in zebrafish, 
including brain and CNS cancer.  We targeted zebrafish rb1, the central protein of the RB 
pathway, for disruption using TALENs. 
120 
 
 We generated genetic mosaic adults by TALEN-mediated somatic inactivation of rb1 
and showed that these fish develop brain tumors at a high frequency beginning as early as 3.5 
months.  As with the Tg(flk1:RFP)is18 line we performed histopathological analysis to 
determine tumor location and type and identify similarities with human brain cancers.  
Tumors exhibited a range of histological features with the majority (8/12) exhibiting 
histological features suggestive of primitive neuroectodermal-like tumors, including 
hyperchromatic or oval/wedge-shaped nuclei with rosette formation.  One of the tumors 
contained multilayered tubular structures similar to those seen in medulloepithelioma, a 
subgroup of CNS-PNET.  Tumors were frequently located in the diencephalon and 
cerebellum.  Human CNS-PNETs are WHO grade IV tumors (Louis DN et al., 2007).  
Consistent with high-grade CNS-PNET the tumors exhibited numerous mitoses and variable 
numbers of individually apoptotic cells (Louis DN et al., 2007).  33% (4/12) of the tumors 
showed histological features consistent with a more differentiated glial or mixed glial-like 
phenotype.   
 We investigated the mitotic index and variable differentiation phenotype of four of the 
rb1 somatic inactivation-induced tumors by immunolabeling with mitotic marker pH3 and 
differentiation markers S100, HuC/D, and SV2.  Consistent with the observation of mitotic 
figures in hematoxylin and eosin sections, many cells expressing phospho-histone H3 were 
observed throughout each tumor. Expression of glial marker S100 within densely cellular 
regions of the tumors was limited to a few cells with similar appearance to astrocytes.  Little 
to no expression of neuronal markers HuC/D and SV2 was observed in these tumor regions. 
The lack of expression of differentiation markers for glia (S100) and neurons (HuC/D and 
SV2) suggests the tumors may lack differentiated cell types, but this is not definitive.  
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 The histological features, tumor location, and varying differentiation phenotypes of the 
rb1 inactivation-induced brain tumors suggest a neuroglial progenitor tumor origin.  The 
recently developed tissue specific CRISPR/Cas9 system is currently being adapted for 
analysis of rb1 inactivation in neural progenitors.  To further characterize the rb1 somatic 
inactivation-induced brain tumors we are currently performing RNA sequencing gene 
expression analysis on brain tumors.  Preliminary data suggests rb1 somatic inactivation-
induced brain tumors resemble the oligoneural subgroup of human CNS-PNETs identified by 
Picard and colleagues.  A thorough characterization of rb1 inactivation-induced CNS-PNETs 
allows for comparative analysis with human CNS-PNETs.  These comparative studies have the 
potential to reveal the conserved molecular mechanisms that underlie CNS-PNET formation and 
aggressive progression. 
 We have shown that targeted somatic inactivation of the rb1 tumor suppressor in 
zebrafish embryos results in genetic mosaic adults that develop tumors at high frequency, 
located in the brain. In contrast to genetic mosaic animals, adult  rb1–/+ heterozygotes with a 
stable germline rb1 mutation do not develop tumors.  Furthermore, germline mutants 
homozygous for a frameshift allele die at ~8 dpf, preventing analysis of tumor formation.  
This study reveals a conserved role for rb1 in tumor suppression in zebrafish.  This is the first 
demonstration that somatic inactivation of a tumor suppressor causes cancer in zebrafish, and 
highlights the utility of site-specific nucleases to create genetic mosaic zebrafish for tumor 
suppressor gene discovery. This system presents a rapid and scalable strategy to study tumor 
suppressor gene function in zebrafish brain cancer models.   
 Next-generation sequencing of human brain cancers has provided insights into the 
molecular biology underlying tumor initiation and progression while identifying novel tumor 
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suppressor candidates at rates faster than we can functionally validate them (The Cancer 
Genome Atlas et al., 2008).  Mouse models have long been the standard for the in vivo 
investigation of candidate tumor suppressor function in brain cancer (Kegelman TP et al., 
2014, Chen J et al., 2012, Jacques TS et al., 2010)  However, the generation of genetically 
engineered, complex mouse models is time-consuming and costly.  Our rb1 somatic 
inactivation results highlight the use of nuclease-mediated somatic mutagenesis in zebrafish 
as a high-throughput technique for investigating tumor suppressor function in brain and CNS 
cancer as well as other types of cancers.  This approach in zebrafish will complement 
genetically engineered mouse model and human studies.  Candidate tumor suppressor genes 
can be quickly prioritized by first investigating their function in zebrafish cancer models that 
are similar to both the mouse model and human cancer.  The development of more effective 
treatments for pediatric brain and CNS cancers will rely on a multifaceted approach that 
includes zebrafish cancer models.  We have characterized two distinct zebrafish brain tumor 
models, a low-grade, glial-like tumor model and a high-grade CNS primitive neuroectodermal-
like tumor model that will be useful for the study of pediatric brain and CNS tumorigenesis.  
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